

# CTAD Alzheimer 2022

Clinical Trials on Alzheimer's Disease

## Program



ONSITE



ONLINE

November 29 - December 2, 2022  
San Francisco, USA

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11  
Monte Carlo '12 / San Diego '13 / Philadelphia '14 / Barcelona '15  
San Diego '16 / Boston '17 / Barcelona '18 / San Diego '19 / Virtual '20 / Boston '21

[www.ctad-alzheimer.com](http://www.ctad-alzheimer.com)

Email: [ctad@ant-congres.com](mailto:ctad@ant-congres.com)





# SUMMARY

Editorial	3
Organizing & Scientific Committees	4
Lifetime Achievement Award	5
Keynotes	6
Program at a glance	9
Onsite Program	
Tuesday, November 29	10
Wednesday, November 30	11
Thursday, December 1	14
Friday, December 2	18
Poster presentations	23

# Editorial

Dear colleagues,

The field of Alzheimer's disease diagnostics and therapeutics has become one of the most exciting areas in all of medical research. The Clinical Trials on Alzheimer's Disease (CTAD) meeting, being held this **November 29-December 2, 2022**, promises to continue the excitement!

Why is our field so exciting? Rapid progress in our field has resulted from huge investments by governments into basic science research, followed by more recent huge investments by the private sector into diagnostic, biotech, and pharmaceutical companies. It has only been 15 years since molecular imaging with amyloid PET scans first demonstrated the ability to detect Alzheimer's disease pathology in living people. Now, amyloid PET is widely available, tau PET is being employed by many clinical trials, and very recently blood tests for Alzheimer's disease have shown great promise for screening, and even for diagnosis.

But, without question there is growing evidence that monoclonal antibodies, which remove amyloid plaque, appear to slow cognitive decline. Unfortunately, these treatments are also associated with ARIA, including brain swelling and bleeding in the brain. There is considerable controversy concerning the significance and impact of these findings, including whether or not governments and medical insurance will provide financial coverage for such treatments.

These issues will be at the center of the CTAD meeting being held in San Francisco this Fall. Experts from academics and industry will be attending, presenting their data and discussing the pros and cons of various controversial topics. In addition to the formal program there will be extensive networking and discussions around the poster sessions, coffee breaks, formal receptions, and in the hallways.

San Francisco is an especially beautiful city, surrounded by the Pacific Ocean and the San Francisco Bay. Golden Gate Park, and the Presidio are huge parks filled with trees, flowers and historical sites. We have three internationally famous universities, the worlds' largest biotech hub just south of the city, and Silicon Valley further south. Don't forget to include some vacation time and consider visiting the Muir Woods, the Napa Valley, and Carmel/Big Sur to the south.

I'm looking forward to seeing old friends, and making new ones at the CTAD meeting this Fall in beautiful San Francisco.

Dr. Mike Weiner  
President of the CTAD22 Scientific Committee





## President of the CTAD22 Scientific Committee

Michael W. WEINER, MD  
University of California at San Francisco (UCSF)

## Organizing and Scientific Committees

Susan ABUSHAKRA (San Francisco, USA); Paul AISEN\* (San Diego, USA); Rebecca E. AMARIGLIO (Boston, USA); Randall J. BATEMAN (St. Louis, USA); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, USA); Maria CARRILLO (Chicago, USA); Suzanne CRAFT (Winston-Salem, USA); Steven DEKOSKY (Miami, USA); Michael C. DONOHUE (San Diego, USA); Rachele DOODY (Basel, Switzerland); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, USA); Howard FELDMAN (San Diego, USA); Nick FOX (London, UK); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Michael GRUNDMANN (San Diego, USA); Harald HAMPEL (Nutley, USA); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Homburg, Germany); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, USA); Zaven KHACHATURIAN (Washington DC, USA); Yan LI (St. Louis, USA); Jorge J. LLIBRE GUERRA (St. Louis, USA); Constantine G. LYKETSOS (Baltimore, USA); Gad A. MARSHALL (Boston, USA); Lefkos T. MIDDLETON (London, UK); José Luis MOLINUEVO (Barcelona, Spain); Ronald PETERSEN (Minnesota, USA); Michael S. RAFII (San Diego, USA); Rema RAMAN (San Diego, USA); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, USA); Marwan SABBAGH (Las Vegas, USA); Stephen SALLOWAY (Providence, USA); Rachel SCHINDLER (New York, USA); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, USA); Eric SIEMERS (Philadelphia, USA); Yong SHEN (Heife, China); Jiong SHI (Las Vegas, USA); Reisa SPERLING (Boston, USA); Yaakov STERN (New York, USA); Jacques TOUCHON\* (Montpellier, France); Christopher H. VAN DYCK (New Haven, USA); Bruno VELLAS\* (Toulouse, France); Michael W. WEINER\* (San Francisco, USA); Bengt WINBLAD (Stockholm, Sweden); Jin-Tai YU (Shanghai, China)

\* Organizing Committee Member

# CTAD 2022 Lifetime Achievement Award

This year the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research is awarded to Reisa Sperling MD, Ph.D. and Keith Johnson, MD, in recognition for their outstanding contributions to the advancement of AD clinical trials research.



## Reisa SPERLING MD

Professor of Neurology at Harvard Medical School and Director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital, Boston, MA (USA)

Dr. Reisa Sperling is a neurologist focused on the detection and treatment of Alzheimer's disease (AD) at the pre-symptomatic or "preclinical" stage of AD. Dr. Sperling is a Professor in Neurology at Harvard Medical School, and Director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital and Massachusetts General Hospital. Dr. Sperling is the co-Principal Investigator of the Harvard Aging Brain Study, and the NIH funded Alzheimer's Clinical Trial Consortium (ACTC). She co-leads the Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease (A4) Study, and recently launched two new prevention trials in the AHEAD 3-45 Study with the ACTC.



## Keith JOHNSON MD

Professor of Radiology and Neurology at Harvard Medical School and Director of Molecular Neuroimaging in the Division of Nuclear Medicine and Molecular Imaging at the Massachusetts General Hospital, Boston, MA (USA)

Dr. Johnson is a Professor of Radiology and Neurology at the Harvard Medical School. He is also an Associate Radiologist and the Director of Molecular Neuroimaging in the Division of Nuclear Medicine and Molecular Imaging at the Massachusetts General Hospital (MGH). He also serves as an associate physician and staff neurologist in the Memory Disorders Unit at the Brigham and Women's Hospital as well as a Clinical Associate in Neurology at the MGH. He is co-director of the Neuroimaging Program of the Massachusetts Alzheimer's Disease Research Center and its Dominantly Inherited Alzheimer Network (DIAN) research initiatives. He oversees the Clinical Brain Positron Emission Tomography (PET) Service at the MGH and also practices as a neurologist that specializes in neurodegenerative disorders. Dr. Johnson also maintains an Internet teaching atlas of neuroimaging known as the Whole Brain Atlas. His major research interests include the early diagnosis and treatment monitoring of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and dementia with Lewy bodies.

# Keynotes



## “The Current and Future State of AD plasma biomarkers”

**Kaj Blennow, MD, PhD**

Academic Chair in Clinical Neurochemistry, University of Gothenburg, Head of the Clinical Neurochemistry Lab, Sahlgrenska University Hospital, Gothenburg, Sweden

Kaj Blennow is Professor and Academic Chair in Clinical Neurochemistry at University of Gothenburg, and Head of the Clinical Neurochemistry Lab at Sahlgrenska University Hospital, Gothenburg, Sweden. His main research interest is CSF and blood biomarkers for Alzheimer’s disease (AD) and other brain disorders, and the application of these to increase the understanding of AD pathophysiology, as well as for screening, diagnostics and in therapy monitoring in clinical trials. Dr. Blennow has published more than 1700 original research papers and review articles in peer-reviewed journals, with more than 110.000 citations, and he has an H-index of 151. He is President of the Society for CSF analysis and Clinical Neurochemistry and head of the Alzheimer’s Association QC program for CSF and blood biomarkers.



## “Targeting Immuno-Metabolic Pathways in Alzheimer’s Disease: Novel Mechanisms and Therapeutic Opportunities”

**Suzanne Craft, PhD**

Professor in Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, NC (USA)

Dr. Suzanne Craft received her Ph.D. from the University of Texas at Austin, and then completed fellowships at Boston University and Harvard Medical School. She has been a faculty member at Washington University in St. Louis and at the University of Washington. In 2012, she joined the faculty at Wake Forest School of Medicine, where she is Professor of Medicine, and Founding Director of the National Institute on Aging-funded Wake Forest Alzheimer’s Disease Research Center. Dr. Craft has served as a member of the Alzheimer’s Association Medical and Scientific Advisory Group, the NIA Board of Scientific Counselors, and the Executive Committee of the Alzheimer’s Clinical Trial Consortium. Dr. Craft’s research program investigates the role of metabolic disorders in the development of Alzheimer’s disease, through translational studies and innovative clinical trials of pharmacologic and dietary intervention to treat or prevent Alzheimer’s disease. She led a ground-breaking multi-site trial of intranasal insulin for the treatment of Alzheimer’s disease that was funded by the National Alzheimer’s Project Act. She has received a prestigious Zenith Award from the Alzheimer’s Association and a National Institute of Health MERIT award for research excellence. Her work has been featured in HBO’s Emmy-award winning series “The Alzheimer’s Project: Momentum in Science”, in the New York Times and Time magazine, as well as on BBC Newshour, and PBS Newshour.

# Keynotes



## “Precision Prevention of Dementia and Alzheimer’s Disease: Advancing Multidomain Interventions”

**Miia Kivipelto, MD, PhD**

Professor in Clinical Geriatrics at Karolinska Institutet, Center for Alzheimer Research, and Director of Research and Development at Karolinska University Hospital, Stockholm (Sweden)

Miia Kivipelto is Professor in Clinical Geriatrics at Karolinska Institutet (KI), Center for Alzheimer Research and senior geriatrician and Director of Research & Development at Theme Aging and Inflammation and Medical Unit Aging at Karolinska University Hospital, Stockholm, Sweden. Part of her Nordic Brain Network multidisciplinary research team (around 100 researchers and clinical staff) is located at University of Eastern Finland and Imperial College London, UK, where she has part time position as Professor. Her frontline research findings have been published in leading journals (340+ publications, H-index 78) and she has received numerous prestigious awards. Dr. Kivipelto’s translational research focuses on the prevention, early diagnosis and treatment of cognitive impairment, dementia and Alzheimer’s disease (AD). Through epidemiological studies, Prof. Kivipelto has identified various lifestyle and vascular risk factors for dementia and interactions with genetic factors and clarified underlying mechanisms. She is the PI of the landmark FINGER trial and founder and scientific leader of World-Wide FINGERS network. Professor Kivipelto is often invited to leading global dementia conferences and task forces.



## “Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer’s Disease”

**Roger Nitsch, MD**

CEO and President Neurimmune, Schlieren (Switzerland)

Roger Nitsch serves as CEO and President of Neurimmune, which he founded in 2006 with two business partners. A neuroscientist with a background in medicine, Roger is recognized as an opinion leader in neurodegenerative diseases with over 30 years of experience in Alzheimer’s disease research. He is a Potamkin Prize winner and Member of the German Academy of Sciences and served as a founding director of the Institute for Regenerative Medicine (IREM), University of Zurich. Roger holds an MD degree from the University of Heidelberg and earned his post-doctoral qualification at the Massachusetts Institute of Technology and Harvard Medical School.

A large audience is seated in a conference hall, facing a stage. Two large presentation screens are visible on the stage, displaying a slide titled "High dose regimen: Individual-level dosing". The audience is diverse in age and appearance, and many are looking towards the stage. The room has a high ceiling with exposed lighting rigs and speakers. The overall atmosphere is professional and focused.

**ONSITE  
PROGRAM**  
in San Francisco  
Available via livestream  
on the CTAD22  
digital platform



# Program at a glance

## ● Tuesday, NOVEMBER 29

- 4.00 p.m. Opening Ceremony and CTAD Lifetime Achievement Award
- 4.30 p.m. **KEYNOTE 1:** Targeting Immuno-Metabolic Pathways in Alzheimer's Disease: Novel Mechanisms and Therapeutic Opportunities
- 4.50 p.m. **Clarity AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating Lecanemab in Early Alzheimer's Disease**
- 6.30 p.m. CTAD Welcome Reception with the support of the Alzheimer's Association 

## ● Wednesday, NOVEMBER 30

- 8.00 a.m. Welcome coffee - Poster Walking Tour
- 9.00 a.m. **KEYNOTE 2:** Precision Prevention of Dementia and Alzheimer's Disease: Advancing Multidomain Interventions
- 9.20 a.m. **SYMPOSIUM 1:** CTAD 2022 fluid biomarker symposium: Recent advances in plasma and CSF Alzheimer biomarkers to improve clinical practice and trials
- 10.00 a.m. Coffee break and poster session
- 10.30 a.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 11.00 a.m. **ORAL COMMUNICATIONS**
- 12.15 p.m. Lunch and poster sessions
- 1.20 p.m. **SYMPOSIUM 2:** Decentralization Approaches for Clinical Trials on Alzheimer's Disease
- 2.00 p.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** New Insights for Amyloid and Tau PET Imaging
- 3.00 p.m. **LATE BREAKING COMMUNICATIONS**
- 3.45 p.m. Coffee break and poster session
- 4.15 p.m. **Topline Results of Phase III GRADUATE I & II Pivotal Trials with Subcutaneous Gantenerumab**

## ● Thursday, DECEMBER 1

- 8.00 a.m. Welcome coffee - Poster Walking Tour
- 9.00 a.m. **KEYNOTE 3:** The Current and Future State of AD plasma biomarkers
- 9.20 a.m. CTAD open discussion: Anti Amyloid Phase 3 results
- 9.50 a.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** Beyond Amyloid and Tau: Emerging solutions
- 10.55 a.m. Coffee break and poster session
- 11.20 a.m. **Tackling Agitation in Alzheimer's Dementia: Brexpiprazole phase III trial results**
- 12.00 p.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 12.30 p.m. Lunch and poster sessions
- 1.30 p.m. **ORAL COMMUNICATIONS**
- 2.30 p.m. **ROUNDTABLE 1:** Investments in Innovation: Advancing the Path Forward to New Alzheimer's Treatments
- 3.00 p.m. **ORAL COMMUNICATIONS**
- 4.00 p.m. Coffee break and poster session
- 4.30 p.m. **LATE BREAKING ORAL COMMUNICATIONS**

## ● Friday, DECEMBER 2

- 8.00 a.m. Welcome coffee - Poster Walking Tour
- 9.00 a.m. **KEYNOTE 4:** Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer's Disease
- 9.20 a.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 10.20 a.m. Coffee break and poster session
- 10.45 a.m. **ROUNDTABLE 2:** The Alzheimer's disease Patient Pathway from a sex and gender lens
- 11.15 a.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** Interim or preliminary data and study design
- 12.05 p.m. Lunch and poster sessions
- 1.05 p.m. **ORAL COMMUNICATIONS**
- 1.35 a.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** Clinical Trials Phase 1 Results
- 2.05 p.m. **ORAL COMMUNICATIONS**
- 3.05 p.m. Coffee break and poster session
- 3.35 p.m. **LATE BREAKING ORAL COMMUNICATION**
- 3.50 p.m. **ORAL COMMUNICATIONS**

# ● Tuesday, NOVEMBER 29

4.00 p.m

## Opening Ceremony

Mike Weiner, UCSF, San Francisco, CA (USA), Jacques Touchon, Montpellier University, Montpellier (France), Paul Aisen, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA (USA), Bruno Vellas, Gerontopole, Toulouse University, Toulouse (France)

## CTAD Lifetime Achievement Award Alzheimer's Disease Therapeutic Research

Presented to Reisa Sperling MD, and Keith Johnson, MD, in recognition for their outstanding contributions to the advancement of AD clinical trials research

Introduction by Paul Aisen, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA (USA).

4.30 p.m

## KEYNOTE 1

Targeting Immuno-Metabolic Pathways in Alzheimer's Disease: Novel Mechanisms and Therapeutic Opportunities

Suzanne Craft, Wake Forest University School of Medicine, Winston-Salem, NC (USA)

4.50 p.m

## Clarity AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating Lecanemab in Early Alzheimer's Disease

Chairman: Takeshi Iwatsubo, University of Tokyo - Tokyo (Japan)

Presentation 1: Clarity AD: Clinical Trial Background and Study Design Overview

Michael Irizarry, Eisai Inc. - Nutley, NJ (United States)

Presentation 2: Lecanemab for the Treatment of Early Alzheimer's Disease: Topline Efficacy Results from Clarity AD

Christopher van Dyck, Yale School of Medicine - New Haven, CT (United States)

Presentation 3: Safety Profile of Lecanemab in Early Alzheimer's Disease

Marwan Sabbagh, Barrow Neurological Institute - Phoenix, AZ (United States)

Presentation 4: Imaging, Plasma, and CSF Biomarkers Assessments from Clarity AD

Randall Bateman, Washington University - St. Louis, MO (United States)

Presentation 5: Context of Clarity AD Results

Sharon Cohen, Toronto Memory Program - Toronto, Ontario (Canada)

Panel Discussion and Q&A

6.05 p.m

## End of the Conference Day

6.30 p.m

CTAD Welcome Reception with the support of the Alzheimer's Association



# ● Wednesday, NOVEMBER 30



- 08.00 a.m. Welcome coffee - **NEW this year at CTAD > Poster Walking Tour** 
- 9.00 a.m. **KEYNOTE 2**  
**Precision Prevention of Dementia and Alzheimer's Disease: Advancing Multidomain Interventions**  
Miia Kivipelto, Karolinska Institutet, Center for Alzheimer Research, Karolinska University Hospital, Stockholm (Sweden)
- 9.20 a.m. **SYMPOSIUM 1**  
**CTAD 2022 fluid biomarker symposium: Recent advances in plasma and CSF Alzheimer biomarkers to improve clinical practice and trials**  
Chair: Kaj Blennow, University of Gothenburg, Gothenburg (Sweden)
- Presentation 1: Relationship between blood plasma and CSF measures of A $\beta$  42/40, tau, and NFL species for tracking drug effects in clinical trials of Alzheimer's disease  
Randall J. Bateman, Washington University School of Medicine, St. Louis, MO (USA)
- Presentation 2: Consideration and use of AT(N) blood-based biomarkers for community screening  
Michelle M. Mielke, Wake Forest University School of Medicine, Winston-Salem, NC (USA)
- Presentation 3: Implementation of plasma biomarkers into clinical practice and trials  
Oskar Hansson, Lund University, Lund (Sweden)
- 10.00 a.m. Coffee break and poster session 
- 10.30 a.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 10.30 a.m. **LB1 - Tau PET associated with plasma p-tau217 and cognitive testing in preclinical AD: Screening data from the AHEAD Study A3 and A45 Trials**  
Keith Johnson<sup>1</sup>, Aaron Schultz<sup>1</sup>, Robert Rissman<sup>2</sup>, Oliver Langford<sup>2</sup>, Emma Thibault<sup>1</sup>, Matthew Meyer<sup>3</sup>, Kristopher Kirmess<sup>3</sup>, Michael Irizarry<sup>4</sup>, Jin Zhou<sup>4</sup>, Michael Donohue<sup>2</sup>, Rema Raman<sup>2</sup>, Paul Aisen<sup>2</sup>, Reisa Sperling<sup>5,1</sup>, Ahead 3-45 Study Team<sup>6</sup>  
<sup>1</sup>Massachusetts General Hospital - Boston (United States), <sup>2</sup>University of Southern California - San Diego (United States), <sup>3</sup>C2N Diagnostics - St. Louis (United States), <sup>4</sup>Eisai - Nutley (United States), <sup>5</sup>Brigham and Women's Hospital - Boston (United States), <sup>6</sup>ACTC - Many Sites (United States)
- 10.45 a.m. **LB2 - Plasma levels of Abeta42/40 and p-tau217 ratios increase accuracy of amyloid PET prediction in preclinical AD**  
Robert Rissman<sup>1,2</sup>, Oliver Langford<sup>2</sup>, Michael Donohue<sup>2</sup>, Rema Raman<sup>2</sup>, Sara Abdel-Latif<sup>2</sup>, Matthew Meyer<sup>3</sup>, Kristopher Kirmess<sup>3</sup>, Joel Braunstein<sup>3</sup>, Michael Irizarry<sup>4</sup>, Keith Johnson<sup>5</sup>, Paul Aisen<sup>2</sup>, Reisa Sperling<sup>6</sup>, Team Ahead 3-45 Study<sup>7</sup>  
<sup>1</sup>UC San Diego - La Jolla, Ca (United States), <sup>2</sup>University of Southern California - San Diego, Ca (United States), <sup>3</sup>C2N Diagnostics - St. Louis, Mo (United States), <sup>4</sup>Eisai - Indianapolis, In (United States), <sup>5</sup>Massachusetts General Hospital, Harvard University - Boston, Ma (United States), <sup>6</sup>Brigham and Woman's Hospital, Harvard - Boston, Ma (United States), <sup>7</sup>ACTC - San Diego, Ca (United States)
- 11.00 a.m. **ORAL COMMUNICATIONS**
- 11.00 a.m. **OC1 - ACI-35.030 and JACI-35.064, two novel anti-phospho-Tau vaccines for the treatment of Alzheimer's Disease: Interim Phase 1b/2a data on safety, tolerability and immunogenicity**  
Johannes Streffer<sup>1,2</sup>, Julien Mermoud<sup>1</sup>, Olivier Sol<sup>1</sup>, Marija Vukicevic<sup>1</sup>, Emma Fiorini<sup>1</sup>, Eva Gollwitzer<sup>1</sup>, Valérie Hliva<sup>1</sup>, David Hickman<sup>1</sup>, Julian Gray<sup>1</sup>, Piergiorgio Donati<sup>1</sup>, Maria Pilar Lopez Deber<sup>1</sup>, Julien Rongère<sup>1</sup>, Andrea Pfeifer<sup>1</sup>, Marie Kosco-Vilbois<sup>1</sup>, Philip Scheltens<sup>3</sup>  
<sup>1</sup>AC Immune SA - Lausanne (Switzerland), <sup>2</sup>University of Antwerp - Antwerp (Belgium), <sup>3</sup>VUMC - Amsterdam (The Netherlands)
- 11.15 a.m. **OC2 - Results of a Phase 2/3 Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Study to Evaluate the Efficacy and Safety of 12 Week Treatment with the Phosphodiesterase 9 (PDE9) inhibitor Irsenontrine (E2027) in Subjects With Dementia With Lewy Bodies**  
Michael Irizarry<sup>1</sup>, Robert Lai<sup>2</sup>, Steven Hersch<sup>1</sup>, Kate Pinner<sup>2</sup>, Shobha Dhadda<sup>1</sup>, Lynn Kramer<sup>1</sup>  
<sup>1</sup>Eisai Inc. - Nutley (United States), <sup>2</sup>Eisai Ltd. - Hattfield (United Kingdom)

# ● Wednesday, NOVEMBER 30

- 11.30 a.m. **OC3 - HMTM Topline Results of Phase 3 LUCIDITY – The First Tau Aggregation Inhibitor**  
Bjoern Schelter<sup>1,2</sup>  
<sup>1</sup>TauRx Therapeutics Ltd - Aberdeen (United Kingdom), <sup>2</sup>University of Aberdeen - Aberdeen (United Kingdom)
- 11.45 a.m. **OC4 - Janssen Simoa Plasma p217+tau assay as a precision prescreening tool in Autonomy Ph2 anti-tau monoclonal Ab trial in early Alzheimer's Disease**  
Gallen Triana-Baltzer<sup>1</sup>, Ziad Saad <sup>1</sup>, Setareh Moughadam <sup>1</sup>, Randy Slemmon <sup>1</sup>, Mary Quiceno <sup>1</sup>, David Henley <sup>1</sup>, Hartmuth Kolb <sup>1</sup>  
<sup>1</sup>Janssen Research & Development - San Diego (United States)
- 12.00 p.m. **OC5 - Long term and economic outcomes for mirtazapine and carbamazepine versus placebo: new data from the SYMBAD RCT**  
Sube Banerjee On Behalf Of The Symbad Group <sup>1</sup>  
<sup>1</sup>University Of Plymouth - Plymouth (United Kingdom)
- 12.15 p.m. Lunch break and poster session
- 1.20 p.m. **SYMPOSIUM 2**  
**Decentralization Approaches for Clinical Trials on Alzheimer's Disease**  
Chair: Holly Massett, National Institute on Aging – Bethesda, MD (United States)
- Presentation 1: Remote assessments in a follow-on study from TRAILBLAZER-ALZ  
Jessica Langbaum, Banner Alzheimer's Institute - Phoenix, AZ (United States)
- Presentation 2: Effects of supervision on cognitive and functional assessment outcomes  
Paul Maruff, CogState - Melbourne (Australia)
- Presentation 3: Decentralization approaches in TRAILBLAZER-ALZ 3  
Roy Yaari, Eli Lilly and Company - Indianapolis, IN (United States)
- Presentation 4: Investigator experience in a decentralized clinical trial on Alzheimer's Disease  
Ralph Lee, Irvine Clinical Research - Irvine, CA (United States)
- 2.00 p.m. **ORAL COMMUNICATIONS' FOCUS SESSION: New Insights for Amyloid and Tau PET Imaging**
- 2.00 p.m. **OC6 - Combination of regional flortaucipir quantification and event-based modeling in clinical trial analyses**  
Ixavier Higgins<sup>1</sup>, Amanda Morris <sup>1</sup>, John Sims <sup>1</sup>, Mark Mintun <sup>1</sup>, Sergey Shcherbinin <sup>1</sup>  
<sup>1</sup>Eli Lilly and Company - Indianapolis (United States)
- 2.10 p.m. **OC7 - Longitudinal Tau PET increase is highest in brain regions with strongest functional connectivity to regions with most NFT at Baseline: An independent validation**  
Ziad S. Saad<sup>1</sup>, Ritobrato Datta <sup>1</sup>, Christopher Rowe <sup>2</sup>, Hartmuth C. Kolb <sup>1</sup>  
<sup>1</sup>Janssen R&D, Johnson & Johnson - San Diego (United States), <sup>2</sup>Austin Health and University of Melbourne - Melbourne (Australia)
- 2.20 p.m. **OC8 - Individualised tau-PET measures might be superior to group level measures when determining change in tau deposition over time in Alzheimer's disease**  
Antoine Leuzy<sup>1</sup>, Alexa Pichet-Binette <sup>1</sup>, Jacob W. Vogel <sup>2</sup>, Gregory Klein <sup>3</sup>, Edilio Borroni <sup>3</sup>, Matteo Tonietto <sup>3</sup>, Olof Strandberg <sup>1</sup>, Niklas Mattsson-Carlgrén <sup>1</sup>, Sebastian Palmqvist <sup>1</sup>, Erik Stomrud <sup>1</sup>, Rik Ossenkoppele <sup>1</sup>, Ruben Smith <sup>1</sup>, Oskar Hansson <sup>1</sup>  
<sup>1</sup>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund (Sweden), <sup>2</sup>Penn/CHOP Lifespan Brain Institute, University of Pennsylvania, Philadelphia (United States), <sup>3</sup>F. Hoffmann-La Roche Ltd, Basel (Switzerland)

# ● Wednesday, NOVEMBER 30



2.30 p.m. **OC9 - Prevalence and longitudinal clinical outcomes of visually 18F-flortaucipir PET-positive individuals across the Alzheimer's disease spectrum**

Alexis Moscoso<sup>1</sup>, Fiona Heeman<sup>1</sup>, Valle Camacho<sup>2</sup>, Martijn Van Essen<sup>3</sup>, Michel J Grothe<sup>4</sup>, Li Lin<sup>5</sup>, Ismini Mainta<sup>6</sup>, Federica Ribaldi<sup>7</sup>, Michael D Devous<sup>8</sup>, Michael J Pontecorvo<sup>8</sup>, Giovanni B Frisoni<sup>7</sup>, Valentina Garibotto<sup>7</sup>, Michael Schöll<sup>1</sup>  
<sup>1</sup>Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg - Gothenburg (Sweden), <sup>2</sup>Department of Nuclear Medicine, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. - Barcelona (Spain), <sup>3</sup>Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden. - Gothenburg (Sweden), <sup>4</sup>Movement Disorders Group, Institute of Biomedicine of Seville-IBiS, Seville, Spain. - Sevilla (Spain), <sup>5</sup>Department of radiology, the third affiliated hospital of sun yat-sen university. - Guangzhou (China), <sup>6</sup>Division of Nuclear Medicine, Geneva University Hospitals, Geneva, Switzerland. - Genève (Switzerland), <sup>7</sup>Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland - Genève (Switzerland), <sup>8</sup>Avid Radiopharmaceuticals, Philadelphia, PA, USA - Philadelphia (United States)

2.40 p.m. **OC10 - Concordance of Visual and Quantitative Analysis for Amyloid PET Imaging With Three 18F Tracers in the CHARIOT-PRO Substudy**

Gerald Novak<sup>1</sup>, Ziad Saad<sup>2</sup>, David Scott<sup>3</sup>, Chi Udeh-Momoh<sup>4</sup>, Luc Bracoud<sup>5</sup>, Craig Ritchie<sup>6</sup>, Lefkos Middleton<sup>7</sup>  
<sup>1</sup>Janssen R&D - Titusville, Nj (United States), <sup>2</sup>Janssen R&D - La Jolla, Ca (United States), <sup>3</sup>Clario (formerly Bioclinica) - San Mateo, Ca (United States), <sup>4</sup>Imperial College - London (United Kingdom), <sup>5</sup>Clario (formerly Bioclinica) - Lyon (France), <sup>6</sup>University of edinburgh - Edinburgh (United Kingdom), <sup>7</sup>Imperial College - Edinburgh (United Kingdom)

2.50 p.m. **OC11 - Amyloid IQ quantification strongly agrees with both histopathology and visual reads across multiple amyloid tracers**

Alex Whittington<sup>1</sup>, Santiago Bullich<sup>2</sup>, Lily Porat<sup>1</sup>, Roger Gunn<sup>1</sup>  
<sup>1</sup>Invicro - London (United Kingdom), <sup>2</sup>Life Molecular Imaging - Berlin (Germany)

## 3.00 p.m. LATE BREAKING ORAL COMMUNICATIONS

3.00 p.m. **LB3 - TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer's disease**

Stephen Salloway<sup>1</sup>, Elly Lee<sup>2</sup>, Michelle Papka<sup>3</sup>, Andrew Pain<sup>4</sup>, Ena Oru<sup>4</sup>, Margaret B. Ferguson<sup>4</sup>, Hong Wang<sup>4</sup>, Michael Case<sup>4</sup>, Ming Lu<sup>4</sup>, Emily C. Collins<sup>4</sup>, Dawn Brooks<sup>4</sup>, John Sims<sup>4</sup>  
<sup>1</sup>Department of Neurology and Department of Psychiatry, Alpert Medical School of Brown University, Providence, RI, USA; Butler Hospital - Providence (United States), <sup>2</sup>Irvine Clinical Research - Irvine (United States), <sup>3</sup>The Cognitive and Research Center of New Jersey LLC - Springfield (United States), <sup>4</sup>Eli Lilly and Company - Indianapolis (United States)

3.15 p.m. **LB4 - CSF MTBR-tau243 is a non-amyloid specific biomarker of neurofibrillary tangles of Alzheimer's disease**

Kanta Horie<sup>1,2</sup>, Gemma Salvadó<sup>3</sup>, Nicolas Barthélemy<sup>1</sup>, Yan Li<sup>1</sup>, Benjamin Saef<sup>1</sup>, Charlie Chen<sup>1</sup>, Hong Jiang<sup>1</sup>, Brian Gordon<sup>1</sup>, Tammie Benzinger<sup>1</sup>, David Holtzman<sup>1</sup>, Suzanne Schindler<sup>1</sup>, Oskar Hansson<sup>3,4</sup>, Randall Bateman<sup>1</sup>  
<sup>1</sup>Washington University School of Medicine - St. Louis (United States), <sup>2</sup>Eisai Inc. - Nutley (United States), <sup>3</sup>Lund University - Lund (Sweden), <sup>4</sup>Skåne University Hospital - Malmö (Sweden)

3.30 p.m. **LB5 - Top-line Results from the 2-Year Systematic Multi-domain Alzheimer's Risk Reduction Trial (SMARRT)**

Kristine Yaffe<sup>1</sup>, Eric Vittinghoff<sup>1</sup>, Sascha Dublin<sup>2</sup>, Carrie Peltz<sup>1</sup>, Lynn Fleckenstein<sup>2</sup>, Dori Rosenberg<sup>2</sup>, Deborah Barnes<sup>1</sup>, Benjamin Balderson<sup>2</sup>, Eric Larson<sup>3</sup>  
<sup>1</sup>University of California, San Francisco - San Francisco, Ca (United States), <sup>2</sup>Kaiser Permanente Washington Health Research Institute - Seattle, Wa (United States), <sup>3</sup>University of Washington - Seattle, Wa (United States)

3.45 p.m. Coffee break and poster session 

# ● Wednesday, NOVEMBER 30

4.15 p.m

## **Topline Results of Phase III GRADUATE I & II Pivotal Trials with Subcutaneous Gantenerumab**

Chair: Jeffrey F Cummings, Chambers-Grundq Center for Transformative Neuroscience, University of Nevada Las Vegas (UNLV) - Las Vegas, NV (United States)

Presenter: [Randall J Bateman](#), Washington University School of Medicine - Saint Louis, MO, (United States)

Panelists: Rachele S Doody <sup>1,2</sup>, Stephen P Salloway <sup>3</sup> Sandra E Black <sup>4,5</sup>

<sup>1</sup>F. Hoffmann-La Roche Ltd - Basel (Switzerland), <sup>2</sup>Genentech, Inc - South San Francisco, CA, (United States), <sup>3</sup>Butler Hospital and Warren Alpert Medical School of Brown University - Providence, RI, (United States), <sup>4</sup>Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre - Toronto, Ontario (Canada), <sup>5</sup> LC Campbell Cognitive Neurology Research Unit, Dr Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto -Toronto, Ontario (Canada)

5.15 p.m

## **End of the Conference Day**

# Thursday, DECEMBER 1



- 08.00 a.m. Welcome coffee - **NEW this year at CTAD > Poster Walking Tour** 
- 9.00 a.m. **KEYNOTE 3**  
**The Current and Future State of AD plasma biomarkers**  
**Kaj Blennow**, University of Gothenburg, and Sahlgrenska University Hospital - Gothenburg (Sweden)
- 9.20 a.m. **CTAD open discussion: Anti Amyloid Phase 3 results**  
**Maria Carrillo<sup>1</sup>, David Knopman<sup>2</sup>, Lefkos Middleton<sup>3</sup>, Ron Petersen<sup>2</sup>**  
<sup>1</sup> Alzheimer's Association - Chicago, IL (United States), <sup>2</sup> Mayo Clinic - Rochester, MN (United States), <sup>3</sup> Imperial College - London (United Kingdom)
- 9.50 a.m. **ORAL COMMUNICATIONS' FOCUS SESSION: Beyond Amyloid and Tau: Emerging solutions**  
Chair: **Howard Fillit**, Alzheimer's Drug Discovery Foundation, New York, NY (USA)
- 9.55 a.m. **OC12 - Topline Results of EXERT: Can Exercise Protect Against Cognitive Decline in MCI?**  
**Carl Cotman<sup>1</sup>, Howard Feldman<sup>2</sup>, Andrea Lacroix<sup>2</sup>, Aladdin Shadyab<sup>2</sup>, Diane Jacobs<sup>2</sup>, David Salmon<sup>2</sup>, Ron Thomas<sup>2</sup>, Shelia Jin<sup>2</sup>, Judy Pa<sup>2</sup>, Jeffrey Katula<sup>3</sup>, Robert Rissman<sup>4</sup>, James Brewer<sup>2</sup>, Youngkyoo Jung<sup>5</sup>, Jing Zhang<sup>2</sup>, Laura Baker<sup>6</sup>**  
<sup>1</sup>UCI (United States), <sup>2</sup>UCSD (United States), <sup>3</sup>Wake Forest University (United States), <sup>4</sup>USC (United States), <sup>5</sup>UC Davis (United States), <sup>6</sup>Wake Forest University School of Medicine (United States)
- 10.10 a.m. **OC13 - Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (StoMP-AD) – Pilot Study Results on Central Nervous System Penetration and Alzheimer's Disease Biomarkers**  
**Mitzi Gonzales<sup>1</sup>, Valentina Garbarino<sup>1</sup>, Tiffany Kautz<sup>1</sup>, Ronald Petersen<sup>2</sup>, Tamara Tchkonja<sup>2</sup>, James Kirkland<sup>2</sup>, Suzanne Craft<sup>3</sup>, Sudha Seshadri<sup>1</sup>, Nicolas Musi<sup>1</sup>, Miranda Orr<sup>3</sup>**  
<sup>1</sup>UT Health San Antonio - San Antonio (United States), <sup>2</sup>Mayo Clinic - Rochester (United States), <sup>3</sup>Wake Forest School Of Medicine - Winston-Salem (United States)
- 10.25 a.m. **OC14 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of T2001 in Alzheimer Patients**  
**Ronald Van Der Geest<sup>1</sup>, Anastasia Lili<sup>1</sup>, Oscar Van Loosbroek<sup>1</sup>, Andreia Almeida<sup>1</sup>, Marlies Oosthoek<sup>2</sup>, Charlotte Teunissen<sup>2</sup>, Sietske Sikkes<sup>3</sup>, Everard Vijverberg<sup>2</sup>**  
<sup>1</sup>Treeway T2001AD BV - Tilburg (Netherlands), <sup>2</sup>Neurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), <sup>3</sup>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands)
- 10.40 a.m. **OC15 - Protein Biomarkers in Autosomal Dominant Alzheimer's Disease Cerebrospinal Fluid Identify Early Changes in Brain Glucose Metabolism and the Matrisome**  
**Shijia Bian<sup>1</sup>, E. Kathleen Carter<sup>1</sup>, Rafi Haque<sup>1</sup>, Caroline Watson<sup>1</sup>, Brian Gordon<sup>2</sup>, Lingyan Ping<sup>1</sup>, Duc Duong<sup>1</sup>, Michael Epstein<sup>1</sup>, James Lah<sup>1</sup>, Blaine Roberts<sup>1</sup>, Anne Fagan<sup>2</sup>, Nicholas Seyfried<sup>1</sup>, Allan Levey<sup>1</sup>, Erik Johnson<sup>1</sup>**  
<sup>1</sup>Emory University - Atlanta (United States), <sup>2</sup>Washington University - St. Louis (United States)
- 10.55 a.m. Coffee break and poster session 
- 11.20 a.m. **Tackling Agitation in Alzheimer's Dementia: Brexpiprazole phase III trial results**  
**George Grossberg<sup>1</sup>, Daniel Lee<sup>2</sup>, Mary Slomkowski<sup>2</sup>, Nanco Hefting<sup>3</sup>, Dalei Chen<sup>2</sup>, Klaus Larsen<sup>3</sup>, Eva Kohegyi<sup>2</sup>, Mary Hobart<sup>2</sup>, Jeffrey Cummings<sup>4</sup>**  
<sup>1</sup>Department of Psychiatry and Behavioral Neuroscience at Saint Louis University School of Medicine - St. Louis, Missouri (United States), <sup>2</sup>Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), <sup>3</sup>H. Lundbeck A/S - Valby, Copenhagen (Denmark), <sup>4</sup>Chambers-Grundy Center for Transformative Neuroscience at School of Integrated Health Sciences University of Nevada Las Vegas (UNLV) - Las Vegas, Nevada (United States)
- Panel discussion: Mary Sano<sup>1</sup>, Bruno Vellas<sup>2</sup>, Clive Ballard<sup>3</sup>, Alireza Atri<sup>4</sup>**  
<sup>1</sup>Mount Sinai School of Medicine - New York, NY (United States), <sup>2</sup>Toulouse University Hospital - Toulouse (France), <sup>3</sup>University of Exeter Medical School - Exeter (United Kingdom), <sup>4</sup>Banner Sun Health Research Institute - Phoenix, AZ (United States)

# ● Thursday, DECEMBER 1

12.00 p.m

## LATE BREAKING ORAL COMMUNICATIONS

12.00 p.m

### LB6 - Two-year prognostic utility of plasma p217+tau in the Alzheimer continuum

Azadeh Feizpour <sup>1,2</sup>, Vincent Doré <sup>2,3</sup>, James D. Doecke <sup>4</sup>, Ziad S. Saad <sup>5</sup>, Gallen Triana-Baltzer <sup>5</sup>, Natasha Krishnadas <sup>1,2</sup>, Christopher Fowler <sup>1</sup>, Larry Ward <sup>1</sup>, Ralph N. Martins <sup>6,7</sup>, Colin L. Masters <sup>1</sup>, Victor L. Villemagne <sup>2,8</sup>, Jurgen Fripp <sup>4</sup>, Hartmuth C. Kolb <sup>5</sup>, Christopher C. Rowe <sup>2,1,9</sup>

<sup>1</sup>The Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia - Melbourne (Australia), <sup>2</sup>Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia - Melbourne (Australia), <sup>3</sup>The Australian e-Health Research Centre, CSIRO, Melbourne, Victoria, Australia - Melbourne (Australia), <sup>4</sup>The Australian e-Health Research Centre, CSIRO, Brisbane, Queensland, Australia - Brisbane (Australia), <sup>5</sup>Neuroscience Biomarkers, Janssen Research and Development, La Jolla, CA, USA - San Diego (United States), <sup>6</sup>Edith Cowan University - Perth (Australia), <sup>7</sup>McCusker Alzheimer's Research Foundation, Nedlands, - Perth (Australia), <sup>8</sup>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA - Pittsburgh (United States), <sup>9</sup>Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia - Melbourne (Australia)

12.15 p.m

### LB7 - ALZ-NET: Using Real World Evidence to Define the Future of Alzheimer's Treatment and Care

Maria Carrillo <sup>1</sup>, Gil Rabinovici <sup>2</sup>, Michael Rafii <sup>3</sup>

<sup>1</sup>Alzheimer's Association - Chicago (United States), <sup>2</sup>Memory and Aging Center, Departments of Neurology, Radiology & Biomedical Imaging, University of California, San Francisco - San Francisco (United States), <sup>3</sup>Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California - San Diego (United States)

12.30 p.m

Lunch break and poster session

1.30 p.m

## ORAL COMMUNICATIONS

1.30 p.m

### OC16 - Leveraging novel technologies to design and implement more patient focused clinical trials

Dave Miller <sup>1</sup> <sup>1</sup>Unlearn.AI - Berkeley (United States)

1.45 p.m

### OC17 - Amyloid and Tau PET positive cognitively unimpaired individuals: Destined to decline?

Rik Ossenkoppele <sup>1</sup>, Alexa Pichet Binette <sup>1</sup>, Colin Groot <sup>1</sup>, Reisa Sperling <sup>2</sup>, Colin Masters <sup>3</sup>, Wiesje Van Der Flier <sup>4</sup>, William Jagust <sup>5</sup>, Petersen Ronald <sup>6</sup>, Clifford Jack <sup>6</sup>, Oskar Hansson <sup>1</sup>

<sup>1</sup>Lund University - Lund (Sweden), <sup>2</sup>MGH - Boston (United States), <sup>3</sup>The Florey Institute Of Neuroscience And Mental Health Melbourne Victoria Australia - Parkville (Australia), <sup>4</sup>Amsterdam University Medical Center - Amsterdam (Netherlands), <sup>5</sup>UC Berkeley - Berkeley (United States), <sup>6</sup>Mayo Clinic - Rochester (United States)

2.00 p.m

### OC18 - Plasma NT1-tau correlates with age and cognitive decline in two large Down syndrome cohorts

Andrew M. Stern <sup>1</sup>, Kathryn L. Van Pelt <sup>2</sup>, Lei Liu <sup>1</sup>, Amirah K. Anderson <sup>1</sup>, Beth Ostaszewski <sup>1</sup>, Dennis J. Selkoe <sup>1</sup>, Frederick Schmitt <sup>2</sup>, Elizabeth Head <sup>3</sup>

<sup>1</sup>Ann Romney Center For Neurologic Diseases, Brigham And Women's Hospital, Harvard Medical School - Boston, MA (United States), <sup>2</sup>Sanders-Brown Center For Aging, Department Of Neurology, University Of Kentucky - Lexington, KY (United States), <sup>3</sup>Department Of Pathology And Laboratory Medicine, University Of California, Irvine - Irvine, CA (United States)

2.15 p.m

### OC19 - Specific associations between plasma biomarkers and post-mortem amyloid plaque and neurofibrillary tau tangle burden

Gemma Salvadó <sup>1</sup>, Rik Ossenkoppele <sup>1,2</sup>, Nicholas J Ashton <sup>3,4,5</sup>, Thomas G Beach <sup>6</sup>, Geidy E Serrano <sup>6</sup>, Gwendlyn Kollmorgen <sup>7</sup>, Henrik Zetterberg <sup>3,8,9,10</sup>, Shorena Janelidze <sup>1</sup>, Kaj Blennow <sup>3</sup>, Oskar Hansson <sup>1,11</sup>

<sup>1</sup>Clinical Memory Research Unit, Department Of Clinical Sciences, Malmö, Lund University - Lund (Sweden), <sup>2</sup>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center - Amsterdam (Netherlands), <sup>3</sup>Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy, University Of Gothenburg - Gothenburg (Sweden), <sup>4</sup>Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, King's College London - London (United Kingdom), <sup>5</sup>NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley, NHS Foundation - London (United Kingdom), <sup>6</sup>Banner Sun Health Research Institute - Sun City (United States), <sup>7</sup>Roche Diagnostics GmbH - Penzberg (Germany), <sup>8</sup>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), <sup>9</sup>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square - London (United Kingdom), <sup>10</sup>UK Dementia Research Institute at UCL - London (United Kingdom), <sup>11</sup>Memory Clinic, Skåne University Hospital - Malmö (Sweden)



# Thursday, DECEMBER 1



2.30 p.m

## ROUNDTABLE 1

### Investments in Innovation: Advancing the Path Forward to New Alzheimer's Treatments

Chair: Niranjan Bose, *Gates Ventures, Seattle, WA (United States)*

Discussants: Howard Fillit, *Alzheimer's Drug Discovery Foundation (ADDF), New York City, NY (United States)*; Laurence Barker, *Partner in the Dementia Discovery Fund (DDF), London (United Kingdom)*; Philip Scheltens, *LSP Dementia Fund at EQT Life, Alzheimer Centre Amsterdam (University Medical Centre Amsterdam, Amsterdam (The Netherlands))*

3.00 p.m

## ORAL COMMUNICATIONS

3.00 p.m

### OC20 - Systemic inflammation and reduced cerebral A $\beta$ clearance triggered by pancreatic amylin

Florin Despa<sup>1</sup>, Nirmal Verma<sup>1</sup>, Edric Winford<sup>1</sup>, Peter Nelson<sup>1</sup>, Gregory Jicha<sup>1</sup>, Larry Goldstein<sup>1</sup>, Claire Troakes<sup>2</sup>, Henrik Zetterberg<sup>3</sup>, John Hardy<sup>3</sup>, Tammam Lashley<sup>3</sup>

<sup>1</sup>University Of Kentucky - Lexington (United States), <sup>2</sup>King's College London - London (United Kingdom), <sup>3</sup>Dementia Research Institute at UCL - London (United Kingdom)

3.15 p.m

### OC21 - Prazosin for Agitation in Alzheimer's Disease: PEACE-AD

Elaine Peskind<sup>1</sup>, Murray Raskind<sup>2</sup>, Ronald Thomas<sup>3</sup>, Gregory Jicha<sup>4</sup>, Neela Patel<sup>5</sup>, Amy Pierce<sup>6</sup>, Sharon Brangman<sup>7</sup>, Mary Sano<sup>8</sup>, Jeffrey Kaye<sup>6</sup>, Miranda Lim<sup>6</sup>, Michael Au-Yeung<sup>6</sup>, Michelle Herman<sup>9</sup>, Gabriel Leger<sup>9</sup>, Karen Messer<sup>9</sup>, Howard Feldman<sup>9</sup>

<sup>1</sup>VA Northwest Mental Illness Research, Education and Clinical Center (MIRECC), Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine - Seattle (United States), <sup>2</sup>VA Northwest Mental Illness Research, Education and Clinical Center (MIRECC) and Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine - Seattle (United States), <sup>3</sup>Departments of Family Medicine and Neurosciences, University of California San Diego - La Jolla (United States), <sup>4</sup>Department of Neurology, University of Kentucky - Lexington (United States), <sup>5</sup>Department of Family and Community Medicine, UT Health San Antonio - San Antonio (United States), <sup>6</sup>Department of Neurology, OHSU School of Medicine - Portland (United States), <sup>7</sup>Department of Geriatrics, SUNY Upstate Medical University - Syracuse (United States), <sup>8</sup>Department of Psychiatry, Mount Sinai School of Medicine - New York (United States), <sup>9</sup>Department of Neurosciences, University of California San Diego - La Jolla (United States)

3.30 p.m

### OC22 - Demographic Analysis of Industry Sponsored Alzheimer's Disease Trial Populations in the United States

Stephen Peroutka<sup>1</sup> - <sup>1</sup>PPD, Part Of Thermo Fisher Scientific - Carmel, CA (United States)

3.45 p.m

### OC23 - Plasma Biomarker Findings from the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial

Eric M. Reiman<sup>1</sup>, Francisco Lopera<sup>2</sup>, Silvia Rios-Romenets<sup>2</sup>, Courtney Schiffman<sup>3</sup>, Derrek Hibar<sup>3</sup>, Gwendlyn Kollmorgen<sup>4</sup>, Margarita Giraldo<sup>2</sup>, Natalia Acosta<sup>2</sup>, Alejandro Espinosa<sup>2</sup>, Gustavo Villegas<sup>2</sup>, Claudia Muñoz<sup>2</sup>, Laura Serna<sup>2</sup>, Karina Herrera<sup>2</sup>, Yi Su<sup>1</sup>, Robert Alexander<sup>1</sup>

<sup>1</sup>Banner Alzheimer's Institute - Phoenix, Arizona (United States), <sup>2</sup>Neurosciences Group of Antioquia, University of Antioquia - Medellín (Colombia), <sup>3</sup>Genentech, Inc. - South San Francisco, Ca (United States), <sup>4</sup>Roche Diagnostics GmbH - Mannheim (Germany)

4.00 p.m

Coffee break and poster session 

4.30 p.m

## LATE BREAKING ORAL COMMUNICATIONS

4.30 p.m

### LB8 - Top Line Data of ANAVEX®2-73 (blarcamesine) Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2b/3 in Patients with Early Alzheimer's Disease (AD)

Stephen Macfarlane<sup>1</sup>, Timo Grimmer<sup>2</sup>, Terence O'Brien<sup>3</sup>, Edward Hammond<sup>4</sup>, Walter Kaufmann<sup>4</sup>, Emmanuel Fadiran<sup>4</sup>, Christopher Missling<sup>4</sup>

<sup>1</sup>Hammoncare - Melbourne (Australia), <sup>2</sup>THU Munich - Munich (Germany), <sup>3</sup>Monash University, Alfred Health - Melbourne (Australia), <sup>4</sup>Anavex Life Sciences - New York (United States)

4.45 p.m

### LB9 - Higher sensitivity amyloid-PET detection of the earliest focal beta-amyloid accumulation using spatial extent

Michelle E. Farrell<sup>1</sup>, Emma G. Thibault<sup>1</sup>, J. Alex Becker<sup>1</sup>, Julie C. Price<sup>1</sup>, Kuang Gong<sup>1</sup>, Aaron P. Schultz<sup>1</sup>, Michael J Properzi<sup>1</sup>, Rachel F Buckley<sup>1,2</sup>, Heidi I.I. Jacobs<sup>1</sup>, Bernard J. Hanseeuw<sup>1,3</sup>, Reisa A. Sperling<sup>1,2</sup>, Keith A. Johnson<sup>1,2</sup>

<sup>1</sup>Massachusetts General Hospital - Boston, Ma (United States), <sup>2</sup>Brigham & Women's Hospital - Boston, Ma (United States), <sup>3</sup>Cliniques Universitaires Saint-Luc, Université Catholique de Louvain - Brussels (Belgium)

# ● Thursday, DECEMBER 1

5.00 p.m

## LB10 - Sample size estimates for preclinical AD intervention trials based on Wisconsin Registry for Alzheimer's Prevention Longitudinal PET amyloid, plasma P-tau217, and cognitive assessment data

Rebecca Langhough Kosciak<sup>1</sup>, Derek Norton<sup>1</sup>, Tobey Betthausen<sup>1</sup>, Lianlian Du<sup>1</sup>, Erin Jonaitis<sup>1</sup>, Karly Cody<sup>1</sup>, Bruce Hermann<sup>1</sup>, Kimberly Mueller<sup>1</sup>, Rick Chappell<sup>1</sup>, Bradley Christian<sup>1</sup>, Shorena Janelidze<sup>1</sup>, Niklas Mattsson-Carlgren<sup>1</sup>, Oskar Hansson<sup>1</sup>, Sterling Johnson<sup>1</sup>

<sup>1</sup>University of Wisconsin SMPH - Madison (United States)

5.15 p.m

## LB11 - Cerebrospinal Fluid Biomarker Effects From a Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Alzheimer's Disease: Results From the PEGASUS Trial

Steven E. Arnold<sup>1,2</sup>, Newman Knowlton<sup>3</sup>, Victoria J. Williams<sup>4</sup>, Jeffrey M. Burns<sup>5</sup>, Monica Crane<sup>6</sup>, Alison J. Mcmanus<sup>1</sup>, Sanjeev N. Vaishnavi<sup>7</sup>, Zoe Arvanitakis<sup>8</sup>, Judith Neugroschl<sup>9</sup>, Karen Bell<sup>10</sup>, Bianca A. Trombetta<sup>1</sup>, Becky C. Carlyle<sup>11</sup>, Pia Kivisäkk<sup>12,2</sup>, Rudolph E. Tanzi<sup>13,14</sup>, Kent Leslie<sup>15,16</sup>

<sup>1</sup>Department of Neurology, Massachusetts General Hospital, Boston, MA, USA - Boston (United States), <sup>2</sup>Harvard Medical School, Boston, MA, USA - Boston (United States), <sup>3</sup>Pentara Corporation, Millcreek, UT, USA - Millcreek (United States), <sup>4</sup>Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA - Madison (United States), <sup>5</sup>University of Kansas Alzheimer's Disease Center, Kansas City, KS, USA - Kansas City (United States), <sup>6</sup>Genesis Neuroscience Clinic, Knoxville, TN, USA - Knoxville (United States), <sup>7</sup>Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA - Philadelphia (United States), <sup>8</sup>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA - Chicago (United States), <sup>9</sup>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA - New York (United States), <sup>10</sup>Department of Neurology, Columbia University, New York, NY, USA - New York (United States), <sup>11</sup>Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, England, United Kingdom - England (United Kingdom), <sup>12</sup>Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; <sup>2</sup>Harvard Medical School, Boston, MA, USA - Boston (United States), <sup>13</sup>Harvard Medical School, Boston, MA, USA - Boston (United Kingdom), <sup>14</sup>Department of Neurology, Genetics and Aging Research Unit, McCance Center for Brain Health, Massachusetts General Hospital, Harvard University, Boston, MA, USA - Boston (United States), <sup>15</sup>Amylyx Pharmaceuticals, Inc., Cambridge, MA, USA - Cambridge (United States), <sup>16</sup>Present address: Division of Biology and Biological Engineering Graduate Program, California Institute of Technology, Pasadena, CA, USA - Pasadena (United States)

5.30 p.m

## End of the Conference Day

# ● Friday, DECEMBER 2



08.00 a.m Welcome coffee - **NEW this year at CTAD > Poster Walking Tour** 

9.00 a.m **KEYNOTE 4**  
**Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer's Disease**  
Roger Nitsch, *Neurimmune, Schlieren (Switzerland)*

9.20 a.m **LATE BREAKING ORAL COMMUNICATIONS**

9.20 a.m **LB12 - Use of a Blood-Based Biomarker Test Impacts Clinical Decision Making Among Neurologists Evaluating Patients With Symptoms of Cognitive Impairment**  
Joel Braunstein<sup>1</sup>, Mark Monane<sup>1</sup>, Kim Johnson<sup>2</sup>, B. Joy Snider<sup>3</sup>, Raymond Scott<sup>4</sup>, Jonathan Drake<sup>5</sup>, Daniel Jacobs<sup>6</sup>, Julia Ortega<sup>1</sup>, Joni Henderson<sup>1</sup>, Tim West<sup>1</sup>  
<sup>1</sup>C2N Diagnostics - St Louis (United States), <sup>2</sup>Duke University - Durham (United States), <sup>3</sup>Washington University - St Louis (United States), <sup>4</sup>Georgetown University - Washington (United States), <sup>5</sup>Lifespan - Providence (United States), <sup>6</sup>Neurological Services of Orlando - Orlando (United States)

9.35 a.m **LB13 - Phase 1 pharmacokinetic and CNS target engagement properties of the orally administered O-GlcNAcase inhibitor ASN51 in humans**  
Ryan Schubert<sup>1</sup>, Rolf Pokorny<sup>1</sup>, Bruno Permanne<sup>1</sup>, Pearl Fang<sup>1</sup>, Vanessa Teachout<sup>1</sup>, Maud Nény<sup>1</sup>, Solenne Ousson<sup>1</sup>, Jennifer Hantson<sup>1</sup>, Astrid Sand<sup>1</sup>, Ruhi Ahmed<sup>1</sup>, Manfred Schneider<sup>1</sup>, Jean-Francois Stallaert<sup>1</sup>, Anna Quattropani<sup>1</sup>, Eric Yuen<sup>1</sup>, Dirk Beher<sup>1</sup>  
<sup>1</sup>Asceneuron, Lausanne (Switzerland)

9.50 a.m **LB14 - Analysis of 15 software pipelines for validation of [18F]florbetaben PET quantitation**  
Aleksandar Jovalekic<sup>1</sup>, Nuria Roe-Vellve<sup>1</sup>, Norman Koglin<sup>1</sup>, Mariana Lagos Quintana<sup>1</sup>, Aaron Nelson<sup>2</sup>, Markus Diemling<sup>3</sup>, Johan Lilja<sup>3</sup>, Juan Pablo Gomez Gonzalez<sup>4</sup>, Vincent Dore<sup>5</sup>, Pierrick Bourgeat<sup>5</sup>, Alex Whittington<sup>6</sup>, Roger Gunn<sup>6</sup>, Andrew Stephens<sup>1</sup>, Santiago Bullich<sup>1</sup>  
<sup>1</sup>Life Molecular Imaging - Berlin (Germany), <sup>2</sup>MIM Software - Cleveland (United States), <sup>3</sup>Hermes Medical Solutions - Stockholm (Sweden), <sup>4</sup>QuBiotech - A Coruna (Spain), <sup>5</sup>CSIRO - Brisbane (Australia), <sup>6</sup>Invicro - London (United Kingdom)

10.05 a.m **LB15 - Results from a clinical Study of an Anti-Galectin-3 Monoclonal antibody in Patients with Moderate to Severe Alzheimer's Disease**  
Dongxu Sun<sup>1</sup>, George Haig<sup>1</sup>, Suhail Rasool<sup>1</sup>  
<sup>1</sup>Truebinding Inc - Foster City (United States)

10.20 a.m Coffee break and poster session 

10.45 a.m **ROUNDTABLE 2**  
**The Alzheimer's disease Patient Pathway from a sex and gender lens**  
Chair: Frances Catherine Quevenco<sup>1,2</sup>  
Discussants: Maria Carmela Tartaglia<sup>3</sup>, Heather Snyder<sup>4</sup>, Phyllis Ferrell<sup>5</sup>, Pernille Poulsen<sup>6</sup>, Antonella Santuccioni Chadha<sup>7,2</sup>  
<sup>1</sup>Roche (Switzerland), <sup>2</sup>Women's Brain Project (Switzerland), <sup>3</sup>University Of Toronto (Canada), <sup>4</sup>Alzheimer's Association (United States), <sup>5</sup>Eli Lilly (United States), <sup>6</sup>Novo Nordisk (Denmark), <sup>7</sup>Altoida (United States)

11.15 a.m **ORAL COMMUNICATIONS' FOCUS SESSION: Interim or preliminary data and study design**

11.15 a.m **OC24 - Neuroimaging Data From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias**  
Kaya Jordan<sup>1</sup>, Kennedy Mahdavi<sup>1,2</sup>, Jonathan Haroon<sup>1</sup>, Elisabeth Rindner<sup>1</sup>, Margaret Zielinski<sup>1</sup>, Victoria Venkatraman<sup>1,2</sup>, Sergio Becerra<sup>2</sup>, Dayan Goodenowe<sup>3</sup>, Clarence Ahlem<sup>4</sup>, Christopher Reading<sup>4</sup>, Joseph Palumbo<sup>4</sup>, Bijan Pourat<sup>5</sup>, Sheldon Jordan<sup>1,2</sup>  
<sup>1</sup>The Regenesys Project - Santa Monica (United States), <sup>2</sup>Synaptec Network - Santa Monica (United States), <sup>3</sup>Prodrome Sciences USA LLC - Temecula (United States), <sup>4</sup>Biovie Inc. - Carson City (United States), <sup>5</sup>Pourat MD - Beverly Hills (United States)

# ● Friday, DECEMBER 2

- 11.25 a.m **OC25 – HOPE4MCI Trial Targeting Hippocampal Overactivity for the treatment of Mild Cognitive Impairment due to Alzheimer’s disease with AGB101: Baseline Tau and MRI imaging characteristics**  
Richard Mohs<sup>1</sup>, Sharon Rosenzweig-Lipson<sup>1</sup>, Arnold Bakker<sup>2</sup>, Elizabeth Chang<sup>2</sup>, Nisha Rani<sup>2</sup>, Russell Barton<sup>1</sup>, Michela Gallagher<sup>1,2</sup>  
<sup>1</sup>AgeneBio, Inc - Baltimore (United States), <sup>2</sup>Johns Hopkins University - Baltimore (United States)
- 11.35 a.m **OC26 – Design of the ABCA1 agonist CS6253 Phase 1 SAD and MAD study in male and female, APOE4 and non-APOE4 carriers to assess safety, PK and biomarker efficacy**  
Jan Johansson<sup>1</sup>, Hussein Yassine<sup>2</sup>, Danny Michaelson<sup>3</sup>, Henrik Zetterberg<sup>4</sup>, Jeffrey Cummings<sup>5</sup>, Bengt Winblad<sup>6</sup>  
<sup>1</sup>Artery Therapeutics, Inc. - San Ramon (United States), <sup>2</sup>USC - Los Angeles (United States), <sup>3</sup>Tel Aviv University - Tel Aviv (Israel), <sup>4</sup>U of Gothenburg - Gothenburg (Sweden), <sup>5</sup>U Nevada Las Vegas - Las Vegas (United States), <sup>6</sup>Karolinska Institute - Stockholm (Sweden)
- 11.45 a.m **OC27 – Significant Effects of Oral ALZ-801 on Plasma Biomarkers of Alzheimer’s Disease: 12-Month Interim Analysis of Phase 2 Biomarker Study in APOE4 Carriers with Early AD**  
Susan Abushakra<sup>1</sup>, John Hey<sup>1</sup>, Kaj Blennow<sup>2</sup>, Philip Scheltens<sup>3</sup>, Jakub Hort<sup>4</sup>, Katerina Sheardova<sup>5</sup>, Niels Prins<sup>6</sup>, Sterre Rutgers<sup>6</sup>, Paul Dautzenberg<sup>7</sup>, Ladislav Pazdera<sup>8</sup>, Patrick Kessler<sup>1</sup>, Aidan Power<sup>1</sup>, Martin Tolar<sup>1</sup>  
<sup>1</sup>Alzheon Inc. - Framingham, Ma (United States), <sup>2</sup>Gothenburg University, Institute of Neuroscience & Physiology - Molndal (Sweden), <sup>3</sup>Amsterdam University Medical Center - Amsterdam (Netherlands), <sup>4</sup>Charles University Dept. of Neurology - Prague (Czech Republic), <sup>5</sup>St. Anne University Hospital & International Clinical Research Center - Brno (Czech Republic), <sup>6</sup>Brain Research Center - Amsterdam (Netherlands), <sup>7</sup>Brain Research Center - Den Bosch (Netherlands), <sup>8</sup>Vestra Research Clinic - Rychnov Nad Kněžnou (Czech Republic)
- 11.55 a.m **OC28 – Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease**  
Nicola Spotorno<sup>1</sup>, Olof Strandberg<sup>1</sup>, Geraline Vis<sup>2,3</sup>, Erik Stomrud<sup>1</sup>, Markus Nilsson<sup>2,4</sup>, Oskar Hansson<sup>1</sup>  
<sup>1</sup>Clinical Memory Research Unit, Department Of Clinical Sciences, Lund University - Lund (Sweden), <sup>2</sup>Diagnostic Radiology, Institution For Clinical Sciences, Lund University - Lund (Sweden), <sup>3</sup>Memory Clinic, Skåne University Hospital - Malmö (Sweden), <sup>4</sup>Memory Clinic, Skåne University Hospital - Malmö (Sweden)
- 12.05 p.m Lunch break and poster sessions
- 1.05 p.m **ORAL COMMUNICATIONS**
- 1.05 p.m **OC29 – A brief, automated speech-based screener for mild cognitive impairment to support online recruitment at scale**  
Caroline Skirrow<sup>1</sup>, Jack Weston<sup>1</sup>, Marton Meszaros<sup>1</sup>, Udeepa Meepegama<sup>1</sup>, Emil Fristed<sup>1</sup>  
<sup>1</sup>Novoic - London (United Kingdom)
- 1.20 p.m **OC30 – Aβ-structure as Precise Risk Plasma Biomarker for Future Conversion to Alzheimer’s Disease 17 Years in Advance**  
Klaus Gerwert<sup>1,2</sup>  
<sup>1</sup>Ruhr-University Bochum - Bochum (Germany), <sup>2</sup>Center for Protein Diagnostics (ProDi) - Bochum (Germany)
- 1.35 p.m **ORAL COMMUNICATIONS’ FOCUS SESSION: Clinical Trials Phase 1 Results**
- 1.35 p.m **OC31 – NVG-291 Phase 1 Results and Phase 1b/2a Study Design in Individuals with mild cognitive impairment or mild dementia due to Alzheimer’s disease**  
Daniel Mikol<sup>1</sup>, Judy Toews<sup>1</sup>, Martin Farlow<sup>2</sup>, Bruce Lamb<sup>2</sup>, George Perry<sup>3</sup>, Reisa Sperling<sup>4</sup>, Michael Weiner<sup>5</sup>, Henrik Zetterberg<sup>6</sup>, Jeffrey Cummings<sup>7</sup>  
<sup>1</sup>Nervgen - Vancouver (Canada), <sup>2</sup>Indiana University School Of Medicine - Indianapolis (United States), <sup>3</sup>University Of Texas, San Antonio - San Antonio (United States), <sup>4</sup>Harvard Medical School - Cambridge (United States), <sup>5</sup>University Of California, San Francisco - San Francisco (United States), <sup>6</sup>University Of Gothenburg - Gothenburg (Sweden), <sup>7</sup>University Of Nevada, Las Vegas - Las Vegas (United States)

# ● Friday, DECEMBER 2



- 1.45 p.m **OC32 – Introduction to the Veri-T trial: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Verdiperstat in Patients with svPPA Due to FTLD-TDP**  
Peter Ljubenkov<sup>1</sup>, Adam Staffaroni<sup>1</sup>, Lawren Vandevrede<sup>1</sup>, Julio Rojas-Martinez<sup>1</sup>, Mary Koestler<sup>1</sup>, Anton Porsteinsson<sup>2</sup>, Maria B. Pascual<sup>3</sup>, Joseph Masdeu<sup>3</sup>, Ian Grant<sup>4</sup>, David Irwin<sup>5</sup>, David Knopman<sup>6</sup>, Robert Bowser<sup>7</sup>, Murray Grossman<sup>5</sup>, Irfan Qureshi<sup>8</sup>, Adam Boxer<sup>1</sup>  
<sup>1</sup>UCSF Memory and Aging Center - San Francisco (United States), <sup>2</sup>University of Rochester - Rochester (United States), <sup>3</sup>Houston Methodist - Houston (United States), <sup>4</sup>Northwestern University - Chicago (United States), <sup>5</sup>University of Pennsylvania - Philadelphia (United States), <sup>6</sup>Mayo Clinic Rochester - Rochester (United States), <sup>7</sup>Barrow Neurological Institute - Phoenix (United States), <sup>8</sup>Biohaven Pharmaceuticals - New Haven (United States)
- 1.55 p.m **OC33 – A Phase 1, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Biochemical Efficacy of AAV Gene Therapy (LX1001) in Patients with APOE4 Homozygote Alzheimer’s Disease – Interim Data**  
Michael Kaplitt<sup>1</sup>, Philip Leopold<sup>2</sup>, Evan Noch<sup>3</sup>, Jana Ivanidze<sup>4</sup>, Levi Chazen<sup>4</sup>, Ronald Crystal<sup>2</sup>, Stephen Kaminsky<sup>2</sup>, Haley Bowe<sup>2</sup>, Mei Wang<sup>2</sup>, Douglas Ballon<sup>4</sup>, Jonathan Dyke<sup>4</sup>, Dolan Sondhi<sup>2</sup>, Sam Gandy<sup>5</sup>, Gina Giannantoni-Ibelli<sup>6</sup>, Jay Barth<sup>6</sup>  
<sup>1</sup>Department of Neurological Surgery, Weill Cornell Medical College - New York (United States), <sup>2</sup>Department of Genetic Medicine, Weill Cornell Medical College - New York (United States), <sup>3</sup>Department of Neurology, Weill Cornell Medical College - New York (United States), <sup>4</sup>Department of Radiology, Weill Cornell Medical College - New York (United States), <sup>5</sup>Departments of Neurology and Psychiatry, Icahn School of Medicine at Mt Sinai - New York (United States), <sup>6</sup>LEXEO Therapeutics, Inc. - New York (United States)
- 2.05 p.m **ORAL COMMUNICATIONS**
- 2.05 p.m **OC34 – Preliminary evidence for reliability and validity of the Interpersonal Functioning and Daily Activities Questionnaire (IFDAQ) in the A4/LEARN pre-randomization sample**  
Chris Edgar<sup>1</sup>, Rebecca Amariglio<sup>2</sup>, Jordan Barbone<sup>3</sup>, Julie Chandler<sup>4</sup>, Stephen Coons<sup>5</sup>, Michael Donohue<sup>6</sup>, William Lenderking<sup>7</sup>, Reisa Sperling<sup>8</sup>  
<sup>1</sup>Cogstate - London (United Kingdom), <sup>2</sup>Departments of Neurology, Brigham and Women’s Hospital and Massachusetts General Hospital, Harvard Medical School - Boston (United States), <sup>3</sup>Cogstate - New Haven (United States), <sup>4</sup>Eli Lilly and Company - Indianapolis (United States), <sup>5</sup>Clinical Outcome Assessment Program, Critical Path Institute - Tucson (United States), <sup>6</sup>Alzheimer’s Therapeutic Research Institute, University of Southern California - San Diego (United States), <sup>7</sup>Patient-centered Research, Evidera - Bethesda (United States), <sup>8</sup>Department of Neurology, Brigham and Women’s Hospital - Boston (United States)
- 2.20 p.m **OC35 – APOE-Targeted Epigenome Therapy for Alzheimer’s Disease**  
Boris Kantor<sup>1,2</sup>, Ornit Chiba-Falek<sup>1,3</sup>  
<sup>1</sup>Duke University - Durham (United States), <sup>2</sup>CLAIRGene LLC - Durham (United States), <sup>3</sup>CLAIRGene - Durham (United States)
- 2.35 p.m **OC36 – Confounding factors of Alzheimer’s disease plasma biomarkers and their impact on clinical performance**  
Alexa Pichet Binette<sup>1</sup>, Shorena Janelidze<sup>1</sup>, Nicholas Cullen<sup>1</sup>, Jeffrey L. Dage<sup>2</sup>, Randall J. Bateman<sup>3</sup>, Henrik Zetterberg<sup>4,5</sup>, Kaj Blennow<sup>4</sup>, Erik Stomrud<sup>1</sup>, Niklas Mattsson-Carlgrén<sup>1</sup>, Oskar Hansson<sup>1</sup>  
<sup>1</sup>Clinical Memory Research Unit, Faculty Of Medicine, Lund University - Lund (Sweden), <sup>2</sup>Department Of Neurology, Indiana University School Of Medicine - Indianapolis (United States), <sup>3</sup>Department Of Neurology, Washington University School Of Medicine - St. Louis (United States), <sup>4</sup>Department Of Psychiatry And Neurochemistry, The Sahlgrenska Academy, University Of Gothenburg - Gothenburg (Sweden), <sup>5</sup>UK Dementia Research Institute, University College London - London (United Kingdom)
- 2.50 p.m **OC37 – Aducanumab and lecanemab label insoluble, fibrillar, diffusible Aβ aggregates in aqueous extracts of human Alzheimer disease brain**  
Andrew M. Stern<sup>1</sup>, Angela L. Meunier<sup>1</sup>, Wen Liu<sup>1</sup>, Maria Ericsson<sup>2</sup>, Dennis J. Selkoe<sup>2</sup>  
<sup>1</sup>Ann Romney Center For Neurologic Diseases, Brigham And Women’s Hospital, Harvard Medical School - Boston (United States), <sup>2</sup>Harvard Medical School Electron Microscopy Core - Boston (United States)
- 3.05 p.m Coffee break and poster session 

# ● Friday, DECEMBER 2

3.35 p.m

## LATE BREAKING ORAL COMMUNICATION

3.35 p.m

### LB16 - Phase 1 Preventive Adjuvanted Tau Vaccine, AV-1980R

Lon Schneider<sup>1</sup>, Anahit Ghichikyan<sup>2</sup>, Robert Alexander<sup>3</sup>, Henrik Zetterberg<sup>3</sup>, Eric Reiman<sup>3</sup>, Duygu Tosun<sup>4</sup>, Michael Agadjanyan<sup>2</sup>  
<sup>1</sup>USC - Los Angeles (United States), <sup>2</sup>Institute for Molecular Medicine - Huntington Beach (United States), <sup>3</sup>Banner Alzheimer's Institute - Phoenix (United States), <sup>4</sup>University of California San Francisco - San Francisco (United States)

3.50 p.m

## ORAL COMMUNICATIONS

3.50 p.m

### OC38 - A multimodal clinical and lifestyle intervention induces multiomic systemic effects and improves cognitive outcomes in Alzheimer's disease

Jared C. Roach<sup>1</sup>, Lance E. Edens<sup>1</sup>, Sophiya Rajbhandari<sup>1</sup>, Junko Hara<sup>2</sup>, Jennifer Bramen<sup>3,4</sup>, Molly K. Rapozo<sup>5</sup>, Cory Funk<sup>1</sup>, William R. Shankle<sup>6,7,2,8</sup>, Leroy Hood<sup>1</sup>  
<sup>1</sup>Institute For Systems Biology - Seattle, Washington (United States), <sup>2</sup>Pickup Family Neurosciences Institute, Hoag Memorial Hospital Presbyterian - Newport Beach, California (United States), <sup>3</sup>Pacific Brain Health Center, Pacific Neuroscience Institute - Santa Monica, California (United States), <sup>4</sup>Department of Translational Neurosciences and Neurotherapeutics, Saint John's Cancer Institute - Santa Monica, California (United States), <sup>5</sup>Providence St. Joseph Health - Renton, Washington (United States), <sup>6</sup>Shankle Clinic - Newport Beach, California (United States), <sup>7</sup>Department of Cognitive Sciences, University of California - Irvine, California (United States), <sup>8</sup>EMBIC Corporation - Newport Beach, California (United States)

4.05 p.m

### OC39 - Advantages of next generation SupraAntigen® platform liposomal vaccines to immunize against pathological targets of Alzheimer's disease

Marija Vukicevic<sup>1</sup>, Emma Fiorini<sup>1</sup>, David Hickman<sup>1</sup>, Raket Carpintero<sup>2</sup>, Marcela Rincon<sup>2</sup>, Maria Pilar Lopez-Deber<sup>2</sup>, Maxime Ayer<sup>2</sup>, Stefanie Siegert<sup>2</sup>, Chiara Babolin<sup>2</sup>, Eva Gollwitzer<sup>2</sup>, Saskia Delpretti-Anex<sup>2</sup>, Piergiorgio Donati<sup>2</sup>, Johannes Streffer<sup>2,3</sup>, Andrea Pfeifer<sup>2</sup>, Marie Kosco-Vilbois<sup>2</sup>  
<sup>1</sup>Ac Immune SA - Lausanne (Switzerland), <sup>2</sup>AC Immune SA - Lausanne (Switzerland), <sup>3</sup>University of Antwerp - Antwerpen (Belgium)

4.20 p.m

### OC40 - U-p53AZ in prognostication of early onset Alzheimer's disease up to 6 years in advance of the clinical diagnosis

Simona Picciarella<sup>1</sup>, Leander Van Neste<sup>2</sup>, Christofer Fowler<sup>3</sup>, Colin Masters<sup>3</sup>, Jurgen Fripp<sup>4</sup>, James D. Doecke<sup>4</sup>, Chengjie Xiong<sup>5</sup>, Daniela Uberti<sup>6</sup>, Paul Kinnon<sup>1</sup>  
<sup>1</sup>Diadem SpA - Brescia (Italy), <sup>2</sup>Halix BV - Hoegaarden (Belgium), <sup>3</sup>The Florey Institute of Neuroscience and Mental Health - Parkville (Australia), <sup>4</sup>The Australian e-Health Research Centre, CSIRO - Herston (Australia), <sup>5</sup>Washington University School of Medicine, Division of Biostatistics - St. Louis (United States), <sup>6</sup>Department of Molecular and Translational Medicine, University of Brescia - Brescia (Italy)

4.35 p.m

### OC41 - iWHELD: An RCT of a Novel Digital Non-Pharmacological Intervention to Improve Quality of Life and Reduce Antipsychotics in 741 People Living in Nursing Homes During the COVID-19 Pandemic

Clive Ballard<sup>1</sup>, Joanne Mcdermid<sup>1</sup>, Adrienne Sweetnam<sup>1</sup>  
<sup>1</sup>University of Exeter - Exeter (United Kingdom)

4.50 p.m

### OC42 - Making digital measures fit-for-purpose in Alzheimer's trials

Francesca Cormack<sup>1</sup>, Jennifer Sorinas<sup>2</sup>, Claire Meunier<sup>3</sup>  
<sup>1</sup>Cambridge Cognition - Cambridge (United Kingdom), <sup>2</sup>Novartis - Basel (Switzerland), <sup>3</sup>DiMe - San Francisco (United States)

5.05 p.m

## End of the Conference Day



**POSTER PRESENTATIONS**  
presented in San Francisco  
and available on the CTAD22  
digital platform

# POSTERS PRESENTATIONS

All posters are available in Pdf format  
**at all times** on the CTAD22 digital platform.

Poster presentations presented onsite  
in San Francisco are indicated with this icon : 

## Tuesday, November 29 at 4 p.m to Wednesday, November 30 at 6 p.m

THEME: Clinical Trials: Methodology	P001 to LP14B
THEME: New Therapies and Clinical Trials	P024 to LP25
THEME: Clinical Trials: Results	P034 to LP44
THEME: Beyond Amyloid and Tau: Emerging Solutions	P050 to LP49

## Thursday, December 1<sup>st</sup> from 8 a.m to 6 p.m

THEME: Clinical Trials Imaging	P069 to LP62A
THEME: Clinical Trials: Biomarkers including plasma	P090 to LP84B
THEME: Cognitive and Functional Endpoints	P126 to LP89B

## Friday, December 2<sup>nd</sup> from 8 a.m to 5 p.m

THEME: Cognitive assessment and clinical trials	P141 to LP92
THEME: Behavioral disorders and clinical trials	P169 to LP93
THEME: Health economics and clinical trials	P172 to LP95
THEME: Epidemiology and clinical trials	P176 to LP96
THEME: Animal Models and Clinical Trials	P187 to LP98
THEME: Proof of Concept/Translational research for Alzheimer Drug Development interventions	P191 to LP105A
THEME: Digital health/E-trials	P205 to LP109
THEME: AD clinical trials and COVID-19	LP110



## THEME: Clinical Trials: Methodology

-  **P001** **Feasibility of virtual amyloid PET disclosure with cognitively unimpaired research participants**  
Claire Erickson<sup>1</sup>, Nathaniel Chin<sup>1</sup>, Hannah Rosario<sup>1</sup>, Amanda Peterson<sup>1</sup>, Sterling Johnson<sup>1</sup>, Lindsay Clark<sup>1</sup>  
<sup>1</sup>University Of Wisconsin-Madison - Madison (United States)
-  **P002** **Using common-close trial designs for efficiently detecting slowing of progression in Alzheimer's disease**  
Lars Lau Raket<sup>1</sup>, Jeffrey Cummings<sup>2</sup>  
<sup>1</sup>Novo Nordisk - Søborg (Denmark), <sup>2</sup>Chambers-Grundy Center For Transformative Neuroscience, Pam Quirk Brain Health And Biomarker Laboratory, Department Of Brain Health, School Of Integrated Health Sciences, University Of Nevada Las Vegas (unlv) - Las Vegas (United States)
-  **P003** **Evaluating KarXT (xanomeline-tropium) as a treatment for psychosis associated with Alzheimer's disease dementia: design of the phase 3, ADEPT-1, relapse prevention study**  
Carolyn Watson<sup>1</sup>, Jeffrey Cummings<sup>2</sup>, George Grossberg<sup>3</sup>, Minsu Kang<sup>1</sup>, Ronald Marcus<sup>1</sup>  
<sup>1</sup>Karuna Therapeutics - Boston (United States), <sup>2</sup>University Of Nevada Las Vegas School Of Integrated Health Sciences - Las Vegas (United States), <sup>3</sup>Saint Louis University School Of Medicine - Saint Louis (United States)
-  **P004** **Number of Days Between Initial Contact and In-Person Visit Predict Attendance Rates for Potential Alzheimer's Disease Trial Participants**  
Sarah Starling<sup>1</sup>, Gabriela Munoz<sup>1</sup>, Miriam Evans<sup>1</sup>, Jenicka Engler<sup>1</sup>, Stephanie Rutrick<sup>1</sup>  
<sup>1</sup>Adams Clinical - Watertown (United States)
-  **P005** **Power analysis of a prognostic enrichment procedure based on AD Course Map, a simulation study**  
Etienne Maheux<sup>1</sup>, Igor Koval<sup>1</sup>, Juliette Ortholand<sup>1</sup>, Colin Birkenbihl<sup>2</sup>, Vincent Bouteloup<sup>3</sup>, Stanley Durrleman<sup>1</sup>  
<sup>1</sup>Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la Pitié Salpêtrière, Paris (France), <sup>2</sup>Fraunhofer Institute for Algorithms and Scientific Computing SCAI - Sankt Augustin (Germany), <sup>3</sup>Université de Bordeaux, Inserm 1219, CIC1401-EC - Bordeaux (France)
-  **P006** **Implementing Novel Clinical Trial Designs in Dementia with Lewy Bodies: A Roadmap to Personalized Medicine**  
Carla Abdelnour<sup>1</sup>, Jon B. Toledo<sup>2</sup>, Daniel Ferreira<sup>3</sup>, Federico Rodríguez-Porcel<sup>4</sup>, Parichita Choudhury<sup>5</sup>, Maureen Okafor<sup>6</sup>, Sonja Scholz<sup>7</sup>, Bradley Boeve<sup>5</sup>, Irene Litvan<sup>8</sup>, James Leverenz<sup>9</sup>, Laura Bonanni<sup>10</sup>, John-Paul Taylor<sup>11</sup>, Simon J. G. Lewis<sup>12</sup>, Dag Aarsland<sup>13</sup>, Kathleen Poston<sup>1</sup>  
<sup>1</sup>Neurology And Neurological Sciences Department, Stanford University - Palo Alto (United States), <sup>2</sup>Department Of Neurology University Of Florida College Of Medicine - Gainesville (United States), <sup>3</sup>Division Of Clinical Geriatrics, Department Of Neurobiology, Care Sciences And Society, Karolinska Institutet - Stockholm (Sweden), <sup>4</sup>Department Of Neurology, Medical University Of South Carolina - Charleston (United States), <sup>5</sup>Department Of Neurology, Mayo Clinic - Rochester (United States), <sup>6</sup>Department Of Neurology, Emory University School Of Medicine - Atlanta (United States), <sup>7</sup>Neurodegenerative Diseases Research Unit, National Institute Of Neurological Disorders And Stroke. Laboratory Of Neurogenetics, National Institute On Aging - Bethesda (United States), <sup>8</sup>Parkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego - La Jolla (United States), <sup>9</sup>Lou Ruvo Center for Brain Health, Neurological Institute, and Department of Neurology, Cleveland Clinic - Cleveland (United States), <sup>10</sup>Department of Neuroscience Imaging and Clinical Sciences and CESI, University G d'Annunzio of Chieti-Pescara - Chieti (Italy), <sup>11</sup>Translational and Clinical Research Institute, Newcastle University - Newcastle (United Kingdom), <sup>12</sup>Forefront Parkinson's Disease Research Clinic, Brain And Mind Centre, University Of Sydney - Camperdown Nsw 2050 (Australia), <sup>13</sup>Institute of Psychiatry, Psychology, & Neuroscience, King's College London - London (United Kingdom)
-  **P007** **Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is commonly misdiagnosed as Alzheimer's disease (AD) and Frontotemporal Dementia (FTD)**  
Spyros Papapetropoulos<sup>1</sup>, Angela Pontius<sup>2</sup>, Samantha Zappia<sup>1</sup>, Matthew Brennan<sup>2</sup>, Leslie Leahy<sup>2</sup>  
<sup>1</sup>Vigil Neuroscience - Cambridge (United States), <sup>2</sup>Consultant To Vigil Neuroscience - Cambridge (United States)
-  **P008** **Update on the TOGETHER study: a patient- and investigator-blind, randomized, placebo-controlled study evaluating the efficacy, safety and tolerability of bepranemab, UCBO107, in prodromal-to-mild Alzheimer's disease**  
Matthew E. Barton<sup>1</sup>, Bart Van Den Steen<sup>2</sup>, Hans L. G. Van Tricht<sup>2</sup>, William Byrnes<sup>1</sup>, Fiona E. Purcell<sup>3</sup>, Sarah Ann Southcott<sup>3</sup>, Daniel Raby<sup>3</sup>, Yaroslav I. Starshinov<sup>3</sup>, Colin Ewen<sup>2</sup>  
<sup>1</sup>UCB Pharma - Raleigh, North Carolina (United States), <sup>2</sup>UCB Pharma - Brussels (Belgium), <sup>3</sup>ICON plc - Dublin (Ireland)
- P009** **The impact of erratic changes on 1 year change in CDR-SB. An exploratory analysis.**  
Alan Kott<sup>1</sup>, Xingmei Wang<sup>2</sup>, David Miller<sup>2</sup>  
<sup>1</sup>Signant Health - Prague (Czech Republic), <sup>2</sup>Signant Health - Blue Bell (United States)
-  **P010** **Early Engagement with the Alzheimer's Disease Community to Gain Insights into Designing the SKYLINE Trial for Pre-symptomatic Alzheimer's Disease**  
Fiona Rose<sup>1</sup>, Nancy Lynn<sup>2</sup>, Jessica B. Langbaum<sup>3</sup>, Carolyn Langlois<sup>3</sup>, Emma Louise Dodd<sup>1</sup>, Jannice Roeser<sup>4</sup>, Gesine Respondek<sup>4</sup>, Susanne Ostrowitzki<sup>4</sup>  
<sup>1</sup>Roche Products Ltd - Welwyn Garden City (United Kingdom), <sup>2</sup>BrightFocus Foundation - Clarksburg (United States), <sup>3</sup>Banner Alzheimer's Institute - Phoenix (United States), <sup>4</sup>F. Hoffmann-La Roche Ltd - Basel (Switzerland)
-  **P011** **Contrasting the NIH Toolbox Emotional Battery Outcomes Between Caucasians and African American Older Adult Participants in a Randomized Clinical Trial: I-CONNECT Study**  
Kexin Yu<sup>1</sup>, Lisa Silbert<sup>1,2</sup>, Laura Struble<sup>3</sup>, Hiroko H. Dodge<sup>1</sup>  
<sup>1</sup>NIA-Layton Aging and Alzheimer's Disease Center, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA - Portland (United States), <sup>2</sup>Portland Veterans Affairs Health Care System, Portland, OR, USA - Portland (United States), <sup>3</sup>Department of Health Behavior and Biological Sciences, School of Nursing, University of Michigan Ann Arbor, Michigan, USA - Ann Arbor (United States)

## THEME: Clinical Trials: Methodology

-  **P012** **Development and Feasibility of a Data-Driven Approach to Preclinical Alzheimer's Disease Clinical Trial Recruitment through Centralized Pre-screening Data Collection**  
Dylan Kirn<sup>1</sup>, Joshua Grill<sup>2</sup>, Paul Aisen<sup>3</sup>, Karin Ernstrom<sup>3</sup>, Seth Gale<sup>4</sup>, Judith Heidebrink<sup>5</sup>, Gregory Jicha<sup>6</sup>, Gustavo Jimenez-Maggiora<sup>3</sup>, Leigh Johnson<sup>7</sup>, Elaine Peskind<sup>8</sup>, Raymond Scott Turner<sup>9</sup>, David Sultzer<sup>2</sup>, Shunran Wang<sup>3</sup>, Reisa Sperling<sup>4</sup>, Rema Raman<sup>3</sup>  
<sup>1</sup>Department of Neurology, Massachusetts General Hospital - Boston (United States), <sup>2</sup>Institute for Memory Impairments and Neurological Disorders, Department of Psychiatry and Human Behavior, University of California Irvine - Irvine (United States), <sup>3</sup>Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), <sup>4</sup>Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), <sup>5</sup>Department of Neurology, University of Michigan - Ann Arbor (United States), <sup>6</sup>Sanders-Brown Center on Aging, University of Kentucky - Lexington (United States), <sup>7</sup>Institute for Translational Research, University of North Texas Health Science Center - Fort Worth (United States), <sup>8</sup>VA Northwest Mental Illness Research, Education, and Clinical Center (MIRECC), VA Puget Sound Health Care System - Seattle (United States), <sup>9</sup>Department of Neurology, Georgetown University Medical Center - Washington D.c. (United States)
-  **P013** **Design of Pragmatic Trials for Interventions Targeting Cognitive Decline: Benchmarks from the COcoa Supplement and Multivitamin Outcomes Study of the Mind (COSMOS-Mind)**  
Mark Espeland<sup>1</sup>, Joann Manson<sup>2</sup>, Steve Rapp<sup>1</sup>, Howard Sesso<sup>2</sup>, Sarah Gaussoin<sup>1</sup>, Sally Shumaker<sup>1</sup>, Laura Baker<sup>1</sup>  
<sup>1</sup>Wake Forest School of Medicine - Winston-Salem (United States), <sup>2</sup>Brigham and Women's Hospital - Boston (United States)
-  **P014** **Use of the Digit Symbol Substitution Test (DSST) as an entry criterion for a cognitive study of a  $\beta$ 2-AR agonist.**  
 Gabriel Vargas<sup>1</sup>, Renee Martin<sup>1</sup>, Peter Butera<sup>1</sup>, Judy Reynolds<sup>1</sup>, Tim Anderson<sup>2</sup>, Aliya Asher<sup>3</sup>, Erik Buntinx<sup>4</sup>, Anthony Ford<sup>1</sup>, John Harrison<sup>5</sup>  
<sup>1</sup>CuraSen - San Carlos (United States), <sup>2</sup>New Zealand Brain Research Institute - Christchurch (New Zealand), <sup>3</sup>MAC Clinical Research - Manchester (United Kingdom), <sup>4</sup>Anima Research Center - Alken (Belgium), <sup>5</sup>Metis Cognition - Kilmington Common (United Kingdom)
-  **P015** **Examine the Amyloid Reduction as A Surrogate Endpoint Using Latent Class Analysis**  
Guoqiao Wang<sup>1</sup>, Yan Li<sup>1</sup>, Chengjie Xiong<sup>1</sup>, Tammie Benzinger<sup>1</sup>, Brian Gordon<sup>1</sup>, Jason Hassenstab<sup>1</sup>, Andrew Aschenbrenner<sup>1</sup>, Anne Fagan<sup>1</sup>, Eric Mcdade<sup>1</sup>, Paul Delmar<sup>1</sup>, Randall Bateman<sup>1</sup>  
<sup>1</sup>Washington University in St Louis - St Louis (United States)
-  **P016** **Enhancing Recruitment of Underrepresented Communities with the Deployment of a Mobile Research Unit**  
Jill Smith<sup>1</sup>, John Dwyer<sup>1</sup>, Dawn Batchuluun<sup>1</sup>, Tamiko Magee Rodgers<sup>1</sup>, Leigh Zisko<sup>1</sup>  
<sup>1</sup>Global Alzheimer's Platform Foundation - Washington Dc (United States)
-  **P017** **Genotypic effects of the TOMM40\*523 variant and APOE on longitudinal cognitive change over 4 years: The TOMMORROW Study**  
 Haotian Zou<sup>1</sup>, Sheng Luo<sup>2</sup>, Michael W. Lutz<sup>2</sup>, David A. Bennett<sup>3</sup>, Brenda L. Plassman<sup>2</sup>, Kathleen A. Welsh-Bohmer<sup>2</sup>  
<sup>1</sup>University of North Carolina- Chapel Hill - Chapel Hill (United States), <sup>2</sup>Duke University - Durham (United States), <sup>3</sup>Rush University - Chicago (United States)
-  **P018** **Racial/ethnic Group Differences in Response Rate to a Mail Invitation to Participate in a Lifestyle Intervention Trial to Prevent Cognitive Decline (U.S. POINTER Trial)**  
Valory Pavlik<sup>1</sup>, Melissa Yu<sup>1</sup>, Ashley Alexander<sup>2</sup>, John Valenta<sup>2</sup>, Richard Elbein<sup>3</sup>, Annmarie Mcdonald<sup>3</sup>  
<sup>1</sup>Baylor College Of Medicine - Houston (United States), <sup>2</sup>Kelsey Research Foundation - Houston (United States), <sup>3</sup>Alzheimer's Association - Houston (United States)
-  **P019** **Development of an abbreviated pre-screening cognitive battery to enhance referral to clinical trials**  
Abigail O Connell<sup>1</sup>, Eric Fischer<sup>1</sup>, Lauren Latham<sup>1</sup>, Laura Baker<sup>1</sup>, Suzanne Craft<sup>1</sup>  
<sup>1</sup>Wake Forest Alzheimer's Disease Research Center - Winston-Salem (United States)
-  **P020** **Long-Term Nicotine Treatment of Mild Cognitive Impairment (The MIND Study): Baseline Characteristics and Study Progress**  
Paul Newhouse<sup>1</sup>, Rema Raman<sup>2</sup>, Andrew Saykin<sup>3</sup>, Julie Dumas<sup>4</sup>, Edward Levin<sup>5</sup>, Kenneth Kellar<sup>6</sup>, Paul Aisen<sup>2</sup>  
<sup>1</sup>Vanderbilt University - Nashville (United States), <sup>2</sup>USC/ATRI - San Diego (United States), <sup>3</sup>Indiana University - Indianapolis (United States), <sup>4</sup>University of Vermont - Burlington (United States), <sup>5</sup>Duke University - Durham (United States), <sup>6</sup>Georgetown University - Washington, Dc (United States)
-  **P021** **Using an end-to-end deep learning model in older adults with MCI to identify AD risk factors on chromosome 19 that exacerbate cognitive decline**  
Jinhyeong Bae<sup>1</sup>, Liana Apostolova<sup>1</sup>, Valentin Pentchev<sup>1</sup>, Dustin Hammers<sup>1</sup>, Angelina Polsinelli<sup>1</sup>, Kelly Nudelman<sup>1</sup>, Andrew Saykin<sup>1</sup>, Kwangsik Nho<sup>1</sup>  
<sup>1</sup>IUPUI - Indianapolis (United States)
-  **P022** **Pandemic Effects on Duplicate Subjects in Clinical Trials of Alzheimer's Disease**  
Thomas Shiovitz<sup>1</sup>, Chelsea Steinmetz<sup>2</sup>, Brittany Steinmiller<sup>2</sup>  
<sup>1</sup>California Neuroscience Research, CTSdatabase LLC - Sherman Oaks, Ca (United States minor outlying islands), <sup>2</sup>CTSdatabase LLC - Sherman Oaks, Ca (United States minor outlying islands)
-  **P023** **The Time Component Test is Inherently Meaningful Because it Combines Evidence Across Outcomes to Measure the Impact of Treatment on Progression Rate in Degenerative Diseases**  
Samuel Dickson<sup>1</sup>, Suzanne Hendrix<sup>1</sup>  
<sup>1</sup>Pentara Corporation - Salt Lake City (United States)
-  **LP01** **Effect of treatment with the cholinergic precursor Choline Alphoscerate in mild cognitive dysfunction (CARL): Research Protocol**  
Enea Traini<sup>1</sup>, Anna Carotenuto<sup>1</sup>, Vincenzo Andreone<sup>2</sup>, Francesco Amenta<sup>1</sup>  
<sup>1</sup>University of Camerino - Camerino (Italy), <sup>2</sup>Neurology Complex Unit, Cardarelli Hospital - Naples (Italy)

-  **LP02** **A Trichotomy Method for Defining Homogeneous Subgroups in a Dementia Population**  
Gary Rosenberg<sup>1</sup>  
<sup>1</sup>University of New Mexico - Albuquerque (United States)
- LP03** **Compliance and satisfaction in the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Colombia Trial**  
Natalia Acosta-Baena<sup>1</sup>, Claudia Muñoz<sup>1</sup>, Paula Ospina<sup>1</sup>, Sorany Del Rio<sup>1</sup>, Liliana Lopez<sup>1</sup>, Margarita Giraldo<sup>1</sup>, Sindy Duque<sup>1</sup>, Alexander Navarro<sup>1</sup>, Eric M. Reiman<sup>2</sup>, Nan Hu<sup>3</sup>, Kemal Asik<sup>3</sup>, Pierre N. Tariot<sup>2</sup>, Jessica B. Langbaum<sup>2</sup>, Francisco Lopera<sup>1</sup>, Silvia Rios-Romenets<sup>1</sup>  
<sup>1</sup>Grupo de Neurociencias de Antioquia (GNA), Universidad de Antioquia, Medellín, Colombia. - Medellín (Colombia), <sup>2</sup>Banner Alzheimer's Institute - Phoenix (United States), <sup>3</sup>Genentech Inc. - San Francisco (United States)
-  **LP04** **The Global Alzheimer's Platform Foundation's® (GAP's) Inclusive Research Initiative: Enhancing Recruitment of Underrepresented Communities Through Community Connectors**  
Dawn Batchuluun<sup>1</sup>, Tamiko Rodgers<sup>1</sup>, Leigh Zisko<sup>1</sup>, Mickeal Key<sup>1</sup>, Lisa Thurman<sup>1</sup>, John Dwyer<sup>1</sup>  
<sup>1</sup>Global Alzheimer's Platform Foundation - Washington (United States)
-  **LP05** **Mitigating loss of statistical power due to outcome imbalance in clinical trials**  
Angela Tam<sup>1</sup>, César Laurent<sup>1</sup>, Christian Dansereau<sup>1</sup>  
<sup>1</sup>Perceiv AI - Montreal (Canada)
-  **LP06** **A consultant anaesthetist delivered lumbar puncture service for Alzheimer's disease research: An evaluation of success rate and patient feedback**  
Robert Hart<sup>1</sup>, Chris Lochrin<sup>1</sup>, Malcolm Sim<sup>1</sup>, Jennifer Lynch<sup>1</sup>, Ann Nimmo<sup>1</sup>, Alison Cranmer<sup>1</sup>, Fraser Inglis<sup>1</sup>  
<sup>1</sup>Glasgow Memory Clinic - Glasgow (United Kingdom)
-  **LP07** **A Seamless Phase 2A-Phase 2B Multi-Center Trial to test the Benefits of Benfotiamine on the Progression of Alzheimer's disease (BENFO-TEAM)**  
Howard Feldman<sup>1,2</sup>, Jose Luchsinger<sup>3</sup>, Karen Messer<sup>2,4</sup>, Diane Jacobs<sup>1,2</sup>, David Salmon<sup>1</sup>, Carolyn Revta<sup>1,2</sup>, Jody-Lynn Lupo<sup>1,2</sup>, Gary Gibson<sup>5,6</sup>  
<sup>1</sup>Department of Neurosciences, University of California San Diego - La Jolla (United States), <sup>2</sup>Alzheimer's Disease Cooperative Study, University of California San Diego - La Jolla (United States), <sup>3</sup>Departments of Medicine and Epidemiology, Columbia University Irving Medical Center - New York (United States), <sup>4</sup>Division of Biostatistics, University of California San Diego - La Jolla (United States), <sup>5</sup>Brain and Mind Research Institute, Weil Cornell Medicine - New York (United States), <sup>6</sup>Burke Neurological Institute - White Plains (United States)
-  **LP08** **Simulation-based power analysis could improve the design of clinical trials in Alzheimer's disease**  
Daniel Andrews<sup>1,2,3</sup>, Douglas L. Arnold<sup>3,4,5</sup>, Danilo Bzdok<sup>1,3,6</sup>, Simon Ducharme<sup>7,8,3</sup>, Howard Chertkow<sup>9,10,11,12</sup>, D. Louis Collins<sup>1,4,3</sup>  
<sup>1</sup>Department of Biomedical Engineering, McGill University - Montreal (Canada), <sup>2</sup>Department of Bioengineering, McGill University - Montreal (Canada), <sup>3</sup>McConnell Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University - Montreal (Canada), <sup>4</sup>Department of Neurology and Neurosurgery, McGill University - Montreal (Canada), <sup>5</sup>NeuroRx Research - Montreal (Canada), <sup>6</sup>Mila - Quebec Artificial Intelligence Institute - Montreal (Canada), <sup>7</sup>Department of Psychiatry, McGill University - Montreal (Canada), <sup>8</sup>Douglas Mental Health University Institute, McGill University - Montreal (Canada), <sup>9</sup>Baycrest Centre for Geriatric Care - Toronto (Canada), <sup>10</sup>Kimel Centre for Brain Health and Wellness and Anne & Allan Bank Centre for Clinical Research Trials, Baycrest - Toronto (Canada), <sup>11</sup>Canadian Consortium on Neurodegeneration in Aging (Canada), <sup>12</sup>Division of Neurology, Department of Medicine, University of Toronto - Toronto (Canada)
-  **LP09** **The AlzMatch Study: Remote Plasma Acquisition to Pre-screen for Preclinical Alzheimer's Disease Trials**  
Sarah Walter<sup>1</sup>, Rema Raman<sup>1</sup>, Gustavo Jimenez-Maggiora<sup>1</sup>, Robert Rissman<sup>1</sup>, Joshua Grill<sup>2</sup>, Jason Karlawish<sup>2</sup>, Oliver Langford<sup>1</sup>, Stefania Bruschi<sup>1</sup>, Michael Donohue<sup>1</sup>, Kevin Yarasheski<sup>3</sup>, Michael Racke<sup>4</sup>, Reisa Sperling<sup>5</sup>, Jeffrey Cummings<sup>6</sup>, Paul Aisen<sup>1</sup>  
<sup>1</sup>Alzheimer's Therapeutic Research Institute, USC - San Diego (United States), <sup>2</sup>University of California, Irvine - Irvine (United States), <sup>3</sup>C2N Diagnostics - St. Louis (United States), <sup>4</sup>Quest Diagnostics - Secaucus (United States), <sup>5</sup>Brigham And Women's Hospital, Massachusetts General Hospital, Harvard Medical - Boston (United States), <sup>6</sup>Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada - Las Vegas (United States)
-  **LP10** **Disease Progression Modelling Identified MRI-based Subtypes with Cognitive Heterogeneity in A4 Study Preclinical Trial Cohort**  
Cameron Shand<sup>1</sup>, Neil Oxtoby<sup>1</sup>, Michael Donohue<sup>2</sup>, Daniel Alexander<sup>1</sup>, Frederik Barkhof<sup>1,3</sup>  
<sup>1</sup>University College London (United Kingdom), <sup>2</sup>Alzheimer's Therapeutic Research Institute, University Of Southern California (United States), <sup>3</sup>Amsterdam UMC (Netherlands)
-  **LP11** **LatAm-FINGERS study design: a multicultural harmonization work across Latin America**  
Lucía Crivelli<sup>1</sup>, Claudia Suemoto<sup>2</sup>, Ismael Calandri<sup>1</sup>, Paulo Caramelli<sup>3</sup>, Francisco Lopera<sup>4</sup>, Ricardo Nitrini<sup>5</sup>, Ana Luisa Sosa<sup>6</sup>, Rosa Maria Salinas<sup>6</sup>, Lina Marcela Velilla<sup>4</sup>, Monica Yassuda<sup>5</sup>, Ricardo Francisco Allegrí<sup>1</sup>, Heather Snyder<sup>7</sup>, Miia Kivipelto<sup>8</sup>, Maria Carrillo<sup>7</sup>  
<sup>1</sup>Fleni - Buenos Aires (Argentina), <sup>2</sup>Division of Geriatrics, University of Sao Paulo Medical School - Sao Paulo (Brazil), <sup>3</sup>Behavioral and Cognitive Neurology Unit, Faculdade de Medicina, Universidade Federal de Minas Gerais - Belo Horizonte (Brazil), <sup>4</sup>Neuroscience Group of Antioquia Medical School, Antioquia University - Antioquia (Colombia), <sup>5</sup>Department of Neurology, University of São Paulo School of Medicine - Sao Paulo (Brazil), <sup>6</sup>Laboratorio de demencias del Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez - Mexico City (Mexico), <sup>7</sup>Alzheimer's Association - Chicago (United States), <sup>8</sup>Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Stockholm (Sweden)
-  **LP12** **Recruitment Accelerator for Diversity in Aging Research - Cognitive Loss and Dementia (RADAR-CLD): Perspectives on Registry Recruitment**  
Mary Sano<sup>1</sup>, Jennifer Vasconcellos<sup>2</sup>, Margaret Sewell<sup>3</sup>, Judith Neugroschl<sup>3</sup>, Mari Umpierre<sup>3</sup>, Shehan Chin<sup>3</sup>, Sharon Brangman<sup>4</sup>, Sarah Mcnamara<sup>4</sup>, Nancy Smith<sup>4</sup>, Kathy Royal<sup>4</sup>, Mike Splaine<sup>2</sup>  
<sup>1</sup>Icahn School of Medicine at Mount Sinai - New York City (United States), <sup>2</sup>Recruitment Partners LLC - Columbia (United States), <sup>3</sup>Icahn School of Medicine at Mount Sinai - New York (United States), <sup>4</sup>Upstate Medical University - Syracuse (United States)

# POSTER PRESENTATIONS

Tuesday, November 29 at 4 p.m




to Wednesday, November 30 at 6 p.m

-  **LP13** **Physician-Driven Patient Recruitment Addresses Barriers in AD Clinical Trial Enrollment**  
Erin Beck<sup>1</sup>, Micah Eimerbrink<sup>1</sup>, Katie Tyler<sup>1</sup>, Daniel Gautieri<sup>1</sup>  
<sup>1</sup>SiteRx - New York (United States)
-  **LP14** **A Phase 3 Clinical Trial Protocol to Evaluate the Efficacy and Safety of NA-831 In Subjects with Early Onset of Alzheimer's Disease**  
Lloyd Tran<sup>1</sup>, Markku Kurkinen<sup>1</sup>, Fern Vu<sup>1</sup>  
<sup>1</sup>Biomed Industries, Inc. - San Jose (United States)
-  **LP14A** **Development of an abbreviated pre-screening cognitive battery to enhance referral to clinical trials**  
Abigail O'connell<sup>1</sup>, Eric Fischer<sup>1</sup>, Lauren Latham<sup>1</sup>, Laura Baker<sup>1</sup>, Suzanne Craft<sup>1</sup>  
<sup>1</sup>Wake Forest Alzheimer's Disease Research Center - Winston-Salem (United States)
-  **LP14B** **Biomarker-driven independent clinical study design on Sodium Oligomannate in China Aging and Neurodegenerative Disease Initiative (CANDI) cohort**  
Wang Qiong<sup>1</sup>, Gao Feng<sup>1</sup>, Shi Jiong<sup>1</sup>, Shen Yong<sup>1</sup>  
<sup>1</sup>The First Affiliated Hospital of USTC - Hefei (China)

## THEME: New Therapies and Clinical Trials

-  **P024** **Potential Reversal of Alzheimer's Disease pathology by Antibody TBO06 Targeting Galectin-3, a Major Cause of Oligomerization of Amyloid Proteins**  
Suhail Rasool<sup>1</sup>, Jenny Johansson<sup>1</sup>, Ludmila Voloboueva<sup>1</sup>, Sangmi Lee<sup>1</sup>, Nancy Lan<sup>1</sup>, Taufeeq Ahmed<sup>1</sup>, Dongxu Sun<sup>1</sup>  
<sup>1</sup>Truebinding Inc. - Foster City (United States)
-  **P025** **Whole-Brain Low-Intensity Pulsed Ultrasound Therapy For Early Stage Of Alzheimer's Disease (LIPUS-AD): A Randomized, Double-Blind, Placebo-Controlled Trial**  
Hiroaki Shimokawa<sup>1,2</sup>, Tomohiko Shindo<sup>1</sup>, Aiko Ishiki<sup>3</sup>, Naoki Tomita<sup>3</sup>, Kumiko Eguchi<sup>1</sup>, Takashi Shiroto<sup>1</sup>, Jun Takahashi<sup>1</sup>, Kentaro Shiratsuchi<sup>4</sup>, Satoshi Yasuda<sup>1</sup>, Hiroyuki Arai<sup>3</sup>  
<sup>1</sup>Tohoku University Graduate School Of Medicine - Sendai (Japan), <sup>2</sup>International University of Health and Welfare - Narita (Japan), <sup>3</sup>Institute Of Development, Aging And Cancer, Tohoku University - Sendai (Japan), <sup>4</sup>Sound Wave Innovation, Co. - Tokyo (Japan)
-  **P026** **CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with mild cognitive impairment due to Alzheimer's disease**  
Alan Lerner<sup>1,2</sup>, Steven Arnold<sup>3</sup>, Erin Maxfield<sup>4</sup>, Aaron Koenig<sup>3</sup>, Maria Toth<sup>1</sup>, Brooke Fortin<sup>3</sup>, Bianca Trombetta<sup>3</sup>, Andrew Pieper<sup>5,6,7,8</sup>, Curtis Tatsuoka<sup>9</sup>, Irina Pikuleva<sup>4</sup>  
<sup>1</sup>Brain Health And Memory Center, Neurological Institute, University Hospitals Cleveland Medical Center - Cleveland (United States), <sup>2</sup>Department of Neurology, Case Western Reserve University - Cleveland (United States), <sup>3</sup>Alzheimer's Clinical And Translational Research Unit, Massachusetts General Hospital - Boston (United States), <sup>4</sup>Department Of Ophthalmology And Visual Sciences, Case Western Reserve University - Cleveland (United States), <sup>5</sup>Harrington Discovery Institute, University Hospitals Cleveland Medical Center - Cleveland (United States), <sup>6</sup>Department Of Psychiatry, Case Western Reserve University - Cleveland (United States), <sup>7</sup>Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center - Cleveland (United States), <sup>8</sup>Institute For Transformative Molecular Medicine, Case Western Reserve University - Cleveland (United States), <sup>9</sup>Department Of Population And Quantitative Health Sciences, Case Western Reserve University - Cleveland (United States)
-  **P027** **A Phase 2 Study of the Sigma-2 Ligand CT1812 in Participants with Dementia with Lewy Bodies**  
James Galvin<sup>1</sup>, Magdalena Tolea<sup>1</sup>, Michael Grundman<sup>2</sup>, Mary Hamby<sup>3</sup>, Anthony Caggiano<sup>4</sup>  
<sup>1</sup>Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine - Boca Raton, FL (United States), <sup>2</sup>Grnd Partners - San Diego, Ca (United States), <sup>3</sup>Cognition Therapeutics - Pittsburgh, Pa (United States), <sup>4</sup>Cognition Therapeutics - Purchase, Ny (United States)
-  **P028** **ALZLIGHT Pilot: Preliminary Report on Safety and Feasibility From a Randomized Controlled Trial of Light-Based Brain Stimulation With 40 Hz Invisible Spectral Flickering Light in Patients With Mild-to-Moderate Alzheimer's Disease**  
Mikkel Pejstrup Agger<sup>1,2</sup>, Marcus Schultz Carstensen<sup>3</sup>, Maibritt Horning<sup>1,2</sup>, Else Rubæk Danielsen<sup>4</sup>, Anders Ohlhues Baandrup<sup>4</sup>, Mai Nguyen<sup>5</sup>, Mark Alexander Henney<sup>5</sup>, Christopher Ravn Boe Jensen<sup>5</sup>, Kristoffer Hougaard Madsen<sup>6,7</sup>, Troels Wesenberg Kjær<sup>1,2</sup>, Kamilla Miskowiak<sup>8,9</sup>, Paul Michael Petersen<sup>3</sup>, Peter Høgh<sup>1,2</sup>  
<sup>1</sup>Department of Neurology, Zealand University Hospital - Roskilde (Denmark), <sup>2</sup>Department of Clinical Medicine, University of Copenhagen - Copenhagen (Denmark), <sup>3</sup>Dept. of Electrical and Photonics Engineering, Technical University of Denmark - Kgs. Lyngby (Denmark), <sup>4</sup>Department of Radiology, Zealand University Hospital - Roskilde (Denmark), <sup>5</sup>OptoCeutics ApS - Copenhagen (Denmark), <sup>6</sup>Dept. of Applied Mathematics and Computer Science, Technical University of Denmark - Copenhagen (Denmark), <sup>7</sup>Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital - Amager and Hvidovre - Copenhagen (Denmark), <sup>8</sup>Neurocognition and Emotion in Affective Disorders (NEAD) Group, Copenhagen Affective Disorder research Centre (CADIC), Psychiatric Centre Copenhagen - Copenhagen (Denmark), <sup>9</sup>Department of Psychology, University of Copenhagen - Copenhagen (Denmark)
-  **P029** **Characterization of amyloid-beta protofibrils in Alzheimer's disease brain and the unique binding properties of lecanemab**  
Lars Lannfelt<sup>1</sup>, Linda Söderberg<sup>1</sup>, Malin Johannesson<sup>1</sup>, Nicolas Fritz<sup>1</sup>, Eleni Gkanatsiou<sup>1</sup>, Adeline Rachalski<sup>1</sup>, Helen Kylefjord<sup>1</sup>, Gunilla Osswald<sup>1</sup>, Christer Möller<sup>1</sup>  
<sup>1</sup>BioArctic AB - Stockholm (Sweden)
-  **P030** **AD101 - the clinical profile of a new, first-in-class treatment for Alzheimer's Disease**  
Jan Burmeister<sup>1</sup>, Serge Gauthier<sup>2</sup>, Sharon Rogers<sup>1</sup>  
<sup>1</sup>Amyriad Pharma, Inc. - Los Angeles (United States), <sup>2</sup>McGill University - Montréal (Canada)

-  **P031** **Impact of pimavanserin on cognitive measures in patients with neuropsychiatric manifestations of Alzheimer's disease: results from 3 placebo-controlled clinical studies**  
Clive Ballard<sup>1</sup>, Victor Ablner<sup>2</sup>, Sanjeev Pathak<sup>2</sup>, Pierre Tariot<sup>1</sup>, Bruce Coate<sup>2</sup>, Ana Berrio<sup>2</sup>, James M Youakim<sup>2</sup>, Srdjan Stankovic<sup>2</sup>  
<sup>1</sup>Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania - Philadelphia (United States), <sup>2</sup>ACADIA Pharmaceuticals Inc. - Princeton (United States)
-  **P032** **Impact of pimavanserin treatment on motor function in patients with neuropsychiatric manifestations of Alzheimer's disease: results from 3 clinical studies**  
 Daniel Weintraub<sup>1</sup>, Victor Ablner<sup>2</sup>, Clive Ballard<sup>1</sup>, Bruce Coate<sup>2</sup>, Ana Berrio<sup>2</sup>, Sanjeev Pathak<sup>2</sup>, James M Youakim<sup>2</sup>, Srdjan Stankovic<sup>2</sup>  
<sup>1</sup>Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania - Philadelphia (United States), <sup>2</sup>ACADIA Pharmaceuticals Inc. - Princeton (United States)
-  **P033** **Intravenous treatment with BRICHOS molecular chaperone designed against amyloid- $\beta$  toxicity improves features of Alzheimer disease pathology in mice**  
Jan Johansson<sup>1</sup>  
<sup>1</sup>Karolinska Institutet - Huddinge (Sweden)
- LP15** **Computerized Cognitive Training Restores Neural Activity within the Cognition and Apathy-related Network in Mild Cognitive Impairment**  
Jae Myeong Kang<sup>1</sup>, Nambeom Kim<sup>2</sup>, Seon Kyung Yun<sup>3</sup>, Ha-Eun Seo<sup>4</sup>, Sangsoo Kim<sup>5</sup>, Seong-Jin Cho<sup>6</sup>  
<sup>1</sup>Department of Psychiatry, Gil Medical Center, Gachon University College of Medicine - Incheon (Korea, Republic of) - Incheon (Korea, Republic of), <sup>2</sup>Department of Biomedical Engineering Research Center, Gachon University, Incheon, Republic of Korea - Incheon (Korea, Republic of), <sup>3</sup>Department of Nursing, Saekyung University College of Nursing, Yeongwol, Republic of Korea - Yeongwol (Korea, Republic of), <sup>4</sup>Neuroscience Research Institute, Gachon University - Incheon (Korea, Republic of), <sup>5</sup>Department of Psychiatry, Gachon University Gil Medical Center - Incheon (Korea, Republic of), <sup>6</sup>Department of Psychiatry, Gil Medical Center, Gachon University College of Medicine - Incheon (Korea, Republic of)
-  **LP16** **Alzheimer's Cognitive Decline Stopped For at Least 2½ Years by In-Home Transcranial Electromagnetic Treatment**  
Gary Arendash<sup>1</sup>, Haitham Abulaban<sup>2,3</sup>, Susan Steen<sup>2</sup>, Ross Andel<sup>4</sup>, Yanhong Wang<sup>5,6</sup>, Yun Bai<sup>5</sup>, Rob Baranowski<sup>7</sup>, Xiaoyang Lin<sup>5,8</sup>, Ning Shen<sup>9</sup>, Ali Aljassabi<sup>5,6</sup>, Yitong Li<sup>5</sup>, Chuanhai Cao<sup>5,6</sup>  
<sup>1</sup>NeuroEM Therapeutics, Inc. - Phoenix (United States), <sup>2</sup>Axiom Clinical Research of Florida - Tampa (United States), <sup>3</sup>University of South Florida/Byrd Alzheimer's Institute - Tampa (United States), <sup>4</sup>Edson College of Nursing and Health Innovation, Arizona State University - Phoenix (United States), <sup>5</sup>MegaNano Biotech - Tampa (United States), <sup>6</sup>Taneja College of Pharmacy, University of South Florida - Tampa (United States), <sup>7</sup>Left Coast Engineering - Escondido (United States), <sup>8</sup>Taneja College of Pharmacy, University of South Florida - Tampa (United States), <sup>9</sup>School of Arts and Sciences, University of South Florida - Tampa (United States)
-  **LP17** **First-in-Human Clinical Trial of IBC-Ab002, a Proprietary Human anti-PD-L1 Antibody, in Persons with Early Alzheimer's Disease: Trial Design and Objectives**  
Jesse Cedarbaum<sup>1</sup>, Philip Scheltens<sup>2</sup>, Catherine Mummery<sup>3</sup>, Carol David<sup>4</sup>, Dalia Bracha<sup>4</sup>, Eti Yoles<sup>4</sup>, Kuti Baruch<sup>4</sup>, Michal Schwartz<sup>5</sup>  
<sup>1</sup>Immunobrain Checkpoint - Woodbridge, Ct (United States), <sup>2</sup>Amsterdam UMC, Alzheimer Center - Amsterdam (Netherlands), <sup>3</sup>Dementia Research Centre, Institute of Neurology, University College London - London (United Kingdom), <sup>4</sup>Immunobrain Checkpoint - Nes Ziona (Israel), <sup>5</sup>Weizmann Institute - Rehovot (Israel)
-  **LP19** **Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in Phase 2 HD study supports clinical development in an ongoing Phase 1/2 AD study**  
Terrence Fisher<sup>1</sup>, Elizabeth Evans<sup>1</sup>, Megan Boise<sup>1</sup>, Vikas Mishra<sup>1</sup>, Crystal Mallow<sup>1</sup>, Ernest Smith<sup>1</sup>, John Leonard<sup>1</sup>, Andrew Feigin<sup>2</sup>, Eric Siemers<sup>3</sup>, Elizabeth Sheldon<sup>4</sup>, Raymond Turner<sup>5</sup>, Martin Farlow<sup>6</sup>, Anton Porteinsson<sup>7</sup>, Wendy Bond<sup>8</sup>, Maurice Zauderer<sup>1</sup>  
<sup>1</sup>Vaccinex, Inc. - Rochester (United States), <sup>2</sup>NY Langone Health, and for HSG and SIGNAL-HD PIs and coordinators - New York (United States), <sup>3</sup>Siemens Integration LLC - Zionsville (United States), <sup>4</sup>JEM Research Institute - Atlantis (United States), <sup>5</sup>Re-cognition Health - Fairfax (United States), <sup>6</sup>Indiana University - Indianapolis (United States), <sup>7</sup>University of Rochester - Rochester (United States), <sup>8</sup>Neuropsychiatric Research Center of Southwest Florida - Fort Myers (United States)
-  **LP20** **Does brain-gut photobiomodulation have therapeutic potential in Alzheimer's Disease? Design of a pivotal sham-controlled, randomized, double-blind, multicentric clinical investigation**  
 Julien Delrieu<sup>1</sup>, Aroa Relano-Gines<sup>2</sup>, Patrice Cristofini<sup>2</sup>, Julie Bisiaux<sup>3</sup>, Sara Guillemain<sup>3</sup>, Guillaume Blivet<sup>2</sup>, Jacques Touchon<sup>4</sup>  
<sup>1</sup>Toulouse University Hospital Gerontopole - Toulouse (France), <sup>2</sup>REGEnLIFE - Paris (France), <sup>3</sup>RCTS - Lyon (France), <sup>4</sup>University of Montpellier - Montpellier (France)
-  **LP21** **AC-0027875, a novel gamma-secretase modulator for the treatment of Alzheimer's disease**  
Johan Sandin<sup>1</sup>, Märta Dahlström<sup>1</sup>, Veronica Lidell<sup>1</sup>, Azita Rasti<sup>1</sup>, Pontus Forsell<sup>1</sup>, Sanja Juric<sup>1</sup>, Magnus Halldin<sup>1</sup>, Maria Backlund<sup>1</sup>, Gunnar Nordvall<sup>1</sup>  
<sup>1</sup>AlzeCure Pharma AB - Huddinge (Sweden)
- LP22** **Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults: Brain Amyloid and Vascular Effects of Eioscapentaeoic Acid (BRAVE-EPA) Study Design and Baseline Characteristics**  
Carol Van Hulle<sup>1,2</sup>, Hannah Zylstra<sup>3</sup>, Cole Aleshia<sup>4</sup>, Eierman Allison<sup>5</sup>, Elena Beckman<sup>6</sup>, Karen Lazar<sup>7</sup>, Blazel Madeleine<sup>8</sup>, Cronin Kate<sup>1</sup>, Carey Gleason<sup>2</sup>, Sterling Johnson<sup>9,1,2</sup>, Sanjay Asthana<sup>2,1,10</sup>, Carlsson Cynthia<sup>2,11,10,1</sup>  
<sup>1</sup>Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison - Madison (United States), <sup>2</sup>Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison - Madison (United States), <sup>3</sup>School of Medicine and Public Health, University of Wisconsin-Madison - Madison (United States), <sup>4</sup>Wisconsin Alzheimer's Institute Center, University of Wisconsin-Madison - Madison (United States), <sup>5</sup>Medical College of Wisconsin-Green Bay - Madison (United States), <sup>6</sup>Bold Insight - Downer's Grove (United States), <sup>7</sup>Exact Sciences - Madison (United States), <sup>8</sup>Cleveland Clinic Lerner College of Medicine - Cleveland (United States), <sup>9</sup>Wisconsin Alzheimer's Institute, University of Wisconsin-Madison - Madison (United States), <sup>10</sup>Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital - Madison (United States), <sup>11</sup>Wisconsin Alzheimer's Institute, University of Wisconsin-Madison - Madison (United States)

-  **LP23** **A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen® in subjects with Mild Alzheimer's Disease/ MCI**  
Douglas Galasko<sup>1</sup>, Martin Farlow<sup>2</sup>, Brendan Lucey<sup>3</sup>, Lawrence Honig<sup>4</sup>, Abhay Moghekar<sup>5</sup>, Donald Elbert<sup>6</sup>, Randall Bateman<sup>3</sup>, Jeremiah Momper<sup>1</sup>, Ronald Thomas<sup>1</sup>, Robert Rissman<sup>1</sup>, Archana Balasubramaniam<sup>1</sup>, Maria Maccacchini<sup>7</sup>, Howard Feldman<sup>1</sup>  
<sup>1</sup>UC San Diego - San Diego (United States), <sup>2</sup>Indiana University - Indianapolis (United States), <sup>3</sup>Washington University - St. Louis (United States), <sup>4</sup>Columbia University - New York (United States), <sup>5</sup>Johns Hopkins University - Baltimore (United States), <sup>6</sup>University of Washington - Seattle (United States), <sup>7</sup>Annovis Pharmaceuticals - Berwyn (United States)
-  **LP24** **Preclinical characterization of ACD856, a cognitive enhancer in clinical development for the treatment of cognitive dysfunction in Alzheimer's disease, demonstrates increased plasticity, neuroprotection and a possible disease modifying effect**  
 Cristina Parrado-Fernández<sup>1</sup>, Gunnar Nordvall<sup>1</sup>, Sanja Juric<sup>1</sup>, Nather Madjid<sup>1</sup>, Maria Backlund<sup>1</sup>, Märta Dahlström<sup>1</sup>, Johan Sandin<sup>1</sup>, Pontus Forsell<sup>1</sup>  
<sup>1</sup>Alzecure Pharma AB - Huddinge (Sweden)
-  **LP25** **Overview of the preclinical program for OLX-07010 - a novel inhibitor of tau self-association**  
James Moe<sup>1</sup>, Barry Levine<sup>2</sup>, Edward Cheesman<sup>1</sup>, Patricia Lopez<sup>1</sup>, William Erhardt<sup>1</sup>, Eliot Davidowitz<sup>1</sup>  
<sup>1</sup>Oligomerix, Inc. - White Plains (United States), <sup>2</sup>Levine Tox Consulting, LLC - Chicago (United States)

## THEME: Clinical Trials: Results

-  **P034** **Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias**  
Elisabeth Rindner<sup>1</sup>, Kennedy Mahdavi<sup>1,2</sup>, Jonathan Haroon<sup>1</sup>, Kaya Jordan<sup>1</sup>, Margaret Zielinski<sup>1</sup>, Victoria Venkatraman<sup>1,3</sup>, Dayan Goodenowe<sup>4</sup>, Clarence Ahlem<sup>5</sup>, Christopher Reading<sup>5</sup>, Joseph Palumbo<sup>5</sup>, Bijan Pourat<sup>6</sup>, Sheldon Jordan<sup>1,3</sup>  
<sup>1</sup>The Regenesys Project - Santa Monica (United States), <sup>2</sup>Synaptec Network, - Santa Monica (United States), <sup>3</sup>Synaptec Network - Santa Monica (United States), <sup>4</sup>Prodrome Sciences USA LLC - Temecula (United States), <sup>5</sup>Biovie Inc. - Carson City (United States), <sup>6</sup>Pourat MD - Beverly Hills (United States)
-  **P035** **Meta-analysis of high-clearance anti-amyloid immunotherapies trials in early Alzheimer's disease: a significant clinical effect but a low benefit/risk ratio**  
Nicolas Villain<sup>1</sup>, Vincent Planche<sup>2</sup>  
<sup>1</sup>Ap-Hp Sorbonne Université, Hôpital Pitié-Salpêtrière, Department Of Neurology, Institute Of Memory And Alzheimer's Disease - Paris (France), <sup>2</sup>Univ. Bordeaux, Cnrs, Imn, Umr 5293 - Bordeaux (France)
-  **P036** **LilqPADD Trial: Targeting Hippocampal Hyperconnectivity in Cognitively Normal Older Adults at Risk for Alzheimer's Disease with AGB101**  
 Shi-Jiang Li<sup>1</sup>, Arnold Bakker<sup>2</sup>, Yang Wang<sup>1</sup>, B. Doug Ward<sup>1</sup>, Shelby Schold<sup>1</sup>, Piero Antuono<sup>1</sup>, E. G. Deluque<sup>1</sup>, Malgorzata Franczak<sup>1</sup>, Joseph Goveas<sup>1</sup>  
<sup>1</sup>Medical College Of Wisconsin, <sup>2</sup>Johns Hopkins University
-  **P037** **Planning the next generation of Alzheimer's Disease clinical trials using diverse patient-level database from the Critical Path for Alzheimer's Disease (CPAD) Consortium**  
Sudhir Sivakumaran<sup>1</sup>, Nicholas Cullen<sup>1</sup>, Zihan Cui<sup>1</sup>, Eileen Priest<sup>1</sup>, Corissa Lau<sup>1</sup>, Hazel White<sup>1</sup>, Michael Irizarry<sup>2</sup>, Klaus Romero<sup>1</sup>, Yashmin Karten<sup>1</sup>  
<sup>1</sup>Critical Path Institute - Tucson (United States), <sup>2</sup>Eisai Inc. - Nutley (United States)
-  **P038** **Critical Path for Alzheimer's Disease (CPAD) Consortium: Accelerating and de-risking therapeutic development in AD by building regulatory decision-making tools**  
Sudhir Sivakumaran<sup>1</sup>, Nicholas Cullen<sup>1</sup>, Corissa Lau<sup>1</sup>, Eileen Priest<sup>1</sup>, Hazel White<sup>1</sup>, Michael Irizarry<sup>2</sup>, Klaus Romero<sup>1</sup>, Yashmin Karten<sup>1</sup>  
<sup>1</sup>Critical Path Institute - Tucson (United States), <sup>2</sup>Eisai - Nutley (United States)
-  **P039** **Effectiveness of a digitally supported care management program for family and other informal dementia caregivers: baseline data and first results from the GAIN randomized**  
Ingo Kilimann<sup>1</sup>, Olga Klein<sup>2</sup>, Jochen René Thyrian<sup>3</sup>, Melanie Boekholt<sup>3</sup>, Stefan Teipel<sup>1</sup>, Wolfgang Hoffmann<sup>4</sup>  
<sup>1</sup>Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/Greifswald And University Medical Center Rostock, Department Psychosomatics And Psychotherapy - Rostock (Germany), <sup>2</sup>Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/Greifswald - Rostock (Germany), <sup>3</sup>Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/Greifswald - Greifswald (Germany), <sup>4</sup>Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/Greifswald And University Hospital Greifswald, Institute For Community Medicine - Greifswald (Germany)
-  **P040** **Repeat IV and SC dosing of the Anti-Sortilin Antibody AL101**  
 Michael Ward<sup>1</sup>, Felix Yeh<sup>1</sup>, Lovingly Park<sup>1</sup>, Daniel Maslyar<sup>1</sup>, Yijie Liao<sup>1</sup>, Hua Long<sup>1</sup>, Hernan Picard<sup>1</sup>, Michael Kurnellas<sup>1</sup>, Mayura Vadhavkar<sup>1</sup>, Amber Silva<sup>1</sup>  
<sup>1</sup>Alector, Inc. - South San Francisco (United States)
-  **P041** **SAL-AD: A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease**  
Peter Ljubenkov<sup>1</sup>, Lawren Vandevrede<sup>1</sup>, Rojas Rojas<sup>1</sup>, Madison Honey<sup>2</sup>, Argentina Lario Lago<sup>1</sup>, Richard Tsai<sup>3</sup>, Mary Koestler<sup>1</sup>, Renaud La Joie<sup>1</sup>, Keith Alan Johnson<sup>4</sup>, Li Gan<sup>5</sup>, Stephanie Lessig<sup>6</sup>, James Brewer<sup>6</sup>, Howard Feldman<sup>6</sup>, Charlotte Teunissen<sup>7</sup>, Adam Boxer<sup>1</sup>  
<sup>1</sup>UCSF Memory and Aging Center - San Francisco (United States), <sup>2</sup>Amsterdam UMC - Amsterdam (Netherlands), <sup>3</sup>Denali Therapeutics - San Francisco (United States), <sup>4</sup>Harvard Medical School - Boston (United States), <sup>5</sup>Weill Cornell Medical College - New York (United States), <sup>6</sup>UC San Diego - San Diego (United States), <sup>7</sup>Amsterdam UMC - Amsterdam (United States)

-  **P042** Early experience with home administration of subcutaneous gantenerumab by study partner (non-professional care partner) in the GRADUATION study  
Richard Perry<sup>1</sup>, Frank Boess<sup>2</sup>, Marzia Scelsi<sup>3</sup>, Timo Grimmer<sup>4</sup>, Rafael Arroyo<sup>5</sup>, Christopher Lane<sup>3</sup>, Claire Lansdall<sup>2</sup>, Janice Smith<sup>3</sup>  
<sup>1</sup>Imperial College London - London (United Kingdom), <sup>2</sup>F. Hoffmann-La Roche Ltd - Basel (Switzerland), <sup>3</sup>Roche Products Ltd - Welwyn Garden City (United Kingdom), <sup>4</sup>Klinikum rechts der Isar, Technical University of Munich - Munich (Germany), <sup>5</sup>Quirónsalud Madrid University Hospital - Madrid (Spain)
-  **P043** A Phase 1b study to evaluate the safety, tolerability and pharmacodynamics of PRI-002 in MCI and mild AD  
Oliver Peters<sup>1</sup>, Nicoleta-Carmen Cosma<sup>1</sup>, Janine Kutzsche<sup>1</sup>, Dieter Willbold<sup>1</sup>  
<sup>1</sup>Charité - Berlin (Germany)
-  **P044** Enabling subcutaneous dosing of gantenerumab in Alzheimer's Disease  
Beate Bittner<sup>1</sup>, Dietmar Schwab<sup>1</sup>, Agnes Portron<sup>1</sup>, Dominik Lott<sup>1</sup>, Frank Boess<sup>1</sup>, Rémy Kohler<sup>1</sup>, Jakub Wojtowicz<sup>1</sup>, Carsten Hofmann<sup>1</sup>  
<sup>1</sup>F. Hoffmann-La Roche Ltd - Basel (Switzerland)
-  **P045** The Internet-Based Conversational Engagement Clinical Trial (I-CONNECT) in Socially Isolated Adults 75+ Years Old: Primary Analyses Results  
Hiroko Dodge<sup>1</sup>, Patrick Pruitt<sup>1</sup>, Kexin Yu<sup>1</sup>, Chao-Yi Wu<sup>1</sup>, Jeffrey Kaye<sup>1</sup>, Lisa Silbert<sup>1</sup>, I-Connect Connect-Team<sup>1</sup>  
<sup>1</sup>Oregon Health & Science University - Portland (United States)
-  **P046** Computerized Games versus Crosswords Training in Mild Cognitive Impairment  
Davangere Devanand<sup>1</sup>, Terry Goldberg<sup>1</sup>, Min Qian<sup>1</sup>, Murali Doraiswamy<sup>2</sup>  
<sup>1</sup>Columbia University Medical Center - New York (United States), <sup>2</sup>Duke University - Durham (United States)
-  **P047** Pimavanserin and cardiovascular/electrocardiogram safety in patients with Alzheimer's disease  
Pierre Tariot<sup>1</sup>, Victor Abler<sup>2</sup>, Sanjeev Pathak<sup>2</sup>, Bruce Coate<sup>2</sup>, Mary Ellen Turner<sup>2</sup>  
<sup>1</sup>Banner Alzheimer's Institute and University of Arizona College of Medicine - Phoenix, Az (United States), <sup>2</sup>Acadia Pharmaceuticals Inc. - San Diego, Ca (United States)
-  **P048** The effects of the novel phosphodiesterase 9 (PDE9) inhibitor E2027 (irsenontrine) on CSF cGMP, additional CSF and plasma biomarkers, and clinical outcomes in amyloid positive and amyloid negative patients with Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD)  
Pallavi Sachdev<sup>1</sup>, Kate Pinner<sup>2</sup>, Theresa Devins<sup>1</sup>, Larisa Reyderman<sup>1</sup>, David Li<sup>1</sup>, Shobha Dhadda<sup>1</sup>, Lynn Kramer<sup>1</sup>, Akihiko Koyama<sup>1</sup>, Michael Izarrary<sup>1</sup>, Steven Hersch<sup>1</sup>  
<sup>1</sup>Eisai Inc. - Nutley (United States), <sup>2</sup>Eisai Ltd. - Hattfield (United Kingdom)
-  **P049** Clinical Activity of the p38 $\alpha$  kinase inhibitor neflamapimod on verbal list learning may be tau pathology dependent in dementia with Lewy bodies (DLB)  
John Alam<sup>1</sup>, Jennifer Conway<sup>1</sup>, Hui-May Chu<sup>2</sup>, Kelly Blackburn<sup>1</sup>  
<sup>1</sup>EIP Pharma, Inc - Boston (United States), <sup>2</sup>Anoixis Corporation - Natick (United States)
-  **LP26** Final 4 years results of the clinical trial ASCOMALVA  
Anna Carotenuto<sup>1</sup>, Angiola Fasanaro<sup>1</sup>, Enea Traini<sup>1</sup>, Francesco Amenta<sup>1</sup>  
<sup>1</sup>University of Camerino - Camerino (Italy)
-  **LP27** Age-dependent effects of the p75 modulator LM11A-31 on Alzheimer's disease biomarkers in a 26-week safety and exploratory endpoint trial  
Hayley Shanks<sup>1</sup>, Stephen Massa<sup>2,3</sup>, Manfred Windisch<sup>4</sup>, Anne Borjesson-Hanson<sup>5</sup>, Frank Longo<sup>6</sup>, Taylor Schmitz<sup>1</sup>  
<sup>1</sup>Western University - London (Canada), <sup>2</sup>University of California San Francisco - San Francisco (United States), <sup>3</sup>SFVAHCS - San Francisco (United States), <sup>4</sup>Neuroscios - Graz (Austria), <sup>5</sup>Karolinska University Hospital - Stockholm (Sweden), <sup>6</sup>Pharmatrophix - Menlo Park (United States)
-  **LP28** Clinical phase 1b data of the orally available anti-prionic compound RD2 that disassembles A $\beta$  oligomers into A $\beta$  monomers  
Dieter Willbold<sup>1,2,3</sup>, Nicoleta Carmen Cosma<sup>4</sup>, Janine Kutzsche<sup>1</sup>, Oliver Peters<sup>4</sup>  
<sup>1</sup>Institute of Biological Information Processing (IBI-7), Forschungszentrum Jülich - Jülich (Germany), <sup>2</sup>Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf - Düsseldorf (Germany), <sup>3</sup>Priavoid GmbH - Düsseldorf (Germany), <sup>4</sup>Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charité Berlin - Berlin (Germany)
-  **LP29** Late-life depression, subjective cognitive decline, and their additive risk in incidence of dementia: A nationwide longitudinal study  
Sung Yong Park<sup>1</sup>, Won Myong Bahk<sup>2</sup>, Sheng-Min Wang<sup>2</sup>, Hyun Kook Lim<sup>2</sup>, Young-Joon Kwon<sup>3</sup>, Bo-Hyun Yoon<sup>4</sup>, Kwang Hun Lee<sup>5</sup>, Sang-Yeol Lee<sup>6</sup>, Moon-Doo Kim<sup>7</sup>, Beom Woo Nam<sup>8</sup>, Eun Sung Lim<sup>9</sup>  
<sup>1</sup>Keyo hospital - Uiwang-Si (Korea, Republic of), <sup>2</sup>Yeouido St. Mary's Hospital - Seoul (Korea, Republic of), <sup>3</sup>Soonchunhyang University Cheonan Hospital - Cheonan (Korea, Republic of), <sup>4</sup>Naju National Hospital - Naju (Korea, Republic of), <sup>5</sup>College of Medicine, Dongguk University - Gyeongju (Korea, Republic of), <sup>6</sup>Wonkwang University Hospital - Iksan (Korea, Republic of), <sup>7</sup>Jeju National University School of Medicine - Jeju (Korea, Republic of), <sup>8</sup>Dr. Nam's Psychiatric Clinic - Chungju (Korea, Republic of), <sup>9</sup>Shinsegae Hyo Hospital - Kimje (Korea, Republic of)
-  **LP30** Baseline findings of PreventE4: a double-blind placebo controlled clinical trial testing high dose DHA in APOE4 carriers before the onset of dementia  
Hussein Yassine<sup>1</sup>, Michael Harrington<sup>1</sup>, Isabella Cordova<sup>1</sup>, Naoko Kono<sup>1</sup>, Wendy Mack<sup>1</sup>, Meredith Braskie<sup>1</sup>, Lon Schneider<sup>1</sup>  
<sup>1</sup>University of Southern California - Los Angeles (United States)
-  **LP31** Efficacy and safety of benfotiamine plus donepezil for the treatment of patients with mild-to-moderate Alzheimer's disease in a phase 2 clinical trial  
Xiaoli Pan<sup>1</sup>, Qianhua Zhao<sup>2</sup>, Shaoming Sang<sup>1</sup>, Chunjiu Zhong<sup>1</sup>  
<sup>1</sup>Zhongshan Hospital, Fudan University - Shanghai (China), <sup>2</sup>Huashan Hospital, Fudan University - Shanghai (China)

-  **LP32** **VIVIAD, A Phase 2b Study Investigating Varoglutamstat in Patients with MCI and Mild AD: Update on Dose Selection and Interim Blinded Safety Results**  
Frank Weber<sup>1</sup>, Michael Schaeffer<sup>2</sup>  
<sup>1</sup>CMO Vivoryon Therapeutics N.V. - München (Germany), <sup>2</sup>CBO Vivoryon Therapeutics N.V. - München (Germany)
-  **LP33** **Quantitative EEG results from a multiple ascending dose study in healthy volunteers with NeuroRestore ACD856, a positive modulator of Neurotrophin Trk-receptors**  
Martin Jönsson<sup>1</sup>, Kristin Önnestam<sup>1</sup>, Boel Nilsson<sup>1</sup>, Matthias Rother<sup>1</sup>, Erik Rein-Hedin<sup>2</sup>, Peter Anderer<sup>3</sup>, Manuel Kemethofer<sup>3</sup>, Magnus Halldin<sup>1</sup>, Pontus Forsell<sup>1</sup>, Gunnar Nordvall<sup>1</sup>, Johan Sandin<sup>1</sup>, Märta Segerdahl<sup>1</sup>  
<sup>1</sup>AlzeCure Pharma AB - Huddinge (Sweden), <sup>2</sup>CTC Clinical Trial Consultants AB - Uppsala (Sweden), <sup>3</sup>The Siesta Group Schlafanalyse GmbH - Vienna (Austria)
-  **LP34** **A Randomized Double-Blind Study to Assess the Skin Irritation and Sensitization Potential of Once-Weekly Donepezil Transdermal Delivery System**  
 Marwan Sabbagh<sup>1</sup>, Philip Mathew<sup>2</sup>, Alan Blau<sup>3</sup>  
<sup>1</sup>Barrow Neurological Institute - Phoenix (United States), <sup>2</sup>Novum Pharmaceutical Research Services - Toronto (Canada), <sup>3</sup>Corium Inc - Grand Rapids (United States)
-  **LP35** **Repetitive magnetic stimulation of the precuneus in mild-to-moderate Alzheimer's disease patients: a phase 2, randomized, sham-controlled trial**  
Giacoimo Koch<sup>1</sup>, Elias Casula<sup>2</sup>, Sonia Bonni<sup>2</sup>, Borghi Ilaria<sup>2</sup>, Assogna Martina<sup>2</sup>, Maiella Michele<sup>2</sup>, Santarnecchi Emiliano<sup>3</sup>, Marco Bozzali<sup>4</sup>, Alessandro Martorana<sup>5</sup>  
<sup>1</sup>Santa Lucia Foundation IRCCSf Rome Tor Vergata - Rome (Italy), <sup>2</sup>Santa Lucia Foundation IRCCS - Rome (Italy), <sup>3</sup>MGH Harvard University - Boston (United States), <sup>4</sup>University of Turin - Turin (Italy), <sup>5</sup>University of Rome Tor Vergata - Rome (Italy)
- LP36** **ABvac40 elicits a predominantly Th2 immune response that supports its excellent safety profile**  
María Montañés<sup>1</sup>, Carlos Martín-Fortún<sup>1</sup>, Sergio Castillo<sup>1</sup>, Elisabeth Molina<sup>1</sup>, Jose Terencio<sup>1</sup>, Manuel Sarasa<sup>1</sup>  
<sup>1</sup>Araclon Biotech-Grifols - Zaragoza (Spain)
-  **LP37** **CY6463 administration in healthy participants was associated with improvements in Alzheimer's disease-relevant biomarkers based on a systematic analysis of multiple Phase 1 clinical trials using KEM® eXplainable AI**  
 Martin Kindermans<sup>1</sup>, Hichem Chakroun<sup>1</sup>, Jennifer Chickering<sup>2</sup>, Chad Glasser<sup>2</sup>, Pablo Iriso<sup>1</sup>, Frederic Parmentier<sup>1</sup>, Todd Milne<sup>2</sup>, Phebe Wilson<sup>2</sup>, Mohammad Afshar<sup>1</sup>  
<sup>1</sup>Ariana Pharma - Paris (France), <sup>2</sup>Cyclerion - Cambridge (United States)
-  **LP38** **A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy**  
Philippe Verwaerde<sup>1</sup>, Noelle Callizot<sup>1</sup>, Susanna Del Signore<sup>1</sup>, Aurelien Blondel<sup>1</sup>, Cecilia Estrella<sup>1</sup>  
<sup>1</sup>Alzprotect - Loos (France)
-  **LP39** **Three-year omega-3 PUFA trial targeting cerebral white matter lesions and integrity breakdown in older adults: ApoE stratified and exploratory results**  
Gene Bowman<sup>1</sup>, Charles Murchison<sup>2</sup>, Lisa Silbert<sup>3</sup>, Hiroko Dodge<sup>4</sup>, Kristen Hagen<sup>4</sup>, David Lahna<sup>4</sup>, Harris William<sup>5</sup>, Jeffrey Kaye<sup>3</sup>, Joseph Quinn<sup>3</sup>, Lynne Shinto<sup>4</sup>  
<sup>1</sup>McCance Center for Brain Health, Department of Neurology, Massachusetts General Brigham and Harvard Medical School - Boston (United States), <sup>2</sup>Department of Biostatistics, University of Alabama at Birmingham - Birmingham (United States), <sup>3</sup>Department of Neurology, Oregon Health & Science University and Veterans Affairs Portland Health Care System - Portland (United States), <sup>4</sup>Department of Neurology, Oregon Health & Science University - Portland (United States), <sup>5</sup>Department of Internal Medicine, University of South Dakota School of Medicine and Fatty Acid Research Institute - Sioux Falls (United States)
-  **LP40** **Accounting for Disease Modification in Models of Cost Effectiveness of MABs Such As Lecanemab and Donanemab**  
Suzanne Hendrix<sup>1</sup>, Craig Mallincrodt<sup>1</sup>, Samuel Dickson<sup>1</sup>  
<sup>1</sup>Pentara Corporation - Millcreek (United States)
-  **LP41** **Effectiveness of Digital-Based Multidomain Intervention for Mild Cognitive Impairment**  
Michael D. Patterson<sup>1</sup>, Jacklyn Leonardo<sup>1</sup>, Syaheed B. Jabar<sup>1</sup>, Yuri G. Rykov<sup>1</sup>, Bikram A Gangwar<sup>1</sup>, Jeremy Yee<sup>1</sup>, Nagaendran Kandiah<sup>2</sup>, Kok Pin Ng<sup>3</sup>  
<sup>1</sup>Neuroglee Therapeutics - Singapore (Singapore), <sup>2</sup>Lee Kong Chian School of Medicine - Singapore (Singapore), <sup>3</sup>National Neuroscience Institute - Singapore (Singapore)
-  **LP42** **The SENSE-Cog trial: A Europe-wide randomised controlled trial of hearing and vision augmentation in dementia**  
Iracema Leroi<sup>1</sup>, Elizabeth Camacho<sup>2</sup>, Nathalie Chaghil-Boissier<sup>3</sup>, Anna Pavlina Charalambous<sup>4</sup>, John-Paul Connolly<sup>1</sup>, Fofi Constantinidou<sup>5</sup>, Renaud David<sup>6</sup>, Rachel A Elliott<sup>2</sup>, Eric Frison<sup>3</sup>, Mark Hann<sup>2</sup>, Alison Holden<sup>2</sup>, Sean P Kennelly<sup>1</sup>, Brian A Lawlor<sup>1</sup>, Julie Longobardi<sup>3</sup>, Antonios M Politis<sup>7</sup>  
<sup>1</sup>Trinity College Dublin - Dublin (Ireland), <sup>2</sup>University of Manchester - Manchester (United Kingdom), <sup>3</sup>University of Bordeaux - Bordeaux (France), <sup>4</sup>European University of Cyprus - Nicosia (Cyprus), <sup>5</sup>University of Cyprus - Nicosia (Cyprus), <sup>6</sup>University of Nice Sophia Antipolis - Nice (France), <sup>7</sup>National and Kapodistrian University - Athens (Greece)
-  **LP43** **MRI changes following treatment of GLP-1 analogue, liraglutide, in patients with Alzheimer's disease (ELAD Study)**  
Paul Edison<sup>1</sup>, Gracia Daniela Femminella<sup>1</sup>, Ritche Craig<sup>2</sup>, Nowell Joseph<sup>2</sup>, Livingston Nicholas<sup>1</sup>, Zuzana Walker<sup>3</sup>, Ridha Basil<sup>4</sup>, Archer Hilary<sup>5</sup>, Karim Salman<sup>6</sup>, Tados George<sup>7</sup>, Koranteng Paul<sup>7</sup>, Holscher Christian<sup>8</sup>, Hinz Rainer<sup>9</sup>, Passmore Peter<sup>10</sup>, Ballard Clive<sup>11</sup>  
<sup>1</sup>Imperial College London - London (United Kingdom), <sup>2</sup>The university of Edinburgh - Edinburgh (United Kingdom), <sup>3</sup>University College London - London (United Kingdom), <sup>4</sup>Brighton and Sussex University Hospitals NHS Trust - Brighton (United Kingdom), <sup>5</sup>University of Bristol - University Of Bristol (United Kingdom), <sup>6</sup>Lancashire NHS Trust - Lancashire (United Kingdom), <sup>7</sup>Birmingham University Hospital - Birmingham (United Kingdom), <sup>8</sup>Henan University of Chinese Medicine - Henan (China), <sup>9</sup>University of Manchester - Manchester (United Kingdom), <sup>10</sup>Queens University - Belfast (United Kingdom), <sup>11</sup>University of Exeter - Exeter (United Kingdom)
- LP44** **The effects of Pomegranate Seed Oil on Mild Cognitive Impairment**  
Thanos Chatzikostopoulos<sup>1</sup>, Magda Tsolaki<sup>1</sup>  
<sup>1</sup>Greek Association of Alzheimer's Disease and Related Disorders - Thessaloniki (Greece)



## THEME: Beyond Amyloid and Tau: Emerging Solutions

-  **P050** **Mitochondrial methylcytosines as novel blood-based biomarkers for predicting progression to Alzheimer's disease dementia at the mild cognitive impairment stage: a machine learning approach**  
 Jose Luis Mosquera<sup>1</sup>, Marta Blanch<sup>1</sup>, Nuria Rojo<sup>2</sup>, Inma Rico<sup>2</sup>, Jaume Campdelacreu<sup>2</sup>, Beatriz Fontal<sup>1</sup>, Paula Ferrer<sup>1</sup>, Christopher Fowler<sup>3</sup>, Simon Laws<sup>4</sup>, Adrià Tort-Merino<sup>5</sup>, Raquel Sanchez-Valle<sup>5</sup>, Ramon Rene-Ramirez<sup>2</sup>, Jordi Gascon<sup>2</sup>, Marta Barrachina<sup>1</sup>  
<sup>1</sup>ADmit Therapeutics SL - Barcelona (Spain), <sup>2</sup>Functional Unit of Dementia, Service of Neurology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, IDIBELL - Barcelona (Spain), <sup>3</sup>The Florey Institute, The University of Melbourne - Melbourne (Australia), <sup>4</sup>Collaborative Genomics and Translation Group, Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University - Joondalup (Australia), <sup>5</sup>Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona - Barcelona (Spain)
-  **P051** **Improvement of cognitive dysfunction following repeated infusion of adipose tissue-derived stem cells**  
Kazuo Shigematsu<sup>1</sup>, Mitsuko Ideno<sup>2</sup>, Noyuki Komori<sup>3</sup>, Hisakazu Yamagishi<sup>4</sup>  
<sup>1</sup>Minami Kyoto Hospital - Joyo (Japan), <sup>2</sup>Takara Bio Inc. - Kyoto (Japan), <sup>3</sup>Nagitsuji Hospital - Kyoto (Japan), <sup>4</sup>Kyoto Prefectural University Of Medicine - Kyoto (Japan)
-  **P052** **Novel application of deep canonical correlation analysis identifies regional brain atrophy linked to proinflammatory gut microbial genera before cognitive decline**  
Margo Heston<sup>1,2</sup>, Zihang Meng<sup>3</sup>, Akshay Kohli<sup>1,2</sup>, Antonio González<sup>4</sup>, Sterling Johnson<sup>1,2,5</sup>, Rob Knight<sup>4,6,7,8</sup>, Rima Kaddurah-Daouk<sup>9,10,11,12</sup>, Federico Rey<sup>13</sup>, Vikas Singh<sup>3,14,15</sup>, Barbara Bendlin<sup>1,2,5</sup>  
<sup>1</sup>Wisconsin Alzheimer's Disease Research Center - Madison (United States), <sup>2</sup>Division of Geriatrics, Department of Medicine, University of Wisconsin School of Medicine and Public Health - Madison (United States), <sup>3</sup>Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison - Madison (United States), <sup>4</sup>Department of Pediatrics, University of California, San Diego - La Jolla (United States), <sup>5</sup>Wisconsin Alzheimer's Institute - Madison (United States), <sup>6</sup>Department of Bioengineering, University of California, San Diego - La Jolla (United States), <sup>7</sup>Department of Computer Science & Engineering, University of California, San Diego - La Jolla (United States), <sup>8</sup>Center for Microbiome Innovation, University of California, San Diego - La Jolla (United States), <sup>9</sup>Department of Psychiatry and Behavioral Sciences, Duke University - Durham (United States), <sup>10</sup>Department of Medicine, Duke University - Durham (United States), <sup>11</sup>Duke Institute of Brain Sciences, Duke University - Durham (United States), <sup>12</sup>Duke University Medical Center - Durham (United States), <sup>13</sup>Department of Bacteriology, University of Wisconsin - Madison (United States), <sup>14</sup>Department of Computer Sciences, University of Wisconsin-Madison - Madison (United States), <sup>15</sup>Department of Statistics, University of Wisconsin-Madison - Madison (United States)
-  **P053** **Beyond targeting Ab and tau: Novel formulations of alpha-cyclodextrins for the safe (not ototoxic) and convenient (oral) Prevention and Treatment of Alzheimer's Disease**  
Knut Wittkowski<sup>1</sup>  
<sup>1</sup>Asdera LLC - New York (United States)
-  **P054** **Lomecel-B as a Geroscience Therapeutic Candidate for Dementia and Frailty**  
Anthony Oliva<sup>1</sup>, Kevin Ramdas<sup>1</sup>, Lisa McClain-Moss<sup>1</sup>, Dan Gincel<sup>1</sup>, Danial Mehranfarid<sup>1</sup>, K. Chris Min<sup>1</sup>, Joshua Hare<sup>1</sup>  
<sup>1</sup>Longeveron Inc. - Miami (United States)
-  **P055** **Establishing fluid biomarkers associated with cellular senescence in Alzheimer's disease**  
Bryan Ng<sup>1</sup>, Amanda Heslegrave<sup>1,2</sup>, Nick Fox<sup>1,3</sup>, Henrik Zetterberg<sup>1,2,4</sup>  
<sup>1</sup>Dementia Research Institute, University College London - London (United Kingdom), <sup>2</sup>Department of Neurodegenerative Disease, University College London - London (United Kingdom), <sup>3</sup>Dementia Research Centre, Queen Square Institute of Neurology, University College London - London (United Kingdom), <sup>4</sup>Department of Psychiatry and Neurochemistry, University of Gothenburg - Mölndal (Sweden)
- P056** **The Gut-PRO Study: A Pilot Probiotic Intervention Study in Alzheimer's Disease**  
Jea Woo Kang<sup>1</sup>, Sandra J. Harding<sup>1</sup>, Margo Heston<sup>1</sup>, Alfred Eiji s Braceros<sup>1</sup>, Nancy Davenport-Sis<sup>1</sup>, Nathaniel Chin<sup>1</sup>, Henrik Zetterberg<sup>2</sup>, Federico Rey<sup>1</sup>, Barbara b Bendlin<sup>1</sup>  
<sup>1</sup>University of Wisconsin-Madison - Madison (United States), <sup>2</sup>University of Gothenburg, Sahlgrenska University Hospital - Mölndal (Sweden)
-  **P057** **The potential of flavonoids to enhance mitochondrial function and protect neurons from degeneration in Alzheimer's disease**  
Maria Ankarcrona<sup>1</sup>, Luana Naia<sup>1</sup>, Giacomo Dentoni<sup>1</sup>, Makoto Shimozawa<sup>1</sup>, Erika Bereczki<sup>1</sup>, Xidan Li<sup>2</sup>, Jianping Liu<sup>3</sup>, Nuno Santos Leal<sup>3</sup>, Benjamin Portal<sup>4</sup>, Maria Lindskog<sup>4</sup>, Per Nilsson<sup>1</sup>, Massimiliano Gaetani<sup>1</sup>  
<sup>1</sup>Karolinska Institutet (KI) - Solna (Sweden), <sup>2</sup>Tsinghua University - Tsinghua (China), <sup>3</sup>Karolinska Institutet (KI) - Huddinge (Sweden), <sup>4</sup>Uppsala University - Uppsala (Sweden)
- P058** **An online dementia prevention using the Cogstim model: A pilot study**  
Raymond Ownby<sup>1,2</sup>  
<sup>1</sup>Nova Southeastern University - Fort Lauderdale FL (United States), <sup>2</sup>Enlan Communications, Inc. - Fort Lauderdale FL (United States)
-  **P059** **Effects of non-invasive brain stimulation on individual alpha power**  
Oezguer A. Onur<sup>1</sup>, Ronja Fassbender<sup>1</sup>  
<sup>1</sup>Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany - Cologne (Germany)
-  **P060** **A pragmatic assessment of ultra-fast MRI in real-life clinical and research cognitive practice**  
Miguel Rosa-Grilo<sup>1</sup>, Eoin Mulroy<sup>1</sup>, Millie Beament<sup>1</sup>, Haroon Chughtai<sup>2</sup>, Dave Thomas<sup>1</sup>, Geoff Parker<sup>2</sup>, Nick Fox<sup>1</sup>, Catherine Mummery<sup>1</sup>  
<sup>1</sup>UK Dementia Research Centre at University College London (UCL) - London (United Kingdom), <sup>2</sup>Centre for Medical Image Computing, Department of Medical Physics & Biomedical Engineering and Department of Neuroinflammation at University College London (UCL) - London (United Kingdom)
- P061** **Optimal conditions for entraining gamma waves using sensory stimulation in older adults**  
Yeseung Park<sup>1</sup>, Euisuk Yoon<sup>1</sup>, Ki Woong Kim<sup>1</sup>  
<sup>1</sup>Seoul National University - Seoul (Korea, Republic of)

- P062** Serum levels of glucan epitope correlate with tau and predict progression to dementia in combination with APOE4 allele status  
Robin Ziyue Zhou<sup>1</sup>, Davide Liborio Vetrano<sup>2</sup>, Giulia Grande<sup>2</sup>, Bengt Winblad<sup>1</sup>, Lars Tjernberg<sup>1</sup>, Sophia Schedin-Weiss<sup>1</sup>  
<sup>1</sup>Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet - Solna (Sweden), <sup>2</sup>Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University - Stockholm (Sweden)
- P063** Serum proBDNF predicts memory gains after lifestyle changes in elderly persons - A subgroup analysis among adherent participants in the FINGER study  
Anna Matton<sup>1</sup>, Krister Håkansson<sup>1</sup>, Julen Goicolea<sup>1</sup>, Makrina Daniilidou<sup>1</sup>, Tiia Ngandu<sup>2</sup>, Gorka Gerenu<sup>1</sup>, Alina Solomon<sup>3</sup>, Hilka Soininen<sup>3</sup>, Tiina Laatikainen<sup>2</sup>, Miia Kivipelto<sup>1</sup>  
<sup>1</sup>Karolinska Institutet - Solna (Sweden), <sup>2</sup>Finnish Institute on Health and Welfare - Helsinki (Finland), <sup>3</sup>University of Eastern Finland - Kuopio (Finland)
- P064** Evaluation of long-term safety and compliance to a multinutrient intervention for up to 8 years in mild cognitive impairment / prodromal Alzheimer's disease: data from the randomised controlled LipiDiDiet trial  
Tobias Hartmann<sup>1,2</sup>, Alina Solomon<sup>3,4,5</sup>, Pieter Visser<sup>6,7</sup>, Kai Blennow<sup>8,9</sup>, Miia Kivipelto<sup>10,11,5</sup>, Hilka Soininen<sup>12,10</sup>  
<sup>1</sup>Deutsches Institut für Demenzprävention, Saarland University - Homburg (Germany), <sup>2</sup>Experimental Neurology - Homburg (Germany), <sup>3</sup>Neurology, Institute of Clinical Medicine, University of Eastern Finland - Kuopio (Finland), <sup>4</sup>Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute - Stockholm (Sweden), <sup>5</sup>Clinical Trials Unit, Theme Aging, Karolinska University Hospital - Huddinge (Sweden), <sup>6</sup>Department of Neurology, Alzheimer Center, VU University Medical Center - Amsterdam (Netherlands), <sup>7</sup>Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht - Maastricht (Netherlands), <sup>8</sup>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg - Mölndal (Sweden), <sup>9</sup>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), <sup>10</sup>Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland - Kuopio (Finland), <sup>11</sup>Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute - Stockholm (Sweden), <sup>12</sup>Neurocenter, Department of Neurology, Kuopio University Hospital - Kuopio (Finland)
- P066** Clinical utility of non-invasive whole transcriptomic profiling of Alzheimer's disease  
 Shusuke Toden<sup>1</sup>, Jiali Zhuang<sup>1</sup>, Stephen Quake<sup>2</sup>, Robert Rissman<sup>3</sup>, James Brewer<sup>3</sup>, John Sninsky<sup>1</sup>  
<sup>1</sup>Molecular Stethoscope - South San Francisco (United States), <sup>2</sup>Stanford University - Stanford (United States), <sup>3</sup>University of California, San Diego - San Diego (United States)
- P067** Development of a selective estrogen  $\beta$ -receptor phytoestrogen formulation - PhytoSERM - for improving cognitive health to reduce Alzheimer's risk and menopausal symptoms: A Phase 2 randomized clinical trial  
 Claudia Lopez<sup>1</sup>, Mark Drew<sup>1</sup>, Gerson Hernandez<sup>1</sup>, Roberta Brinton<sup>1</sup>  
<sup>1</sup>University of Arizona - Tucson (United States)
- P068** Determinants of Individual Differences in the Efficacy of Aerobic Exercise to Improve Brain Health and Reduce Alzheimer's Disease Risk in Older African Americans  
 Mark Gluck<sup>1</sup>, Bernadette Fausto<sup>1</sup>  
<sup>1</sup>Rutgers University-Newark - Newark, Nj (United States)
- LP45** Phylum Firmicutes abundance is associated with brain volumes in a cognitively unimpaired cohort enriched for Alzheimer's disease risk  
Muhaison Ibrahim<sup>1</sup>, Heston Margo<sup>1</sup>, Jea Woo Kang<sup>1</sup>, Gilda Ennis<sup>1</sup>, Sandra Harding<sup>1</sup>, Sterling Johnson<sup>1</sup>, Sanjay Asthana<sup>1</sup>, Barbara Bendlin<sup>1</sup>, Antonio González<sup>2</sup>, Federico Rey<sup>1</sup>, Rob Knight<sup>2</sup>, Rima Kaddurah-Daouk<sup>3</sup>  
<sup>1</sup>University of Wisconsin school of Medicine and Public Health - Madison (United States), <sup>2</sup>department of pediatrics, university of california, san diego - la jolla - La Jolla (United States), <sup>3</sup>Department of Psychiatry and Behavioral Sciences, Duke - Durham (United States)
- LP46** Optimizing detection of prodromal Alzheimer disease in mild cognitive impairment - a 4-year cerebrospinal fluid study of mild behavioral impairment in ADNI and MEMENTO  
Zahinoor Ismail<sup>1</sup>, Rebeca Leon<sup>2</sup>, Byron Creese<sup>3</sup>, Clive Ballard<sup>3</sup>, Philippe Robert<sup>4</sup>, Eric E. Smith<sup>1</sup>  
<sup>1</sup>University of Calgary - Calgary (Canada), <sup>2</sup>Hotchkiss Brain Institute - Calgary (Canada), <sup>3</sup>University of Exeter - Exeter (United Kingdom), <sup>4</sup>Université Côte d'Azur - Nice (France)
- LP47** Comparison of cytokine profile in older adults with positive and negative protein biomarkers A $\beta$ 42, p-Tau, t-Tau and p-Tau /A $\beta$ 42 ratio  
Ivonne Carolina Bolaños Burgos<sup>1,2,3,4</sup>, Gabriela Tomé Oliveira Engelmam<sup>5,6,4</sup>, Erika Oliveira Hansen<sup>7</sup>, Natalia Silva Dias<sup>2,8</sup>, Andréa Teixeira Carvalho<sup>9</sup>, Daniela Valadão<sup>10,4</sup>, Débora Miranda<sup>2,10,11</sup>, Marco Aurélio Romano-Silva<sup>2,10,4</sup>, Bernardo Mattos Viana<sup>2,8,12</sup>, Maria Aparecida Camargos Bicalho<sup>2,5,1,4</sup>  
<sup>1</sup>Adult Health Sciences Applied Program - Belo Horizonte (Brazil), <sup>2</sup>Hospital das Clínicas - Belo Horizonte (Brazil), <sup>3</sup>National Institute of Science and Technology of Molecular Medicine (INCT-MM), Faculdade de Medicina, Universidade Federal de Minas Gerais - Belo Horizonte (Brazil), <sup>4</sup>Universidade Federal de Minas Gerais - Belo Horizonte (Brazil), <sup>5</sup>Molecular Medicine Program - Belo Horizonte (Brazil), <sup>6</sup>Jenny de Andrade Faria Institute- Reference Center for the Elderly Hospital das Clínicas - Belo Horizonte (Brazil), <sup>7</sup>Jenny de Andrade Faria Institute- Reference Center for the Elderly, Hospital das Clínicas - Belo Horizonte (Brazil), <sup>8</sup>Older Adult Psychiatry and Psychology Extension Program (PROEPSI) - Belo Horizonte (Brazil), <sup>9</sup>René Rachou Institute, Oswaldo Cruz Foundation (Fiocruz) - Belo Horizonte (Brazil), <sup>10</sup>National Institute of Science and Technology of Molecular Medicine (INCT-MM) Faculdade de Medicina, Universidade Federal de Minas Gerais - Belo Horizonte (Brazil), <sup>11</sup>Universidade Federal de Minas Gerais - Belo Horizonte (Bouvet Island), <sup>12</sup>Department of Mental Health Faculdade de Medicina, Universidade Federal de Minas Gerais - Belo Horizonte (Brazil)
- LP48** Early Detection of Alzheimer's Disease using microRNAs  
Bruno Steinkraus<sup>1</sup>, Marco Heuvelman<sup>1</sup>, Jeffrey L Cummings<sup>2</sup>, Jean Manson<sup>3</sup>, Craig Ritchie<sup>3</sup>  
<sup>1</sup>Hummingbird Diagnostics - Heidelberg (Germany), <sup>2</sup>Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas - Las Vegas (United States), <sup>3</sup>Centre for Clinical Brain Sciences, The University of Edinburgh - Edinburgh (United Kingdom)
- LP49** Amyloid models for quantitative X-ray imaging  
Karthika Suresh<sup>1</sup>, Eshan Dahal<sup>1</sup>, Aldo Badano<sup>1</sup>  
<sup>1</sup>Division of Imaging, Diagnostics, and Software Reliability, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, Food and Drug Administration - Silver Spring (United States)

## THEME: Clinical Trials Imaging

-  **P069** Do the radiomics or structural and functional magnetic resonance imaging give additional information to predict brain amyloid positivity?  
Yoojin Lee<sup>1</sup>, Sungyang Jo<sup>1</sup>, Jae-Hong Lee<sup>1</sup>  
<sup>1</sup>Asan Medical Center - Seoul (Korea, Republic of)
-  **P070** Differential effects of cardiometabolic syndrome on brain age in relation to sex and ethnicity  
Sung Hoon Kang<sup>1</sup>, Mengting Liu<sup>2</sup>, Sang Won Seo<sup>3</sup>, Hosung Kim<sup>2</sup>  
<sup>1</sup>Department Of Neurology, Korea University Guro Hospital, Korea University College Of Medicine - Seoul (Korea, Republic of), <sup>2</sup>Usc Steven Neuroimaging And Informatics Institute, Keck School Of Medicine Of University Of Southern California - Los Angeles (United States), <sup>3</sup>Departments Of Neurology, Samsung Medical Center, Sungkyunkwan University School Of Medicine - Seoul (Korea, Republic of)
- P071** Genome-Wide Association Study of the functional brain network for Alzheimer's Disease  
Minji Kim<sup>1</sup>, Jong-Min Lee<sup>2</sup>  
<sup>1</sup>Department Of Electronic Engineering, Hanyang University - Seoul (Korea, Republic of), <sup>2</sup>Department Of Biomedical Engineering, Hanyang University - Seoul (Korea, Republic of)
-  **P072** Clinical and radiomic features for predicting the treatment response of repetitive transcranial magnetic stimulation in major neurocognitive disorder  
Hanna Lu<sup>1</sup>, Sandra Sau Man Chan<sup>1</sup>, Suk Ling Ma<sup>1</sup>, Vincent Chung Tong Mok<sup>1</sup>, Lin Shi<sup>1</sup>, Arthur Dun-Ping Mak<sup>1</sup>, Linda Chiu Wa Lam<sup>1</sup>  
<sup>1</sup>The Chinese University of Hong Kong - Hong Kong (Hong Kong)
-  **P073** Association of regional amyloid burden and brain volume with cognitive performances among individuals with subjective cognitive decline  
Chonghee Lee<sup>1</sup>, Dong Won Yang<sup>1</sup>, Yun Jeong Hong<sup>2</sup>, Seonghee Ho<sup>3</sup>, Jee Hyang Jeong<sup>4</sup>, Kee Hyung Park<sup>5</sup>, Sangyun Kim<sup>6</sup>, Min Jeong Wang<sup>7</sup>, Seong Hye Choi<sup>8</sup>, Sanggyu Lee<sup>9</sup>  
<sup>1</sup>Neurology, Catholic University Of Korea, Seoul St. Mary's Hospital - Seoul (Korea, Republic of), <sup>2</sup>Neurology, Catholic University Of Korea, Seoul St. Mary's Hospital - Uijeongbu (Korea, Republic of), <sup>3</sup>Neurology, Changwon Hanmaeum Hospital - Changwon (Korea, Republic of), <sup>4</sup>Neurology, Womans University School Of Medicine, Ewha Womans University Seoul Hospital - Seoul (Korea, Republic of), <sup>5</sup>Neurology, Gachon University Gil Hospital - Incheon (Korea, Republic of), <sup>6</sup>Neurology, Seoul National University College Of Medicine, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of), <sup>7</sup>Neurology, Roa Clinic - Seongnam (Korea, Republic of), <sup>8</sup>Neurology, Inha University School Of Medicine, Inha University Hospital - Incheon (Korea, Republic of), <sup>9</sup>Neolab Convergence Inc. - Seoul (Korea, Republic of)
-  **P074** The role of subthreshold levels of amyloid deposition on dementia conversion-validated with ADNI  
Hyung-Ji Kim<sup>1</sup>, Jae-Hong Lee<sup>2</sup>  
<sup>1</sup>Uijeongbu Eulji Medical Center - Uijeongbu-Si (Korea, Republic of), <sup>2</sup>Asan Medical Center - Seoul (Korea, Republic of)
- P075** Evaluation of a clinically validated digital platform to provide Diffusion MRI biomarkers in Alzheimer's disease  
Etienne Bories<sup>1</sup>, Arthur Bezie<sup>1</sup>, Didier Cassereau<sup>1</sup>, Julie Rachline<sup>1</sup>, Ilyed Trimeche<sup>1</sup>, Jean-Baptiste Martini<sup>1</sup>, Vincent Perlbarg<sup>1</sup>  
<sup>1</sup>BRAINTALE SAS - Strasbourg (France)
-  **P076** Increase in white matter volume and myelination after 6 months of 40Hz gamma sensory stimulation therapy in patients on Alzheimer's Disease spectrum  
Xiao Da<sup>1</sup>, Evan Hempel<sup>1</sup>, Holly Mrozak<sup>1</sup>, Zach Malchano<sup>1</sup>, Brent Vaughan<sup>1</sup>, J. Thomas Megerian<sup>1</sup>, Mihaly Hajos<sup>1,2</sup>, Aylin Cimenser<sup>1</sup>  
<sup>1</sup>Cognito Therapeutics - Cambridge, Ma (United States), <sup>2</sup>Yale University School of Medicine - New Haven, Ct (United States)
-  **P077** Summary of ACR Phantom MRI site qualification findings over 7 years and recommendations moving forward  
Luc Bracoud<sup>1</sup>, Joonmi Oh<sup>2</sup>, Qui Cao<sup>2</sup>, Chris Conklin<sup>3</sup>, Madhura Ingalthalakar<sup>3</sup>, Ha Pham<sup>2</sup>, David Scott<sup>2</sup>, Joyce Suh<sup>2</sup>  
<sup>1</sup>Clario (formerly Bioclinica) - Lyon (France), <sup>2</sup>Clario (formerly Bioclinica) - San Mateo (United States), <sup>3</sup>Clario (formerly Bioclinica) - Princeton (United States)
- P078** Amyloid-based disease models for clinical endpoint prediction in Alzheimer's disease  
Luis Peraza<sup>1</sup>, Richard Joules<sup>1</sup>, Robin Wolz<sup>1</sup>  
<sup>1</sup>IXICO - London (United Kingdom)
-  **P079** Effects of Alzheimer and Lewy Body Disease Pathologies on Brain Metabolism  
Byong Seok Ye<sup>1</sup>, Sungwoo Kang<sup>2</sup>  
<sup>1</sup>MD. PhD - Seoul (Korea, Republic of), <sup>2</sup>MD - Seoul (Korea, Republic of)
-  **P080** REDucing Sleep Apnoea for the PrEvention of Dementia (RESHAPED): The protocol of a multi-site feasibility randomised controlled trial  
Sharon Naismith<sup>1</sup>, Camilla Hoyos<sup>1</sup>, Craig Phillips<sup>1</sup>, Yaffe Kristine<sup>2</sup>, Ralph Martins<sup>3</sup>, Nathaniel Marshall<sup>1</sup>, Jim Lagopoulos<sup>4</sup>, Melinda Jackson<sup>5</sup>, Loren Mowszowski<sup>1</sup>, Ronald Grunstein<sup>1</sup>  
<sup>1</sup>University of Sydney - Sydney (Australia), <sup>2</sup>University of California - San Francisco (United States), <sup>3</sup>University of Macquarie - Sydney (Australia), <sup>4</sup>University of Sunshine Coast - Sunshine Coast (Australia), <sup>5</sup>Monash University - Melbourne (Australia)
-  **P081** Arterial stiffness is associated with cortical tau burden  
Young Noh<sup>1</sup>  
<sup>1</sup>Gachon University Gil Medical Center - Incheon (Korea, Republic of)

-  **P082** **Application of fully automatic Hippocampal sub-field segmentation volumes to standard resolution T1 MR Imaging in Alzheimer's disease**  
Richard Joules <sup>1</sup>, [Robin Wolz](#) <sup>1</sup>  
<sup>1</sup>*IXICO - London (United Kingdom)*
-  **P083** **Amyloid PET centiloid: impact of calibration and processing steps**  
Luca Presotto <sup>1</sup>, Mahnaz Shekari <sup>2</sup>, Lyduine E. Collij <sup>3</sup>, Richard Manber <sup>1</sup>, David Vallez Garca <sup>3</sup>, Juan Domingo Gispert Lopez <sup>2</sup>, [Robin Wolz](#) <sup>1</sup>  
<sup>1</sup>*IXICO - London (United Kingdom)*, <sup>2</sup>*BarcelonaBeta Brain Research Centre, Pasqual Maragall Foundation - Barcelona (Spain)*, <sup>3</sup>*Amsterdam UMC - Amsterdam (Netherlands)*
-  **P084** **Independent effects of hippocampal subfield volumes and p-tau on memory performance in clinically unimpaired older adults**  
[Tammy Tran](#) <sup>1</sup>, Alexandra Trelle <sup>1</sup>, Wilson Edward <sup>1</sup>, Gayle Deutsch <sup>1</sup>, Sharon Sha <sup>1</sup>, Katrin Andreasson <sup>1</sup>, Valerie Carr <sup>1</sup>, Geoffrey Kerchner <sup>1</sup>, Elizabeth Mormino <sup>1</sup>, Anthony Wagner <sup>1</sup>  
<sup>1</sup>*Stanford University - Stanford (United States)*
-  **P085** **Supporting the Communication of Modern Alzheimer's Data through Augmented Reality and Web Technologies**  
[Tyler Ard](#) <sup>1</sup>, Bienkowski Michael <sup>1</sup>, Arthur Toga <sup>1</sup>  
<sup>1</sup>*USC Stevens Neuroimaging and Informatics Institute - Los Angeles (United States)*
-  **P086** **Longitudinal assessment of novel imaging markers of neuroinflammation, axonal density and demyelination as biomarkers in Alzheimer's Disease**  
Maggie Roy <sup>1</sup>, [Jean-Rene Belanger](#) <sup>1</sup>, Matthieu Dumont <sup>1</sup>, Jean-Christophe Houde <sup>1</sup>, Maxime Descoteaux <sup>1</sup>  
<sup>1</sup>*Imeka - Sherbrooke (Canada)*
-  **P087** **Predicting PET-determined ATN biomarker status in Alzheimer's disease with MRI using deep convolutional neural networks**  
[Christopher Lew](#) <sup>1</sup>, Longfei Zhou <sup>1</sup>, Maciej Mazurowski <sup>1</sup>, P Murali Doraiswamy <sup>1</sup>, Susan Landau <sup>2</sup>, Jeffrey Petrella <sup>3</sup>  
<sup>1</sup>*Duke University Medical Center - Durham (United States)*, <sup>2</sup>*University of California, Berkeley - Berkeley (United States)*, <sup>3</sup>*Duke University Medical Center - Durham (United States)*
-  **P088** **Early [18F]-PI-2620 tau PET signal in the stages preceding AD dementia**  
[Christina Young](#) <sup>1</sup>, Hillary Vossler <sup>1</sup>, Edward Wilson <sup>1</sup>, Alexandra Trelle <sup>2</sup>, Kathleen Poston <sup>1</sup>, Michael Zeineh <sup>1</sup>, Michael Greicius <sup>1</sup>, Greg Zaharchuk <sup>1</sup>, Victor Henderson <sup>1</sup>, Anthony Wagner <sup>2</sup>, Katrin Andreasson <sup>1</sup>, Guido Davidzon <sup>1</sup>, Elizabeth Mormino <sup>1</sup>  
<sup>1</sup>*Stanford ADRC - Stanford (United States)*, <sup>2</sup>*Stanford Department of Psychology - Stanford (United States)*
-  **P089** **Amyloid and tau burden in an at-risk, cognitively unimpaired clinical trial cohort: Neuroimaging data from the U.S. POINTER trial**  
[Alice Murphy](#) <sup>1</sup>, Theresa Harrison <sup>1</sup>, Tyler Ward <sup>1</sup>, Prashanthi Vemuri <sup>2</sup>, Robert Koeppe <sup>3</sup>, Samuel Lockhart <sup>4</sup>, Mark Espeland <sup>4</sup>, Danielle Harvey <sup>5</sup>, Joseph Masdeu <sup>6</sup>, Hwamee Oh <sup>7</sup>, Darren Gitelman <sup>8</sup>, Neelum Aggarwal <sup>9</sup>, Laura Baker <sup>4</sup>, Charles Decarli <sup>5</sup>, Susan Landau <sup>1</sup>  
<sup>1</sup>*U.C. Berkeley (United States)*, <sup>2</sup>*Mayo Clinic (United States)*, <sup>3</sup>*University of Michigan (United States)*, <sup>4</sup>*Wake Forest School of Medicine (United States)*, <sup>5</sup>*U.C. Davis (United States)*, <sup>6</sup>*Houston Methodist (United States)*, <sup>7</sup>*Brown University (United States)*, <sup>8</sup>*Advocate Lutheran General Hospital (United States)*, <sup>9</sup>*Rush University Medical Center (United States)*
-  **LP50** **First microtubule-based PET imaging studies in cognitively normal and impaired older adult subjects--a pilot study**  
Naresh Damuka <sup>1</sup>, Bhuvanachandra Bhoopal <sup>1</sup>, Mack Miller <sup>1</sup>, Ivan Krizan <sup>1</sup>, Samuel Lockhart <sup>1</sup>, Melissa Rundle <sup>1</sup>, Akiva Mintz <sup>2</sup>, Suzanne Craft <sup>1</sup>, [Kiran K Solingapuram Sai](#) <sup>1</sup>  
<sup>1</sup>*Wake Forest School of Medicine - Winston Salem (United States)*, <sup>2</sup>*Columbia University Medical Center - New York (United States)*
-  **LP51** **Comparative Study on the Predictive Value of Different Resting-State Functional Magnetic Resonance Imaging Parameters in Preclinical Alzheimer's Disease**  
[Won-Myong Bahk](#) <sup>1</sup>, Young-Joon Kwon <sup>2</sup>, Bo-Hyun Yoon <sup>3</sup>, Kwanghun Lee <sup>4</sup>, Sang-Yeol Lee <sup>5</sup>, Moon-Doo Kim <sup>6</sup>, Beomwoo Nam <sup>7</sup>, Sung-Yong Park <sup>8</sup>, Eunsung Lim <sup>9</sup>, Sheng-Min Wang <sup>1</sup>, Hyun Kook Lim <sup>1</sup>  
<sup>1</sup>*The Catholic University of Korea - Seoul (Korea, Republic of)*, <sup>2</sup>*Soonchunhyang University - Cheonan (Korea, Republic of)*, <sup>3</sup>*Naju National Hospital - Naju (Korea, Republic of)*, <sup>4</sup>*Dongguk University - Gyeongju (Korea, Republic of)*, <sup>5</sup>*Wonkwang University - Iksan (Korea, Republic of)*, <sup>6</sup>*Jeju National University - Jeju (Korea, Republic of)*, <sup>7</sup>*Dr. Nam's Psychiatric Clinic - Chungju (Korea, Republic of)*, <sup>8</sup>*Keyo Hospital - Uiwang (Korea, Republic of)*, <sup>9</sup>*Shinsegae Hyo Hospital - Kimje (Korea, Republic of)*
-  **LP52** **Development of Random Forest Algorithm Based Prediction Model of Alzheimer's Disease Using Neurodegeneration Pattern**  
[Kwanghun Lee](#) <sup>1</sup>, Won-Myong Bahk <sup>2</sup>, Young-Joon Kwon <sup>3</sup>, Bo-Hyun Yoon <sup>4</sup>, Sang-Yeol Lee <sup>5</sup>, Moon-Doo Kim <sup>6</sup>, Beomwoo Nam <sup>7</sup>, Sung-Yong Park <sup>8</sup>, Eunsung Lim <sup>9</sup>, Sheng-Min Wang <sup>2</sup>, Hyun Kook Lim <sup>2</sup>  
<sup>1</sup>*Department of Psychiatry Dongguk University Hospital - Gyeongju (Korea, Republic of)*, <sup>2</sup>*Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)*, <sup>3</sup>*Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University - Cheonan (Korea, Republic of)*, <sup>4</sup>*Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of)*, <sup>5</sup>*Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of)*, <sup>6</sup>*Department of Psychiatry, Jeju National University School of Medicine - Jeju (Korea, Republic of)*, <sup>7</sup>*Dr. Nam's Psychiatric Clinic - Chungju (Korea, Republic of)*, <sup>8</sup>*Department of Psychiatry, Keyo Hospital - Uiwang (Korea, Republic of)*, <sup>9</sup>*Department of Psychiatry, Shinsegae Hyo Hospital - Kimje (Korea, Republic of)*
-  **LP53** **Association between white matter hyperintensities (WMH) volume and cognitive function in Alzheimer's disease**  
[Yoon Bo-Hyun](#) <sup>1</sup>, Bahk Won-Myong <sup>2</sup>, Kwon Young-Joon <sup>3</sup>, Lee Kwanghun <sup>4</sup>, Lee Sang-Yeol <sup>5</sup>, Kim Moon-Doo <sup>6</sup>, Nam Beomwoo <sup>7</sup>, Park Sung-Yong <sup>8</sup>, Lim Eunsung <sup>9</sup>  
<sup>1</sup>*Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of)*, <sup>2</sup>*Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)*, <sup>3</sup>*Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University - Cheonan (Korea, Republic of)*, <sup>4</sup>*Department of Psychiatry, College of Medicine, Dongguk University - Gyeongju (Korea, Republic of)*, <sup>5</sup>*Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of)*, <sup>6</sup>*Department of Psychiatry, Jeju National University School of Medicine - Jeju (Korea, Republic of)*, <sup>7</sup>*Dr. Nam's Psychiatric Clinic - Chungju (Korea, Republic of)*, <sup>8</sup>*Department of Psychiatry, Keyo Hospital - Uiwang (Korea, Republic of)*, <sup>9</sup>*Department of Psychiatry, Shinsegae Hyo Hospital - Kimje (Korea, Republic of)*

-  **LP53A** **Cross sectional association between frailty and white matter hyperintensity among Alzheimer`s disease**  
Kim Moon-Doo<sup>1</sup>, Bahk Won-Myong Bahk<sup>2</sup>, Kwon Young-Joon<sup>3</sup>, Yoon Bo-Hyun<sup>4</sup>, Lee Kwanghun<sup>5</sup>, Lee Sang-Yeol<sup>6</sup>, Nam Beomwoo<sup>7</sup>, Park Sung-Yong<sup>8</sup>, Lim Eunsung<sup>9</sup>  
<sup>1</sup>Department of Psychiatry, Jeju National University School of Medicine - Jeju (Korea, Republic of),<sup>2</sup>Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of),<sup>3</sup>Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University - Cheonan (Korea, Republic of),<sup>4</sup>Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of),<sup>5</sup>Department of Psychiatry, College of Medicine, Dongguk University - Gyeongju (Korea, Republic of),<sup>6</sup>Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of),<sup>7</sup>Dr. Nam's Psychiatric Clinic - Chugju (Korea, Republic of),<sup>8</sup>Department of Psychiatry, Keyo Hospital - Uiwang (Korea, Republic of),<sup>9</sup>Department of Psychiatry, Shinsegae Hyo Hospital - Kimje(Korea, Republic of)
-  **LP54** **Clinical and biomarker characteristics of subjective cognitive decline who progressed to MCI within 24-months follow-up**  
Dong Won Yang<sup>1</sup>, Chunghwee Lee<sup>1</sup>, Yun-Jeong Hong<sup>2</sup>, Seonghee Ho<sup>3</sup>, Jee Hyang Jeong<sup>4</sup>, Kee Hyung Park<sup>5</sup>, Sangyun Kim<sup>6</sup>, Min Jeong Wang<sup>7</sup>, Seong Hye Choi<sup>8</sup>, Sanggyu Lee<sup>9</sup>  
<sup>1</sup>Department Of Neurology, College Of Medicine, The Catholic University Of Korea - Seoul (Korea, Republic of),<sup>2</sup>Department of Neurology, The Catholic University of Korea Uijeongbu St. Mary's Hospital, Uijeongbu, Republic of Korea - Uijeongbu (Korea, Republic of),<sup>3</sup>Department of Neurology, Changwon Hanmaeum Hospitaljeongbu, Republic of Korea - Changwon (Korea, Republic of),<sup>4</sup>Department of Neurology, Womans University School of Medicine, Ewha Womans University Seoul HospitalChangwon Hanmaeum Hospitaljeongbu, Republic of Korea - Seoul (Korea, Republic of),<sup>5</sup>Department of Neurology, Gachon University Gil Hospital - Incheon (Korea, Republic of),<sup>6</sup>Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital - Bundang (Korea, Republic of),<sup>7</sup>Neurology, ROA Clinic - Bundang (Korea, Republic of),<sup>8</sup>Department of Neurology, Inha University School of Medicine, Inha University Hospital - Incheon (Korea, Republic of),<sup>9</sup>NeoLAB convergence Inc - Seoul (Korea, Republic of)
-  **LP55** **In Vivo Head-To-Head Comparison of [18F]GTP1 and [18F]MK6240 in Alzheimer's Disease**  
Matteo Tonietto<sup>1</sup>, Cristian Constantinescu<sup>2</sup>, Sandra Sanabria Bohorquez<sup>3</sup>, Roger Gunn<sup>4</sup>, David Russell<sup>5</sup>, Edmond Teng<sup>3</sup>, Dan Abramzon<sup>3</sup>, Karen Pickthorn<sup>3</sup>, Gregory Klein<sup>1</sup>  
<sup>1</sup>Hoffmann-La Roche, Ltd. - Basel (Switzerland),<sup>2</sup>Invicro, LLC - Needham (United States),<sup>3</sup>Genentech, Inc. - South San Francisco (United States),<sup>4</sup>Invicro, LLC - London (United Kingdom),<sup>5</sup>Invicro, LLC - Needham (United Kingdom)
-  **LP56** **Evaluating the Impact of Carotid Endarterectomy on Cognition and Hippocampal Fractional Anisotropy**  
 Adam Bernstein<sup>1</sup>, Juan Arias<sup>1</sup>, Craig Weinkauff<sup>1</sup>, Theodore Trouard<sup>1</sup>  
<sup>1</sup>University of Arizona - Tucson (United States)
-  **LP57** **New insights into the contribution of tau PET imaging in AD therapeutic trials**  
Julien Lagarde<sup>1,2,3</sup>, Pauline Olivier<sup>1</sup>, Matteo Tonietto<sup>3,4</sup>, Philippe Gervais<sup>3</sup>, Fabien Caillé<sup>3</sup>, Martin Moussion<sup>5</sup>, Michel Bottlaender<sup>3,6</sup>, Marie Sarazin<sup>1,7,8</sup>  
<sup>1</sup>Department of Neurology of Memory and Language, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne - Paris (France),<sup>2</sup>Université Paris Cité - Paris (France),<sup>3</sup>Université Paris-Saclay, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm - Orsay (France),<sup>4</sup>Research and Early Development (pRED), Hoffmann-La Roche - Basel (Switzerland),<sup>5</sup>Centre d'Evaluation Troubles Psychiques et Vieillessement, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne, France - Paris (France),<sup>6</sup>Université Paris-Saclay, UNIACT, Neurospin, Joliot Institute, CEA - Gif Sur Yvette (France),<sup>7</sup>Université Paris Cité - Paris (France) ,<sup>8</sup>Université Paris-Saclay, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, - Orsay (France)
-  **LP58** **Methods to decrease sample size needed for longitudinal Flortaucipir tau PET**  
Suzanne Baker<sup>1</sup>, Pablo Aguilar Dominguez<sup>1</sup>, Susan Landau<sup>2</sup>, Theresa Harrison<sup>2</sup>, Renaud Lajoie<sup>3</sup>, Tyler Ward<sup>2</sup>, Kailin Zhuang<sup>2</sup>, Gil Rabinovici<sup>3</sup>, William Jagust<sup>2</sup>  
<sup>1</sup>Lawrence Berkeley National Lab - Berkeley (United States),<sup>2</sup>University of California, Berkeley - Berkeley (United States),<sup>3</sup>University of California, San Francisco - San Francisco (United States)
-  **LP59** **Prevalence of microhemorrhages, superficial siderosis and other MRI abnormalities in a population of cognitively unimpaired older adults from the CHARLOT-PRO study**  
Luc Bracoud<sup>1</sup>, Chi Udeh-Momoh<sup>2</sup>, Ziad Saad<sup>3</sup>, Dimitra Kafetsouli<sup>4</sup>, Emmett Daly<sup>4</sup>, Onah Okoye<sup>4</sup>, Parthenia Giannakopoulou<sup>4</sup>, David Scott<sup>5</sup>, Joyce Suhy<sup>5</sup>, Susan Baker<sup>6</sup>, Gerald Novak<sup>6</sup>, Craig Ritchie<sup>7</sup>, Lefkos Middleton<sup>2</sup>, Lefkos Middleton<sup>8</sup>  
<sup>1</sup>Clario - Lyon (France),<sup>2</sup>AGE Research, School of Public Health, Imperial College of London - London (United Kingdom) - London (United Kingdom),<sup>3</sup>Janssen Research and Development - La Jolla (United States),<sup>4</sup>AGE Research, School of Public Health, Imperial College of London - London (United Kingdom),<sup>5</sup>Clario - San Mateo (United States),<sup>6</sup>Janssen Research and Development - Titusville (United States),<sup>7</sup>University of Edinburgh - Edinburgh (United Kingdom),<sup>8</sup>Imperial College Healthcare NHS Trust - London (United Kingdom)
-  **LP60** **Prediction of longitudinal change in CDR Sum of Boxes using a cortical microstructural AD signature from baseline diffusion MRI**  
 Ged Ridgway<sup>1</sup>, Mario Torso<sup>1</sup>, Dimitra Tzaferou<sup>1</sup>, Michele Valotti<sup>1</sup>, Ian Hardingham<sup>1</sup>, Steven Chance<sup>1</sup>, Adni Alzheimer's Disease Neuroimaging Initiative<sup>2</sup>  
<sup>1</sup>Oxford Brain Diagnostics Ltd - Oxford (United Kingdom),<sup>2</sup>Alzheimer's Disease Neuroimaging Initiative (United States)
-  **LP61** **Cortical microstructural measures from diffusion MRI correlate with cognitive composite scores and predict their longitudinal changes**  
 Mario Torso<sup>1</sup>, Ged Ridgway<sup>1</sup>, Michele Valotti<sup>1</sup>, Ian Hardingham<sup>1</sup>, Steven Chance<sup>1</sup>, Adni Alzheimer's Disease Neuroimaging Initiative<sup>2</sup>  
<sup>1</sup>Oxford Brain Diagnostics Ltd - Oxford (United Kingdom),<sup>2</sup>Alzheimer's Disease Neuroimaging Initiative (United States)
-  **LP62** **APOEε4 carriership and Aβ positivity for the populational enrichment of clinical trials testing drug effects on tau tangles**  
João Pedro Ferrari-Souza<sup>1</sup>, Pâmela Ferreira<sup>1</sup>, Bruna Bellaver<sup>1</sup>, Guilherme Povala<sup>1</sup>, Firoza Lussier<sup>1</sup>, Douglas Leffa<sup>1</sup>, Cécile Tissot<sup>2</sup>, Joseph Therriault<sup>2</sup>, Thomas Karikari<sup>3</sup>, Jean-Paul Soucy<sup>2</sup>, Serge Gauthier<sup>2</sup>, Eduardo Zimmer<sup>4</sup>, Pedro Rosa-Neto<sup>2</sup>, Tharick Pascoal<sup>1</sup>  
<sup>1</sup>University of Pittsburgh - Pittsburgh (United States),<sup>2</sup>McGill University - Montreal (Canada),<sup>3</sup>University of Gothenburg - Mölndal (Sweden),<sup>4</sup>Universidade Federal do Rio Grande do Sul - Porto Alegre (Brazil)

### THEME: Clinical Trials: Biomarkers including plasma

- P090** **Impacts of amyloid burden on longitudinal cognitive declines in subjective cognitive decline: a prospective cohort study**  
Yun Jeong Hong<sup>1</sup>, Dong Won Yang<sup>2</sup>, Seonghee Ho<sup>2</sup>, Kwonoh Park<sup>3</sup>, Jee Hyang Jeong<sup>4</sup>, Kee Hyung Park<sup>5</sup>, Sangyun Kim<sup>6</sup>, Min Jeong Wang<sup>6</sup>, Seong Hye Choi<sup>7</sup>, Sanggyu Lee<sup>8</sup>  
<sup>1</sup>Uijeongbu St. Mary's Hospital - Uijeongbu (Korea, Republic of), <sup>2</sup>Seoul St. Mary's Hospital - Seoul (Korea, Republic of), <sup>3</sup>Pusan National University Yangsan Hospital - Yangsan (Korea, Republic of), <sup>4</sup>Ewha Womans University Seoul Hospital - Seoul (Korea, Republic of), <sup>5</sup>Gachon University Gil Hospital - Incheon (Korea, Republic of), <sup>6</sup>Seoul National University College Of Medicine, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of), <sup>7</sup>Inha University School Of Medicine - Incheon (Korea, Republic of), <sup>8</sup>Neolab Convergence Inc. - Seoul (Korea, Republic of)
- P091** **Predictive value of plasma p-tau181 versus baseline amyloid-PET for longitudinal amyloid accumulation in asymptomatic Alzheimer's Disease**  
Rik Vandenberghe<sup>1</sup>, Steffi De Meyer<sup>1</sup>, Emma Luckett<sup>1</sup>, Jeroen Vanbrabant<sup>2</sup>, Jolien Schaevebeke<sup>1</sup>, Mariska Reinartz<sup>1</sup>, Isabelle Cleynen<sup>3</sup>, Erik Stoops<sup>2</sup>, Eugene Vanmechelen<sup>2</sup>, Koen Van Laere<sup>4</sup>  
<sup>1</sup>Alzheimer Research Centre Ku Leuven, Leuven Brain Institute - Leuven (Belgium), <sup>2</sup>Adx Neurosciences - Zwijnaarde (Belgium), <sup>3</sup>Laboratory For Complex Genetics - Leuven (Belgium), <sup>4</sup>Nuclear Medicine Service, University Hospitals Leuven - Leuven (Belgium)
- P092** **Blood biomarkers for Alzheimer's disease to predict dementia risk in a large clinic-based cohort: implications for clinical trials**  
Vincent Planche<sup>1</sup>, Vincent Bouteloup<sup>1</sup>, Geneviève Chêne<sup>1</sup>, Carole Dufouil<sup>1</sup>  
<sup>1</sup>Bordeaux University - Bordeaux (France)
- P093** **Independent Effect of Body Mass Index Variation on Amyloid-β Positivity**  
Sung Hoon Kang<sup>1</sup>, Jong Hyuk Kim<sup>2</sup>, Kyunga Kim<sup>2</sup>, Sang Won Seo<sup>3</sup>  
<sup>1</sup>Department Of Neurology, Korea University Guro Hospital, Korea University College Of Medicine - Seoul (Korea, Republic of), <sup>2</sup>Department Of Digital Health, Saitst, Sungkyunkwan University - Seoul (Korea, Republic of), <sup>3</sup>Department Of Neurology, Samsung Medical Center, Sungkyunkwan University School Of Medicine - Seoul (Korea, Republic of)
- P094** **Phase 2 study reveals an adequate PK/PD relationship of bosutinib in Dementia with Lewy Bodies and clears the path for larger Phase 2/3 investigations**  
Charbel Moussa<sup>1</sup>, Fernando Pagan<sup>2</sup>, Torres-Yaghi Yasar<sup>2</sup>, Hebron Michaleine<sup>1</sup>, Turner Raymond S<sup>1</sup>, Ahn Jaeil<sup>1</sup>  
<sup>1</sup>Georgetown University Medical Center - Washington (United States), <sup>2</sup>Medstar Georgetown Hospital - Washington (United States)
- P095** **Biomarker Assessments From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias**  
Jonathan Haroon<sup>1</sup>, Kennedy Mahdavi<sup>1,2</sup>, Kaya Jordan<sup>1</sup>, Elisabeth Rindner<sup>1</sup>, Margaret Zielinski<sup>1</sup>, Victoria Venkatraman<sup>1,2</sup>, Dayan Goodenowe<sup>3</sup>, Kaitlyn Hofmeister<sup>3</sup>, Clarence Ahlem<sup>4</sup>, Christopher Reading<sup>4</sup>, Joseph Palumbo<sup>4</sup>, Bijan Pourat<sup>5</sup>, Sheldon Jordan<sup>1,2</sup>  
<sup>1</sup>The Regenesys Project - Santa Monica (United States), <sup>2</sup>Synaptec Network - Santa Monica (United States), <sup>3</sup>Prodrome Sciences USA LLC - Temecula (United States), <sup>4</sup>Biovie Inc. - Carson City (United States), <sup>5</sup>Pourat MD - Beverly Hills (United States)
- P096** **Robustness of cerebrospinal fluid (CSF) amyloid-β 1-42/amyloid-β 1-40 (Aβ42/Aβ40) and phosphorylated tau/amyloid-β 1-42 (pTau/Aβ42) biomarker ratios in classification of amyloid positron emission tomography (PET) positivity in routine clinical use**  
Chad Logan<sup>1</sup>, Henrik Schinke<sup>1</sup>, Christina Rabe<sup>2</sup>, Maryline Simon<sup>3</sup>, Oskar Hansson<sup>4,5</sup>, Kaj Blennow<sup>6,7</sup>, Erik Stomrud<sup>4,5</sup>  
<sup>1</sup>Roche Diagnostics GmbH - Penzberg (Germany), <sup>2</sup>Genentech, Inc., - South San Francisco (United States), <sup>3</sup>Roche Diagnostics International Ltd - Rotkreuz (Switzerland), <sup>4</sup>Clinical Memory Research Unit, Department Of Clinical Sciences Malmö, Lund University - Malmö (Sweden), <sup>5</sup>Memory Clinic, Skåne University Hospital - Malmö (Sweden), <sup>6</sup>Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy At The University Of Gothenburg - Mölndal (Sweden), <sup>7</sup>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden)
- P097** **The biomarker-based etiological diagnosis of neurocognitive disorders: the European Inter-Societal Delphi Consensus**  
Stefania Orini<sup>1,2</sup>, Cristina Festari<sup>3</sup>, Federico Massa<sup>4</sup>, Matteo Cotta Ramosino<sup>5,6</sup>, Flavio Nobili<sup>7,8</sup>, Giovanni Battista Frisoni<sup>9,10</sup> The European Inter-Societal Consensus On The Biomarker-Based Diagnosis Of Dement<sup>11</sup>  
<sup>1</sup>Alzheimer's Unit-Memory Clinic, Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli - Brescia, (Italy), <sup>2</sup>Dipartimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, - Brescia (Italy), <sup>3</sup>Laboratory Of Alzheimer's Neuroimaging And Epidemiology, Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli - Brescia, (Italy), <sup>4</sup>Department Of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal And Child Health (dino-gmi), University Of Genoa - Genoa (Italy), <sup>5</sup>Unit Of Behavioral Neurology, Irccs Mondino Foundation, - Pavia (Italy), <sup>6</sup>Department of Brain and Behavioral Sciences, University of Pavia, - Pavia, (Italy), <sup>7</sup>Department Of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal And Child Health (dino-gmi), University Of Genoa, - Genoa (Italy), <sup>8</sup>IRCCS Ospedale Policlinico San Martino, - Genoa (Italy), <sup>9</sup>Laboratory Of Neuroimaging Of Aging (lanvie), University Of Geneva, - Geneva (Switzerland), <sup>10</sup>Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, G - Geneva (Switzerland), <sup>11</sup>The European Inter-Societal Consensus On The Biomarker-Based Diagnosis Of Dementia
- P098** **Predicting amyloid positivity with blood-based biomarkers including p-tau181**  
Kwon Hyuk Sung<sup>1</sup>, Lee Eun-Hye<sup>1</sup>, Park Hyun-Hee<sup>1</sup>, Koh Seong-Ho<sup>1</sup>  
<sup>1</sup>Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine - Guri (Korea, Republic of)

-  **P099** **Data-driven 18F-Flortaucipir cut-offs for preclinical and early AD**  
Giulia Quattrini <sup>1,2</sup>, Clarissa Ferrari <sup>3</sup>, Michela Pievani <sup>1</sup>, Federica Ribaldi <sup>4</sup>, Szymon Tomczyk <sup>4</sup>, Giovanni Battista Frisoni <sup>4</sup>, Valentina Garibotto <sup>4</sup>, Moira Marizzoni <sup>1</sup>  
<sup>1</sup>Laboratory Of Alzheimer's Neuroimaging And Epidemiology (lane), Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy - Brescia (Italy), <sup>2</sup>Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy - Brescia (Italy), <sup>3</sup>Unit Of Statistics, Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy - Brescia (Italy), <sup>4</sup>Memory Clinic And Lanvie-Laboratory Of Neuroimaging Of Aging, University Hospitals And University Of Geneva, Geneva, Switzerland - Geneva (Switzerland)
-  **P100** **Biological Brain Age Prediction Using Machine Learning on Structural Neuroimaging Data: Multi-Cohort Validation Against Biomarkers of Alzheimer's Disease and Neurodegeneration stratified by sex**  
Irene Cumpido Mayoral <sup>1,2</sup>, Marta Milà-Alomà <sup>1,2,3,4</sup>, Luigi Lorenzini <sup>5</sup>, Alle Meije Wink <sup>5</sup>, Henk J.m.m. Mutsaerts <sup>5</sup>, Sven Haller <sup>6</sup>, Gael Chetelat <sup>7</sup>, Frederik Barkhof <sup>5,8</sup>, Margherita Carboni <sup>9</sup>, Gwendlyn Kollmorgen <sup>10</sup>, Henrik Zetterberg <sup>11,12,13,14</sup>, Kaj Blennow <sup>11,12</sup>, Marc Suárez-Calvet <sup>1,3,4,15</sup>, Verónica Vilaplana <sup>16</sup>, Juan Domingo Gispert <sup>1,3,17</sup>  
<sup>1</sup>Barcelona@eta Brain Research Center (bbrc), Pasqual Maragall Foundation - Barcelona (Spain), <sup>2</sup>Universitat Pompeu Fabra - Barcelona (Spain), <sup>3</sup>IMIM (Hospital del Mar Medical Research Institute) - Barcelona (Spain), <sup>4</sup>CIBER Fragilidad y Envejecimiento Saludable (CIBERFES) - Madrid (Spain), <sup>5</sup>Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), <sup>6</sup>CIRD Centre d'Imagerie Rive Droite - Geneva (Switzerland), <sup>7</sup>Imaging of Neurological Disorders, Institut Blood and Brain @ Caen-Normandie, Cyceron - Caen (France), <sup>8</sup>Institutes of Neurology and Healthcare Engineering, University College London - London (United Kingdom), <sup>9</sup>Roche Diagnostics International Ltd - Rotkreuz Zg (Switzerland), <sup>10</sup>Roche Diagnostics GmbH - Penzberg (Germany), <sup>11</sup>Institute of Neuroscience and Physiology, University of Gothenburg - Mölndal (Sweden), <sup>12</sup>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), <sup>13</sup>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology - London (United Kingdom), <sup>14</sup>UK Dementia Research Institute at UCL - London (United Kingdom), <sup>15</sup>Servei de Neurologia, Hospital del Mar - Barcelona (Spain), <sup>16</sup>Department of Signal Theory and Communications, Universitat Politècnica de Catalunya - Barcelona (Spain), <sup>17</sup>Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) - Madrid (Spain)
-  **P101** **Cerebrospinal fluid placental growth factor in relation to cerebrovascular disease and diabetes in non-demented elderly**  
Eske Christiane Gertje <sup>1,2</sup>, Shorena Janelidze <sup>1</sup>, Danielle Van Westen <sup>3,4</sup>, Erik Stomrud <sup>1,5</sup>, Sebastian Palmqvist <sup>1,5</sup>, Oskar Hansson <sup>1,5</sup>, Niklas Mattsson-Carlgen <sup>1,6,7</sup>  
<sup>1</sup>Clinical Memory Research Unit, Department Of Clinical Sciences Malmö, Lund University - Malmö (Sweden), <sup>2</sup>Department of Internal Medicine, Skåne University Hospital - Lund (Sweden), <sup>3</sup>Diagnostic Radiology, Department Of Clinical Sciences Lund, Lund University - Lund (Sweden), <sup>4</sup>Imaging and Function, Skåne University Hospital - Lund (Sweden), <sup>5</sup>Memory Clinic, Skåne University Hospital - Malmö (Sweden), <sup>6</sup>Department of Clinical Sciences Lund, Neurology, Lund University, Skåne University Hospital - Lund (Sweden), <sup>7</sup>Wallenberg Center for Molecular Medicine, Lund University - Lund (Sweden)
-  **P102** **Plasma AD biomarkers can Predict Hippocampal Atrophy**  
Hyung-Ji Kim <sup>1</sup>, Jae-Hong Lee <sup>2</sup>  
<sup>1</sup>Uijeongbu Eulji Medical Center - Uijeongbu-Si (Korea, Republic of), <sup>2</sup>Asan Medical Center - Seoul (Korea, Republic of)
-  **P103** **Assessment of Plasma p-tau181 in TANGO, a Phase 2 study of Gosuramemab in Patients with early Alzheimer's Disease**  
Julie Czerkowicz <sup>1</sup>, Jessica Kong <sup>1</sup>, Annie Racine <sup>1</sup>, Carrie Rubel <sup>1</sup>, Jessica Collins <sup>1</sup>, Melanie Shulman <sup>1</sup>, Danielle Graham <sup>1</sup>, John Beaver <sup>1</sup>, Samantha Budd Haeberlein <sup>1</sup>  
<sup>1</sup>Biogen - Cambridge (United States)
-  **P104** **Corneal confocal microscopy and MRI brain volumetry: Prognostic biomarkers for progression from mild cognitive impairment to dementia**  
Georgios Ponirakis <sup>1</sup>, Rayaz Malik <sup>1</sup>  
<sup>1</sup>Weill Cornell Medicine in Qatar - Doha (Qatar)
-  **P105** **Oligomer biomarkers for preclinical and clinical drug development in neurodegenerative disorders**  
Oliver Bannach <sup>1,2</sup>, Lara Blömeke <sup>1,2</sup>, Bettina Kass <sup>1</sup>, Alice Chen-Plotkin <sup>3</sup>, Oliver Peters <sup>4</sup>, Dieter Willbold <sup>1,5</sup>  
<sup>1</sup>Forschungszentrum Jülich - Jülich (Germany), <sup>2</sup>atylloid GmbH - Düsseldorf (Germany), <sup>3</sup>University of Pennsylvania - Philadelphia (United States), <sup>4</sup>Charité Universitätsmedizin Berlin - Berlin (Germany), <sup>5</sup>Heinrich-Heine-Universität Düsseldorf - Düsseldorf (Germany)
-  **P106** **Exploratory study on the proteomic and transcriptomic content of plasma extracellular vesicles in AD patients**  
Maria Solaguren-Beascoa <sup>1</sup>, Ana Gámez-Valero <sup>1,2</sup>, Ana M. Ortiz <sup>3</sup>, Carla Minguet <sup>3</sup>, Ricardo Gonzalo <sup>3</sup>, Georgia Escaramis <sup>1,2</sup>, Montserrat Costa <sup>3</sup>, Eulàlia Martí <sup>1,2</sup>  
<sup>1</sup>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Institut de Neurociències, Universitat de Barcelona - Barcelona (Spain), <sup>2</sup>Centro de Investigación Biomédica en Red sobre Epidemiología y Salud Pública (CIBERESP) - Barcelona (Spain), <sup>3</sup>Grifols Bioscience Research Group - Barcelona (Spain)
-  **P107** **Towards the development and validation of a general-purpose regulatory-grade neuroimage analysis tool**  
Nick Henscheid <sup>1</sup>, Ioannis Pappas <sup>2</sup>, Ryan Cabeen <sup>2</sup>, Jagdeep Podichetty <sup>1</sup>, Samuel Hobel <sup>2</sup>, Christopher Weber <sup>3</sup>, Yashmin Karten <sup>1</sup>, Klaus Romero <sup>1</sup>, Sudhir Sivakumaran <sup>1</sup>, Arthur Toga <sup>2</sup>  
<sup>1</sup>Critical Path Institute - Tucson (United States), <sup>2</sup>University of Southern California - Los Angeles (United States), <sup>3</sup>Alzheimer's Association - Chicago (United States)
- P108** **Comparative performance of plasma Aβ42/Aβ40 and p-tau181 for the detection of early brain amyloid deposition in individuals with subjective cognitive decline**  
María Pascual-Lucas <sup>1</sup>, José Antonio Allué <sup>1</sup>, Leticia Sarasa <sup>1</sup>, Noelia Fandos <sup>1</sup>, Sergio Castillo <sup>1</sup>, Jose Terencio <sup>1</sup>, Manuel Sarasa <sup>1</sup>, Juan Pablo Tartari <sup>2</sup>, Ángela Sanabria <sup>2,3</sup>, Lluís Tàrraga <sup>2,3</sup>, Agustín Ruiz <sup>2,3</sup>, Marta Marquí <sup>2,3</sup>, Mercè Boada <sup>2,3</sup>  
<sup>1</sup>Araclon Biotech-Grifols - Zaragoza (Spain), <sup>2</sup>Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya - Barcelona (Spain), <sup>3</sup>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III - Madrid (Spain)

- P109** **Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer's Disease**  
Charisse N. Winston<sup>1</sup>, Oliver Lanford<sup>2</sup>, Natalie Levin<sup>1</sup>, Rema Raman<sup>2</sup>, Kevin Yarasheski<sup>3</sup>, Tim West<sup>3</sup>, Sarah Abdel-Latif<sup>2</sup>, Michael Donohue<sup>2</sup>, Akinori Nakamura<sup>4</sup>, Kenji Toba<sup>5</sup>, Colin L. Masters<sup>6</sup>, James Doecke<sup>7</sup>, Reisa A. Sperling<sup>8</sup>, Paul S. Aisen<sup>9</sup>, Robert A. Rissman<sup>10</sup>  
<sup>1</sup>Department of Neurosciences, University of California San Diego - La Jolla (United States), <sup>2</sup>Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California - San Diego (United States), <sup>3</sup>C2N Diagnostics - St. Louis (United States), <sup>4</sup>Department of Biomarker Research, National Center for Geriatrics and Gerontology - Obu (Japan), <sup>5</sup>National Center for Geriatrics and Gerontology, Obu, Aichi, Japan, and Tokyo Metropolitan Institute of Gerontology - Obu (Japan), <sup>6</sup>The Florey Institute, The University of Melbourne - Parkville (Australia), <sup>7</sup>The Commonwealth Scientific and Industrial Research Organization - Herston Qld (Australia), <sup>8</sup>Harvard Medical School - Boston (United States), <sup>9</sup>Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California - Los Angeles (United States), <sup>10</sup>Department of Neurosciences, University of California San Diego and VA San Diego Healthcare System - La Jolla (United States)
- P110** **Myocardial sympathetic denervation biomarkers for early detection of prodromal DLB**  
Mee Young Park<sup>1</sup>, Dong Sung Shin<sup>1</sup>  
<sup>1</sup>Neurology Yeungnam University Medical Center - Daegu (Korea, Republic of)
- P111** **pTau181 plasma biomarker performance as an inclusion criterion in the RETHINK-ALZ and REFOCUS-ALZ trials in mild-to-moderate Alzheimer's disease**  
Anna Mammel<sup>1</sup>, Pankaj Kumar<sup>2</sup>, Lindsay Burns<sup>3</sup>, Donald Biehl<sup>1</sup>, Mary Encarnacion<sup>2</sup>, Anna Cruz<sup>2</sup>, Ging-Yuek Robin Hsiung<sup>4</sup>, Ian Mackenzie<sup>4</sup>, Veronica Hirsch-Reinshagen<sup>4</sup>, Ali Mousavi<sup>2</sup>, Ryan Fortna<sup>1,5</sup>, James Kupiec<sup>3</sup>, Hans Frykman<sup>2,4</sup>  
<sup>1</sup>Neurocode - Bellingham, Washington (United States), <sup>2</sup>BC Neuroimmunology - Vancouver (Canada), <sup>3</sup>Cassava Sciences - Austin, Texas (United States), <sup>4</sup>University of British Columbia - Vancouver (Canada), <sup>5</sup>Northwest Pathology - Bellingham, Washington (United States)
- P112** **Critical evaluation and comparison of biomarker values in commercial CSF with Lumipulse® to support assay development for clinical trials**  
Hugo Vanderstichele<sup>1</sup>, Mahsan Rafizadeh<sup>2</sup>, Erika Cline<sup>2</sup>, Johnson Derrick<sup>3</sup>, Erica Simmons<sup>3</sup>, Robert Dean<sup>2</sup>, Jasna Jerecic<sup>2</sup>  
<sup>1</sup>Biomarkable - Gent (Belgium), <sup>2</sup>Acumen Pharmaceuticals - Charlottesville (United States), <sup>3</sup>B2S Life sciences - Indianapolis (United States)
- P113** **Detection of CSF alpha-synuclein in patients with prodromal Lewy body disease**  
Melanie Plastini<sup>1</sup>, Carla Abdelnour<sup>1</sup>, Marian Shahid<sup>1</sup>, Manuel Medina<sup>2</sup>, Nelson Kha<sup>2</sup>, Hanna Hovren<sup>2</sup>, Jennifer Lamoureux<sup>2</sup>, Victor Henderson<sup>1</sup>, Kathleen Poston<sup>1</sup>  
<sup>1</sup>Stanford University - Palo Alto (United States), <sup>2</sup>Amprion Clinical Laboratory - San Diego (United States)
- P114** **Effect of butyrylcholinesterase genotype on patients with Alzheimer's disease treated with rivastigmine**  
Hairin Kim<sup>1,2</sup>, So Yeon Cho<sup>3</sup>, Gieun Nam<sup>2</sup>, Kichul Kim<sup>4,2</sup>, Eosu Kim<sup>3</sup>, Jun-Young Lee<sup>2</sup>  
<sup>1</sup>Emocog Inc. - Seoul (Korea, Republic of), <sup>2</sup>Department of Psychiatry, Seoul Metropolitan Government-Seoul National University Boramae Medical Center - Seoul (Korea, Republic of), <sup>3</sup>Department of Psychiatry, Institute of Behavioral Science in Medicine, Brain Korea 21 Plus Project for Medical Science, Yonsei University College of Medicine - Seoul (Korea, Republic of), <sup>4</sup>Epi Biotech Co., Ltd. - Incheon (Korea, Republic of)
- P115** **Impact of Alzheimer's Disease Biomarker Disclosure to Cognitively Unimpaired Individuals: Experiences from a Truncated Randomized Phase 2b/3 Clinical Trial**  
Joshua Grill<sup>1</sup>, Rema Raman<sup>2</sup>, Garrett Miller<sup>2</sup>, Karin Ernstrom<sup>2</sup>, Michael Donohue<sup>2</sup>, Paul Aisen<sup>2</sup>, Reisa Sperling<sup>3</sup>, David Henley<sup>4</sup>, H. Robert Brashear<sup>4</sup>, Gary Romano<sup>4</sup>, Gerald Novak<sup>4</sup>  
<sup>1</sup>University of California Irvine - Irvine (United States), <sup>2</sup>Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA - San Diego (United States), <sup>3</sup>Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA - Boston (United States), <sup>4</sup>Janssen Research & Development LLC - Titusville (United States)
- P116** **Pharmacodynamic Effects of Semorinemab on Plasma and CSF Tau Biomarkers in a Phase 2 Trial in Mild-to-Moderate Alzheimer's Disease (Lauriet)**  
Stephen Schauer<sup>1</sup>, Julie Lee<sup>1</sup>, Veronica Anania<sup>1</sup>, Balazs Toth<sup>1</sup>, Lee Honigberg<sup>1</sup>, Kristin Wildsmith<sup>1</sup>, Vidya Ramakrishnan<sup>1</sup>, Michael Dolton<sup>1</sup>, Sandra Sanabria Bohorquez<sup>1</sup>, Edmond Teng<sup>1</sup>, Cecilia Monteiro<sup>1</sup>  
<sup>1</sup>Genentech, Inc. - South San Francisco (United States)
- P117** **Novel technology platform for the direct and sensitive detection of circulating AD-related molecules in blood**  
Carine Lim<sup>1</sup>  
<sup>1</sup>Sunbird Bio - Singapore (Singapore)
- P118** **Recruitment of amyloid positive individuals and early Alzheimer's patients in a primary care setting – results from the BioFINDER Primary Care study**  
Sebastian Palmqvist<sup>1</sup>, Pontus Tideman<sup>1</sup>, Erik Stomrud<sup>1</sup>, Ruben Smith<sup>1</sup>, Antoine Leuzy<sup>1</sup>, Sadek Jafar Jasem<sup>1</sup>, Niklas Mattsson-Carlgrén<sup>1</sup>, Anna Orduña Dolado<sup>1</sup>, Shorena Janelidze<sup>1</sup>, Oskar Hansson<sup>1</sup>  
<sup>1</sup>Lund University - Malmö (Sweden)
- P119** **Deep plasma and CSF proteomics profiling of the AMBAR study**  
Chunmiao (mia) Feng<sup>1</sup>, Ricardo Gonzalo<sup>2</sup>, Carla Minguet<sup>2</sup>, Pilar Lafuente<sup>2</sup>, Ana Maria Ortiz<sup>2</sup>, Scott Lohr<sup>1</sup>, Mercè Boada<sup>3</sup>, Oscar López<sup>4</sup>, Antonio Paez<sup>2</sup>, Steven Braithwaite<sup>1</sup>, Montserrat Costa<sup>2</sup>, Benoit Lehallier<sup>1</sup>  
<sup>1</sup>Alkermest, a Grifols company - San Carlos (United States), <sup>2</sup>Grifols - Barcelona (Spain), <sup>3</sup>Universitat Internacional de Catalunya - Barcelona (Spain), <sup>4</sup>University of Pittsburgh - Pittsburgh (United States)
- P120** **Association of neighborhood-level socioeconomic disadvantage with CSF biomarkers of Alzheimer's disease and neurodegeneration**  
Gilda Ennis<sup>1</sup>, Megan Zuelsdorff<sup>1</sup>, Ryan Powell<sup>1</sup>, Tobey Bethausser<sup>1</sup>, William Buckingham<sup>1</sup>, Yue Ma<sup>1</sup>, Carol Van Hulle<sup>1</sup>, Margherita Carboni<sup>2</sup>, Gwendlyn Kollmorgen<sup>3</sup>, Carey Gleason<sup>1</sup>, Sterling Johnson<sup>1</sup>, Kaj Blennow<sup>4</sup>, Henrik Zetterberg<sup>4</sup>, Amy Kind<sup>1</sup>, Barbara Bendlin<sup>1</sup>  
<sup>1</sup>University of Wisconsin - Madison - Madison (United States), <sup>2</sup>Roche Diagnostics International Ltd - Rotkreuz (Switzerland), <sup>3</sup>Roche Diagnostics GmbH - Penzberg (Germany), <sup>4</sup>University of Gothenburg - Gothenburg (Sweden)



-  **P121** **Use of the PrecivityAD blood test in regular clinical practice: Preliminary observations from a dementia clinic**  
Jonathan Drake<sup>1,2</sup>, Lori Daiello<sup>1,2</sup>, Chuang-Kuo Wu<sup>1,2</sup>  
<sup>1</sup>Rhode Island Hospital - Providence (United States), <sup>2</sup>Warren Alpert Medical School of Brown University - Providence (United States)
- P122** **Genome-wide association studies of ARIA from the aducanumab phase 3 ENGAGE and EMERGE studies**  
Stephanie Loomis<sup>1</sup>, Ryan Miller<sup>1</sup>, Carmen Castrillo-Viguera<sup>1</sup>, Kimberly Umans<sup>1</sup>, Wenting Cheng<sup>1</sup>, John O'gorman<sup>1</sup>, Richard Hughes<sup>1</sup>, Samantha Budd Haerberlein<sup>1</sup>, Christopher Whelan<sup>1</sup>  
<sup>1</sup>Biogen - Cambridge (United States)
- P123** **Low plasma Aβ42/Aβ40 ratio in older adults with enlarged perivascular spaces**  
Arunima Kapoor<sup>1</sup>, Aimee Gaubert<sup>1</sup>, Amy Nguyen<sup>1</sup>, Belinda Yew<sup>2</sup>, Jung Yun Jang<sup>1</sup>, Shubir Dutt<sup>2</sup>, Yanrong Li<sup>1</sup>, John P. Alitin<sup>3</sup>, Jean K Ho<sup>1</sup>, Anna E. Blanken<sup>2</sup>, Isabel J Sible<sup>2</sup>, Anisa Marshall<sup>2</sup>, Alessandra Martini<sup>1</sup>, Elizabeth Head<sup>1</sup>, Daniel A Nation<sup>1</sup>  
<sup>1</sup>University of California, Irvine - Irvine (United States), <sup>2</sup>University of Southern California - Los Angeles (United States), <sup>3</sup>University of California, Irvine - Irvine (United States) - Irvine (United States)
-  **P124** **NADALS: An open-label basket trial evaluating the JAK inhibitor baricitinib in Alzheimer's Disease and Amyotrophic Lateral Sclerosis**  
Shayda Daneshvari<sup>1</sup>, Pia Webb<sup>1</sup>, Anne-Marie Wills<sup>1</sup>, James Berry<sup>1</sup>, Steven Arnold<sup>1</sup>, Mark Albers<sup>1</sup>  
<sup>1</sup>MGH - Boston (United States)
-  **P125** **Examining the trajectory of neurodegeneration biomarkers and its association with cognitive profiles and amyloid in late middle-aged adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP)**  
Lianlian Du<sup>1,2</sup>, Tobey Betthausen<sup>1,3,4</sup>, Karly Cody<sup>1,3,4</sup>, Erin Jonaitis<sup>1,3,4</sup>, Cory Burghy<sup>1</sup>, Bruce Hermann<sup>1,5</sup>, Bret Larget<sup>6</sup>, Rick Chappell<sup>3,2</sup>, Sterling Johnson<sup>1,3,4,7</sup>, Rebecca Kosciuk<sup>1,3,4</sup>  
<sup>1</sup>Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health - Madison, WI (United States), <sup>2</sup>Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison - Madison, WI (United States), <sup>3</sup>Wisconsin Alzheimer's Disease Research Center - Madison, WI (United States), <sup>4</sup>Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health - Madison, WI (United States), <sup>5</sup>Department of Neurology, University of Wisconsin-Madison School of Medicine and Public Health - Madison, WI (United States), <sup>6</sup>Department of Statistics, University of Wisconsin-Madison - Madison, WI (United States), <sup>7</sup>Madison VA GRECC, William S. Middleton Memorial Hospital - Madison, WI (United States)
-  **LP63** **Racial Differences in Predicting Concurrent and Longitudinal Cognitive Outcomes by CSF Biomarkers of Alzheimer Disease among Cognitively Normal Individuals**  
Chengjie Xiong<sup>1</sup>, James Lah<sup>2</sup>, Cecelia Manzanares<sup>2</sup>, Allan Levey<sup>2</sup>, David Wolk<sup>3</sup>, Leslie Shaw<sup>3</sup>, Suzanne Schindler<sup>1</sup>, Rachel Henson<sup>1</sup>, Anne Fagan<sup>1</sup>, Jason Hassenstab<sup>1</sup>, Tammie Benzinger<sup>1</sup>, Quoc Bui<sup>1</sup>, Folasade Agboola<sup>1</sup>, Julia Gray<sup>1</sup>, John Morris<sup>1</sup>  
<sup>1</sup>Washington University - St. Louis (United States), <sup>2</sup>Emory University - Atlanta (United States), <sup>3</sup>University of Pennsylvania - Philadelphia (United States)
-  **LP64** **Blood-based dementia pathology stratification utilizing neuron-derived exosomes**  
Erez Eitan<sup>1</sup>, Olga Volpert<sup>1</sup>, Katya Elgart<sup>1</sup>  
<sup>1</sup>NeuroDex - Natick (United States)
-  **LP65** **Sex-specific diagnostic properties of AD plasma biomarkers in cognitively unimpaired at-risk individuals**  
Marta Mila Aloma<sup>1</sup>, Nicholas Ashton<sup>2</sup>, Thomas Karikari<sup>2</sup>, Anna Brugulat Serrat<sup>1</sup>, Eugeen Vanmechelen<sup>3</sup>, Jeroen Vanbrabant<sup>3</sup>, Erik Stoops<sup>3</sup>, Theresa Ann Day<sup>4</sup>, Maria Teresa Ferretti<sup>5</sup>, Jose Luis Molinuevo<sup>1</sup>, Jeffrey L Dage<sup>6</sup>, Henrik Zetterberg<sup>2</sup>, Juan Domingo Gispert<sup>1</sup>, Kaj Blennow<sup>2</sup>, Marc Suárez-Calvet<sup>1</sup>  
<sup>1</sup>BarcelonaBeta Brain Research Center - Barcelona (Spain), <sup>2</sup>University of Gothenburg - Mölndal (Sweden), <sup>3</sup>ADx Neurosciences - Ghent (Belgium), <sup>4</sup>Lilly Research Laboratories, Eli Lilly and Company - Indianapolis (United States), <sup>5</sup>Women's Brain Project - Guntershausen (Switzerland), <sup>6</sup>Stark Neurosciences Research Institute, Indiana University School of Medicine - Indianapolis (United States)
-  **LP66** **Baseline plasma pTau181 improves prediction of cognitive decline in amyloid positive subjects with mild cognitive impairment**  
Viswanath Devanarayan<sup>1</sup>, Pallavi Sachdev<sup>1</sup>, Arnaud Charil<sup>1</sup>, Akihiko Koyama<sup>1</sup>, Larisa Reyderman<sup>1</sup>, Chad Swanson<sup>1</sup>, Harald Hampel<sup>1</sup>, Michael Irizarry<sup>1</sup>, Shobha Dhadha<sup>1</sup>, Lynn Kramer<sup>1</sup>  
<sup>1</sup>Eisai, Inc. - Nutley (United States)
-  **LP67** **Association of circulating brain-enriched microRNAs with demographic and clinical factors in A4 screening plasma samples from cognitively normal individuals**  
Michael Keifer<sup>1</sup>, Kira Sheinerman<sup>2</sup>, Vladimir Tsvinsky<sup>3</sup>, Brittany Martinez<sup>2</sup>, Robert Rissman<sup>4</sup>, Samuil Umansky<sup>2</sup>  
<sup>1</sup>DiamiR Biosciences - San Francisco (United States), <sup>2</sup>DiamiR Biosciences - Monmouth Junction (United States), <sup>3</sup>DiamiR Biosciences - Boston (United States), <sup>4</sup>University of California San Diego School of Medicine - San Diego (United States)
-  **LP68** **Age dependency of plasma β-amyloid measured by fully automated and highly specific immunoassays in a Japanese cohort study (SESSA)**  
Kengo Ishiki<sup>1</sup>, Moniruzzaman<sup>2</sup>, Yuichiro Yano<sup>2</sup>, Keiko Kondo<sup>2</sup>, Aya Kadota<sup>2</sup>, Masahiro Miura<sup>1</sup>, Shigeki Iwanaga<sup>1</sup>, Masaki Nishimura<sup>3</sup>, Hirotsugu Ueshima<sup>2</sup>, Katsuyuki Miura<sup>2</sup>  
<sup>1</sup>Central Research Laboratories, Sysmex Corporation - Kobe (Japan), <sup>2</sup>NCD Epidemiology Research Center (NERC), Shiga University of Medical Science - Otsu (Japan), <sup>3</sup>Molecular Neuroscience Research Center, Shiga University of Medical Science - Otsu (Japan)
-  **LP69** **A Fully-Automated and Scalable Plasma Phospho-Tau181 Assay for Alzheimer's Disease**  
Edward N. Wilson<sup>1</sup>, Christina B. Young<sup>1</sup>, Manu Vandijck<sup>2</sup>, Joseph P. Quinn<sup>3</sup>, Christopher H. Van Dyck<sup>4</sup>, Angus Nairn<sup>4</sup>, Sharon Sha<sup>1</sup>, Victor W. Henderson<sup>1</sup>, Frank M. Longo<sup>1</sup>, Michael D. Greicius<sup>1</sup>, Anthony D. Wagner<sup>1</sup>, Tony Wyss-Coray<sup>1</sup>, Kathleen L. Poston<sup>1</sup>, Elizabeth C. Mormino<sup>1</sup>, Katrin I. Andreasson<sup>1</sup>  
<sup>1</sup>Stanford University - Stanford (United States), <sup>2</sup>Fujirebio NV - Ghent (Belgium), <sup>3</sup>Oregon Health & Science University - Portland (United States), <sup>4</sup>Yale University - New Haven (United States)

- LP70** **Plasma p-tau181 in the Multidomain Alzheimer Prevention Trial (MAPT)**  
 Nicola Coley<sup>1,2</sup>, Henrik Zetterberg<sup>3</sup>, Sophie Guyonnet<sup>2,1</sup>, Philippe De Souto Barreto<sup>1,2</sup>, Kaj Blennow<sup>3</sup>, Nicolas Ashton<sup>3</sup>, Sandrine Andrieu<sup>1,2</sup>, Bruno Vellas<sup>2,1</sup>  
<sup>1</sup>INSERM, University of Toulouse - Toulouse (France), <sup>2</sup>Toulouse University Hospital - Toulouse (France), <sup>3</sup>University of Gothenburg - Gothenburg (Sweden)
- LP71** **The effect of neprilysin inhibition on Alzheimer's disease plasma biomarkers: results from a randomized controlled trial evaluating sacubitril/valsartan in cognitively unimpaired individuals at risk for heart failure**  
 Wagner S. Brum<sup>1</sup>, Kieran F. Docherty<sup>2</sup>, Nicholas J. Ashton<sup>1</sup>, Shorena Janelidze<sup>3</sup>, Pardeep S. Jhund<sup>2</sup>, Oskar Hansson<sup>3</sup>, Henrik Zetterberg<sup>1</sup>, John J. V. McMurray<sup>4</sup>, Kaj Blennow<sup>1</sup>  
<sup>1</sup>Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg - Mölndal (Sweden), <sup>2</sup>BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow - Glasgow (United Kingdom), <sup>3</sup>Clinical Memory Research Unit, Faculty of Medicine, Lund University - Lund (Sweden), <sup>4</sup>New British Heart Foundation Cardiovascular Research Centre, University of Glasgow - Glasgow (United Kingdom)
- LP72** **Simultaneous mass spectrometric quantification of multiple tau species in blood shows differential association with amyloid and tau pathology**  
 Laia Montoliu-Gaya<sup>1</sup>, Andrea L. Benedet<sup>1</sup>, Agathe Vrillon<sup>2</sup>, Cécile Tissot<sup>3</sup>, Wagner S. Brum<sup>1</sup>, Nicholas J. Ashton<sup>1</sup>, Juan Lantero-Rodriguez<sup>1</sup>, Gunnar Brinkmalm<sup>1</sup>, Johanna Nilsson<sup>1</sup>, Henrik Zetterberg<sup>1</sup>, Johan Gobom<sup>1</sup>, Claire Paquet<sup>2</sup>, Pedro Rosa-Neto<sup>3</sup>, Kaj Blennow<sup>1</sup>  
<sup>1</sup>Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. - Gothenburg (Sweden), <sup>2</sup>Cognitive Neurology Center, GHU Nord APHP Hospital Lariboisière Fernand Widal, Université de Paris, Paris, France. - Paris (France), <sup>3</sup>Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, McGill University, Montreal, Quebec, Canada. - Montréal (Canada)
- LP73** **Cerebrospinal fluid proteomics reveal 5 molecular subtypes in Alzheimer's disease: implications for personalised treatment**  
 Betty Tijms<sup>1</sup>, Wiesje Van Der Flier<sup>1</sup>, Charlotte Teunissen<sup>1</sup>, Jort Vijverberg<sup>1</sup>, Yolande Pijnenburg<sup>1</sup>, Even Birkeland<sup>2</sup>, Frode Berven<sup>2</sup>, Pieter Jelle Visser<sup>1</sup>  
<sup>1</sup>Amsterdam UMC, location VUmc - Amsterdam (Netherlands), <sup>2</sup>University of Bergen - Bergen (Norway)
- LP74** **Effects of pre-analytical parameters on plasma  $\beta$ -amyloid level**  
 Kengo Ishiki<sup>1</sup>, Kazuto Yamashita<sup>1</sup>, Shunsuke Watanabe<sup>1</sup>, Masahiro Miura<sup>1</sup>, Shigeaki Iwanaga<sup>1</sup>, Toshiyuki Sato<sup>1</sup>  
<sup>1</sup>Central Research Laboratories, Sysmex Corporation - Kobe (Japan)
- LP75** **Effect of a 1-year nutritional blend supplementation on plasma p-tau181 levels among community-dwelling older adults: a secondary analysis of the Nolan Study**  
 Kelly Giudici<sup>1</sup>, Sophie Guyonnet<sup>1,2</sup>, Christelle Cantet<sup>1,2</sup>, Philippe De Souto Barreto<sup>1,2</sup>, Kaj Blennow<sup>3,4</sup>, Henrik Zetterberg<sup>3,4</sup>, Corina Boschat<sup>5</sup>, Julie Hudry<sup>5</sup>, Sandrine Andrieu<sup>6,2</sup>, Bruno Vellas<sup>1,2</sup>, Jeroen Schmitt<sup>5,7,8</sup>  
<sup>1</sup>Institute of Aging, Gerontopole of Toulouse, Toulouse University Hospital - Toulouse (France), <sup>2</sup>CERPOP UMR1295, University of Toulouse III, Inserm, UPS - Toulouse (France), <sup>3</sup>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg - Mölndal (Sweden), <sup>4</sup>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), <sup>5</sup>Société des Produits Nestlé SA, Nestlé Research - Lausanne (Switzerland), <sup>6</sup>Department of Epidemiology and Public Health, Toulouse University Hospital - Toulouse (France), <sup>7</sup>Singapore Institute of Food and Biotechnology Innovation, Agency for Science, Technology and Research - Singapore (Singapore), <sup>8</sup>Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research - Singapore (Singapore)
- LP76** **A novel accessible and scalable assay for pTau217 in blood**  
 Stuart Portbury<sup>1</sup>, Inge Verberk<sup>2</sup>, Sherif Bayoumy<sup>2</sup>, Wiesje Van Der Flier<sup>2</sup>, Jeroen Vandrabrant<sup>3</sup>, Charlotte Teunissen<sup>2</sup>, Eric Stoops<sup>3</sup>, Andreas Jeromin<sup>1</sup>  
<sup>1</sup>ALZpath - Carlsbad, Ca (United States), <sup>2</sup>Amsterdam UMC - Amsterdam (Netherlands), <sup>3</sup>ADX Neurosciences - Gent (Belgium)
- LP77** **Longitudinal associations of changes in blood-based markers for neurodegenerative diseases in clinical trials on Alzheimer's disease**  
 Danni Li<sup>1</sup>, Matthew Glittenberg<sup>1</sup>, Dereck Salisbury<sup>1</sup>, Vankee Feng Lin<sup>2</sup>, Fang Yu<sup>3</sup>  
<sup>1</sup>University of Minnesota - Minneapolis (United States), <sup>2</sup>Stanford University - San Francisco (United States), <sup>3</sup>Arizona State University (United States)
- LP78** **Plasma p-tau and NFL potential utility as surrogate biomarkers in preventive clinical trials**  
 Pamela L. Ferreira<sup>1</sup>, João Pedro Ferrari-Souza<sup>1</sup>, Cécile Tissot<sup>2</sup>, Bruna Bellaver<sup>1</sup>, Douglas T. Leffa<sup>1</sup>, Guilherme Povala<sup>1</sup>, Firoza Z. Lussier<sup>1</sup>, Joseph Theriault<sup>2</sup>, Jean-Paul Soucy<sup>2</sup>, Serge Gauthier<sup>2</sup>, Victor L. Villemagne<sup>1</sup>, Pedro Rosa-Neto<sup>2</sup>, Thomas K. Karikari<sup>1</sup>, Tharick A. Pascoal<sup>1</sup>  
<sup>1</sup>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA. - Pittsburgh (United States), <sup>2</sup>Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada. - Montreal (Canada)
- LP79** **Fosgonimeton provides congruent benefit on diverse biomarkers of neurodegeneration, significantly correlating with a composite clinical score of cognition and function in Alzheimer's disease**  
 Hans Moebius<sup>1</sup>, Kai-Bin Ooi<sup>1</sup>, Michael Hale<sup>1</sup>, Sharay Setti<sup>1</sup>, Kayla Kleist<sup>1</sup>, Charles Bernick<sup>2</sup>  
<sup>1</sup>Athira Pharma - Bothell (United States), <sup>2</sup>Cleveland Clinic Lou Ruvo Center for Brain Health - Las Vegas (United States)
- LP80** **In an optimized CSF collection protocol the ptau181/A $\beta$ 1-42 ratio increases preanalytical variability over measuring A $\beta$ 1-42 alone**  
 Rianne Esquivel<sup>1</sup>, Sara Ho<sup>2</sup>, Jacqueline Darrow<sup>2</sup>, Amanda Calabro<sup>1</sup>, Parmi Thakker<sup>2</sup>, Sara Gannon<sup>1</sup>, Francesca De Simone<sup>1</sup>, Abhay Moghekar<sup>2</sup>  
<sup>1</sup>Fujirebio Diagnostics Inc - Malvern (United States), <sup>2</sup>Johns Hopkins School of Medicine - Baltimore (United States)
- LP81** **Analytical Feasibility of Composite Plasma Phosphorylated Tau and A $\beta$  Biomarker for Predicting Amyloid PET Positivity**  
 Anthony W. Bannon<sup>1</sup>, William Z. Potter<sup>2</sup>, Stephen Zicha<sup>3</sup>, Leslie M. Shaw<sup>4</sup>, Henrik Zetterberg<sup>5</sup>, Ziad S. Saad<sup>6</sup>, Jeffrey Dage<sup>7</sup>, Iwona Dobler<sup>8</sup>, David L. Raunig<sup>9</sup>, Kyle Ferber<sup>10</sup>, Carrie E. Rubel<sup>10</sup>, Suzanne E. Schindler<sup>11</sup>, Mike Baratta<sup>3</sup>, Emily A. Meyers<sup>12</sup>, Erin G. Rosenbaugh<sup>13</sup>  
<sup>1</sup>AbbVie - North Chicago (United States), <sup>2</sup>Subject Matter Expert (United States), <sup>3</sup>Takeda, Pharmaceutical Company Ltd. - Cambridge (United States), <sup>4</sup>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania - Philadelphia (United States), <sup>5</sup>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg - Mölndal (Sweden), <sup>6</sup>Neuroscience Biomarkers, Janssen Research and Development LLC - La Jolla (United States), <sup>7</sup>Stark Neurosciences Research Institute at Indiana University School of Medicine - Indianapolis (United States), <sup>8</sup>Takeda, Pharmaceutical Company Ltd - Cambridge (United States), <sup>9</sup>Takeda, Pharmaceutical Company Ltd. - Cambridge (United States), <sup>10</sup>Biogen - Cambridge (United States), <sup>11</sup>Department of Neurology, Washington University School of Medicine - St. Louis (United States), <sup>12</sup>Alzheimer's Association - Chicago (United States), <sup>13</sup>Foundation for the National Institutes of Health - North Bethesda (United States)

-  **LP82** **The development of an automated EEG-based machine learning pipeline for the detection of Alzheimer's Disease, a proof-of-concept study for clinical trial biomarkers**  
Nicholas Chedid<sup>1</sup>  
<sup>1</sup>SynapseBio Inc - New York (United States)
-  **LP83** **Towards implementation of plasma phospho-tau 181 as a screening tool for patient recruitment**  
Andreja Emersic<sup>1</sup>, Bjørn-Eivind Kirsebom<sup>2,3</sup>, Wagner S Brum<sup>4,5</sup>, Marianne Wettergreen<sup>6,7</sup>, Bengt Winblad<sup>8,9</sup>, Kaj Blennow<sup>10,11</sup>, Milica Gregoric Kramberger<sup>1,12</sup>, Tormod Fladby<sup>6,13</sup>  
<sup>1</sup>Department of Neurology, University Medical Centre - Ljubljana (Slovenia), <sup>2</sup>Department of Neurology, University Hospital of North Norway - Tromsø (Norway), <sup>3</sup>Department of Neurology, Medical faculty, University of Ljubljana - Ljubljana (Slovenia), <sup>4</sup>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Clinical Neurochemistry Laboratory, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Gothenburg (Sweden), <sup>5</sup>Department of Psychology, Faculty of Health Sciences, UiT, The Arctic University of Norway - Tromsø (Norway), <sup>6</sup>Department of Neurology, Akershus University Hospital - Lørenskog (Norway), <sup>7</sup>Institute of Clinical Medicine, University of Oslo - Lørenskog (Norway), <sup>8</sup>Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics Karolinska Institutet - Stockholm (Sweden), <sup>9</sup>Clinical Molecular Biology (EpiGen), University of Oslo - Oslo (Norway), <sup>10</sup>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Clinical Neurochemistry Laboratory, The Sahlgrenska Academy at the University of Gothenburg - Gothenburg (Sweden), <sup>11</sup>Karolinska University Hospital - Stockholm (Sweden), <sup>12</sup>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Gothenburg (Sweden), <sup>13</sup>Universidade Federal do Rio Grande do Sul (UFRGS) - Porto Alegre (Brazil)
-  **LP84** **Leukocyte-Derived Ratios Are Associated With Dementia**  
Yu Na Kim<sup>1,2</sup>, Saleena Arif<sup>2</sup>  
<sup>1</sup>Boston University - Boston (United States), <sup>2</sup>DotHouse Health - Boston (United States)
-  **LP84A** **Three group classification of participants based on fully automated plasma  $\beta$ -amyloid measurements to achieve high positive and negative predictive values**  
Kazuto Yamashita<sup>1</sup>, Masahiro Miura<sup>1</sup>, Kota Nagai<sup>2</sup>, David Verbel<sup>3</sup>, Shigeki Iwanaga<sup>1</sup>, Toshiyuki Sato<sup>1</sup>, Tomokazu Yoshida<sup>4</sup>, Atsushi Iwata<sup>5</sup>  
<sup>1</sup>Central Research Laboratories, Sysmex Corporation - Kobe (Japan), <sup>2</sup>Japan and Asia Clinical Development Department, Eisai Co., Ltd - Tokyo (Japan), <sup>3</sup>Biostatistics, Eisai Inc. - Nutley (United States), <sup>4</sup>Sysmex Corporation - Kobe (Japan), <sup>5</sup>Department of Neurology, Tokyo Metropolitan Geriatric Hospital and Institute of gerontology - Tokyo (Japan)
-  **LP84B** **The biomarkers for Alzheimer's disease clinical diagnosis in Chinese population: China Aging and Neurodegenerative Disease Research Cohort (CANDI) study**  
Gao Feng<sup>1</sup>, Lv Xinyi<sup>1</sup>, Dai Linbin<sup>2</sup>, Wang Qiong<sup>1</sup>, Wang Peng<sup>3</sup>, Xie Qiang<sup>4</sup>, Ni Ming<sup>5</sup>, Wang Shicun<sup>4</sup>, Deng Kexue<sup>3</sup>, Tang Qiqiang<sup>6</sup>, Shi Jiong<sup>1</sup>, Shen Yong<sup>7</sup>  
<sup>1</sup>Department of Neurology, Institute on Aging and Brain Disorders, The First Affiliated Hospital of USTC, University of Science and Technology of China - Hefei (China), <sup>2</sup>Institute on Aging and Brain Disorders, The First Affiliated Hospital of USTC, University of Science and Technology of China - Hefei (China), <sup>3</sup>Department of Radiology, The First Affiliated Hospital of USTC, University of Science and Technology of China - Hefei (China), <sup>4</sup>Department of Nuclear Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China - Hefei (China), <sup>5</sup>Department of Nuclear Medicine, The First Affiliated Hospital of USTC, - Hefei (China), <sup>6</sup>Department of Neurology, The First Affiliated Hospital of USTC, University of Science and Technology of China - Hefei (China), <sup>7</sup>Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, University of Science and Technology of China - Hefei (China)

## THEME: Cognitive and Functional Endpoints

-  **P126** **Visit-to-visit blood pressure variability and cognition in the SPRINT MIND trial**  
Isabel Sible<sup>1</sup>, Daniel Nation<sup>2</sup>  
<sup>1</sup>Usc - Los Angeles (United States), <sup>2</sup>Uc Irvine - Irvine (United States)
-  **P127** **Classification and Prediction of Different Cognitive Trajectories in Cognitively Normal Elderly**  
Young Ju Kim<sup>1</sup>, Si Eun Kim<sup>2</sup>, Alice Hahn<sup>3</sup>, Soo Hyun Cho<sup>4</sup>, Duk L. Na<sup>1</sup>, Jun Pyo Kim<sup>1</sup>, Hyemin Jang<sup>1</sup>, Hee Jin Kim<sup>1</sup>, Juhee Chin<sup>1</sup>, Sang Won Seo<sup>1</sup>  
<sup>1</sup>Samsung Medical Center - Seoul (Korea, Republic of), <sup>2</sup>Haeundae Paik Hospital - Busan (Korea, Republic of), <sup>3</sup>Johns Hopkins Bloomberg School Of Public Health - Baltimore (Korea, Republic of), <sup>4</sup>Chonnam National University Hospital - Chonnam (Korea, Republic of)
-  **P128** **What's in a score: Comparing and aligning scores based on item response theory and classical test theory for the Amsterdam Instrumental Activities of Daily Living Questionnaire**  
Mark Dubbelman<sup>1</sup>, Merel Postema<sup>1</sup>, Roos Jutten<sup>2</sup>, John Harrison<sup>1</sup>, Craig Ritchie<sup>3</sup>, Benjamin Schalet<sup>4</sup>, Caroline Terwee<sup>5</sup>, Wiesje Van Der Flier<sup>1</sup>, Philip Scheltens<sup>1</sup>, Sietske Sikkes<sup>1</sup>  
<sup>1</sup>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Umc Location Vumc - Amsterdam (Netherlands), <sup>2</sup>Department Of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States), <sup>3</sup>University Of Edinburgh - Edinburgh (United Kingdom), <sup>4</sup>Department Of Medical Social Sciences, Feinberg School Of Medicine, Northwestern University - Chicago (United States), <sup>5</sup>Amsterdam Umc Location Vumc, Epidemiology And Data Science, Amsterdam Umc - Amsterdam (Netherlands)
-  **P129** **Slowing of Alzheimer's Disease Progression with NeuroAid**  
Christopher Li-Hsian Chen<sup>1</sup>, Yogesh Pokharkar<sup>2</sup>, Narayanaswamy Venketasubramanian<sup>3</sup>  
<sup>1</sup>National University of Singapore - Singapore (Singapore), <sup>2</sup>Singapore Clinical Research Institute - Singapore (Singapore), <sup>3</sup>Raffles Hospital - Singapore (Singapore)
-  **P130** **A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Investigation of Safety and Efficacy of Nilotinib BE in Early Alzheimer's Disease (NILEAD)**  
Yasar Torres-Yaghi<sup>1</sup>, Marwan Sabbagh<sup>2</sup>, Chris Hoyt<sup>3</sup>, Kimberly Guedes<sup>3</sup>, Fernando Pagan<sup>1</sup>, Raymond Turner<sup>1</sup>, Jaeil Ahn<sup>1</sup>, Charbel Moussa<sup>1</sup>  
<sup>1</sup>Georgetown - Washington, DC (United States), <sup>2</sup>Barrow - Phoenix, AZ (United States), <sup>3</sup>Keifex - Washington, DC (United States)

-  **P131** **Subjective illness representations in an early-stage Alzheimer's disease population: psychometric properties of the RADIX questionnaire**  
Alberto Villarejo-Galende <sup>1</sup>, Elena García-Arcelay <sup>2</sup>, Gerard Piñol-Ripoll <sup>3</sup>, Antonio Del Olmo-Rodríguez <sup>4</sup>, Felix Viñuela <sup>5</sup>, Mercè Boada <sup>6</sup>, Emilio Franco-Macias <sup>7</sup>, Almudena Ibañez De La Peña <sup>8</sup>, Mario Riverol <sup>9</sup>, Jorge Maurino <sup>2</sup>  
<sup>1</sup>Department Of Neurology, Hospital Universitario 12 De Octubre - Madrid (Spain), <sup>2</sup>Medical Department, Roche Farma - Madrid (Spain), <sup>3</sup>Unitat Trastorns Cognitius, Hospital Universitari De Santa Maria - Lleida (Spain), <sup>4</sup>Department Of Neurology, Hospital Universitario Dr. Peset - Valencia (Spain), <sup>5</sup>Department Of Neurology, Hospital Universitario Virgen Macarena - Sevilla (Spain), <sup>6</sup>Ace Alzheimer Center Barcelona - Barcelona (Spain), <sup>7</sup>Department Of Neurology, Hospital Universitario Virgen Del Rocío - Sevilla (Spain), <sup>8</sup>Centro De Investigación De Parkinson, Policlínica Guipúzcoa - San Sebastián (Spain), <sup>9</sup>Department Of Neurology, Clínica Universidad De Navarra - Pamplona (Spain)
-  **P132** **Impact of Disease Progression on Dependency in Patients with Mild and Moderate Alzheimer Disease**  
Wenyu Ye <sup>1</sup>, Julie Chandler <sup>1</sup>, Xiaojuan Mi <sup>2</sup>, Antje Tockhorn-Heidenreich <sup>1</sup>, Joseph Johnston <sup>1</sup>, Erin Doty <sup>1</sup>  
<sup>1</sup>Eli Lilly And Company - Indianapolis (United States), <sup>2</sup>Techdata Services Company - King Of Prussia (United States)
-  **P133** **The responsiveness of cognitive and functional outcome measures in preclinical Alzheimer's disease: Implications for trial design**  
Mark Dubbelman <sup>1</sup>, Heleen Hendriksen <sup>1</sup>, Lois Ottenhoff <sup>1</sup>, Everard Vijverberg <sup>1</sup>, Niels Prins <sup>2</sup>, Lior Kroeze <sup>1</sup>, Argonde Van Harten <sup>1</sup>, Bart Van Berckel <sup>1</sup>, John Harrison <sup>1</sup>, Wiesje Van Der Flier <sup>1</sup>, Sietske Sikkes <sup>1</sup>  
<sup>1</sup>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Umc Location Vumc - Amsterdam (Netherlands), <sup>2</sup>Brain Research Center - Amsterdam (Netherlands)
-  **P134** **The effect of dietary habit on the progression of Alzheimer's disease: A CREDOS (Clinical Research Center for Dementia of South Korea) study**  
Yangki Minn <sup>1</sup>, Seonghye Choi <sup>2</sup>  
<sup>1</sup>Kangnam Sacred Heart Hospital, Hallym University - Seoul (Korea, Republic of), <sup>2</sup>Inha University Medicval Center - Incheon (Korea, Republic of)
-  **P135** **Length of administration of ADAS-Cog and CDR assessment impacts data quality**  
Barbara Echevarria <sup>1</sup>  
<sup>1</sup>WCG Clinical Endpoint Solutions - Hamilton (United States)
-  **P136** **A randomized study to evaluate the efficacy of Donepezil in improving visuospatial abilities in patients with mild cognitive impairment using eye-tracker**  
Kim Ko Woon <sup>1</sup>, Wang Qi <sup>2</sup>, Koo Se Hee <sup>3</sup>, Shin Byoung-Soo <sup>1</sup>  
<sup>1</sup>Department of Neurology, Jeonbuk National University Medical School and Hospital - Jeonju (Korea, Republic of), <sup>2</sup>Jeonbuk National University Medical School - Jeonju (Korea, Republic of), <sup>3</sup>Biomedical Research Institute of Jeonbuk National University Hospital - Jeonju (Korea, Republic of)
-  **P137** **A Phase 2b, Randomized, Placebo-Controlled Trial to Evaluate the Effects of SAGE-718 in Patients with Alzheimer's Disease: Study Design**  
Aaron Koenig <sup>1</sup>, Tiffany Lago <sup>1</sup>, Jason Johannesen <sup>1</sup>, Sigui Li <sup>1</sup>, Emily Freitag <sup>1</sup>, Jeffrey Wald <sup>1</sup>, Katrina Paumier <sup>1</sup>, Michael Quirk <sup>1</sup>, James Doherty <sup>1</sup>  
<sup>1</sup>Sage Therapeutics, Inc. - Cambridge, Massachusetts (United States)
-  **P138** **Bringing meaning to personalised Brain Health: a tool that empowers individuals to define and monitor personally meaningful change**  
Stina Saunders <sup>1</sup>, David Bates <sup>2</sup>, Ankur Bharija <sup>2,3</sup>, Joyce Gomes-Osman <sup>2,4</sup>, Saturnino Luz <sup>1</sup>, Graciela Muniz-Terrera <sup>1</sup>, Álvaro Pascual-Leone <sup>2,5</sup>, Craig Ritchie <sup>1</sup>  
<sup>1</sup>Centre for Clinical Brain Sciences, University of Edinburgh, UK - Edinburgh (United Kingdom), <sup>2</sup>Linus Health Inc., Boston, MA, USA - Boston (United States), <sup>3</sup>Department of Medicine, Division of Primary Care and Population Health, Stanford Medicine, Stanford, USA - Stanford (United States), <sup>4</sup>Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA - Miami (United States), <sup>5</sup>Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA - Boston (United States)
- P139** **Dementia conversion rate differences between patients with high- and low-risk amnesic mild cognitive impairment in the real-world: A prospective, multicenter, observational study**  
Hyemin Jang <sup>1</sup>, Duk L. Na <sup>2</sup>, Jay Cheol Kwon <sup>3</sup>, Mee Young Park <sup>4</sup>, Yeonsil Moon <sup>5</sup>, Jung Seok Lee <sup>6</sup>, Kyung-Won Park <sup>7</sup>, Ae Young Lee <sup>8</sup>, Hanna Cho <sup>9</sup>, Jae-Hong Lee <sup>10</sup>, Byeong Chae Kim <sup>11</sup>, Kee Hyung Park <sup>12</sup>, Byung-Chul Lee <sup>13</sup>, Hojin Choi <sup>14</sup>, Kim Jieun <sup>15</sup>, Na-Yeon Jung <sup>16</sup>  
<sup>1</sup>Samsung Alzheimer's Convergence Research Center, Samsung Medical Center - Seoul (Korea, Republic of), <sup>2</sup>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), <sup>3</sup>Department of Neurology, Changwon Fatima Hospital - Changwon (Korea, Republic of), <sup>4</sup>Department of Neurology, Yeungnam University College of Medicine - Daegu (Korea, Republic of), <sup>5</sup>Department of Neurology, Konkuk University Medical Center, Konkuk University School of Medicine - Seoul (Korea, Republic of), <sup>6</sup>Department of Neurology, Jeju National University College of Medicine - Jeju (Korea, Republic of), <sup>7</sup>Department of Neuroscience, Cognitive Disorders and Dementia Center, Dong-A University College of Medicine and Institute of Convergence Bio-Health - Busan (Korea, Republic of), <sup>8</sup>Department of Neurology, Chungnam National University School of Medicine - Daejeon (Korea, Republic of), <sup>9</sup>Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), <sup>10</sup>Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine - Seoul (Korea, Republic of), <sup>11</sup>Department of Neurology, Chonnam National University Medical School & Hospital - Gwangju (Korea, Republic of), <sup>12</sup>Department of Neurology, College of Medicine, Gachon University Gil Hospital - Incheon (Korea, Republic of), <sup>13</sup>Department of Neurology, Hallym University College of Medicine - Seoul (Korea, Republic of), <sup>14</sup>Department of Neurology, Hanyang University Guri Hospital - Guri (Korea, Republic of), <sup>15</sup>Department of Medical, Eisai Korea Inc. - Seoul (Korea, Republic of), <sup>16</sup>Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine - Yangsan (Korea, Republic of)
-  **P140** **Predicting tau PET signal in prodromal-to mild Alzheimer's disease from speech biomarkers and machine learning**  
Mario Mina <sup>1</sup>, Johannes Troeger <sup>1</sup>, Louisa Schwed <sup>1</sup>, Nicklas Linz <sup>1</sup>, Sandra Sanabria Bohórquez <sup>2</sup>, Somaye Hashemifar <sup>2</sup>, Tina Boggiano <sup>3</sup>, Edmond Teng <sup>2</sup>  
<sup>1</sup>ki:elements - Saarbruecken (Germany), <sup>2</sup>Genentech Inc - San Francisco (United States), <sup>3</sup>F. Hoffmann-La Roche Ltd - Basel (Switzerland)

-  **LP85** **A multicenter, Randomised, Open-label, prospective study to estimate the add-on effects of Memantine as Ebixa® Oral pump (solution) on language in moderate to severe Alzheimer's Disease patients already receiving donepezil (ROMEQ-AD)**  
Hee-Jin Kim<sup>1</sup>, Hyun Jeong Han<sup>2</sup>, Yongsoo Shim<sup>3</sup>, Byeong C. Kim<sup>4</sup>, Kee Hyung Park<sup>4</sup>, So Young Moon<sup>5</sup>, Seong Hye Choi<sup>6</sup>, Dong Won Yang<sup>7</sup>, Bora Yoon<sup>8</sup>, Eun-Joo Kim<sup>9</sup>, Jee Hyang Jeong<sup>10</sup>, Seol-Heui Han<sup>11</sup>  
<sup>1</sup>Professor of Neurology Department of College of Medicine, Hanyang University - Seoul (Korea, Republic of), <sup>2</sup>Department of Neurology, Myongji Hospital, Hanyang University College of Medicine - Seoul (Korea, Republic of), <sup>3</sup>Department of Neurology, The Catholic university of Korea Eunpyeong St. Mary's Hospital - Seoul (Korea, Republic of), <sup>4</sup>Department of Neurology, Chonnam National University Medical School - Seoul (Korea, Republic of), <sup>5</sup>Department of Neurology, Ajou University School of Medicine - Seoul (Korea, Republic of), <sup>6</sup>Department of Neurology, Inha University School of Medicine - Seoul (Korea, Republic of), <sup>7</sup>Department of Neurology, The Catholic University of Korea, Seoul St. Mary's hospital - Seoul (Korea, Republic of), <sup>8</sup>Department of Neurology, Konyang University College of Medicine - Seoul (Korea, Republic of), <sup>9</sup>Department of Neurology, Pusan National University Hospital - Seoul (Korea, Republic of), <sup>10</sup>Department of Neurology, Ewha Womans University Seoul Hospital - Seoul (Korea, Republic of), <sup>11</sup>Department of Neurology, Konkuk University College of Medicine - Seoul (Korea, Republic of)
-  **LP86** **Effectiveness of Vortioxetine in Patients With Major Depressive Disorder and Early Dementia: The MEMORY Study**  
Michael Cronquist Christensen<sup>1</sup>, Simon Nitschky Schmidt<sup>1</sup>, Iria Grande<sup>2</sup>  
<sup>1</sup>H. Lundbeck A/S - Valby (Denmark), <sup>2</sup>Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM - Barcelona (Spain)
-  **LP87** **Assessing Clinically Meaningful Functional Outcomes in Preclinical Alzheimer's Disease**  
Carla Romano<sup>1</sup>, Gerald Novak<sup>2</sup>, Jiyoung Choi<sup>3</sup>, Shanshan Qin<sup>1</sup>, David Henley<sup>2</sup>, Mike Donohue<sup>3</sup>, Gary Romano<sup>4</sup>, Rema Raman<sup>3</sup>, Rebecca Amariglio<sup>5</sup>, Paul Aisen<sup>3</sup>, Reisa Sperling<sup>5</sup>  
<sup>1</sup>RTI-HS - Research Triangle Park (United States), <sup>2</sup>Janssen - Titusville (United States), <sup>3</sup>USC - San Diego (United States), <sup>4</sup>Alector - San Francisco (United States), <sup>5</sup>Harvard - Boston (United States)
-  **LP88** **Characterizing Cognitive Changes in Early-Stage Alzheimer's Disease using Latent Cognitive Measures from the ADNI Dataset**  
Jason Bock<sup>1,2</sup>, Junko Hara<sup>1,3</sup>, Dennis Fortier<sup>1</sup>, Bruce Albala<sup>4,5</sup>  
<sup>1</sup>Embic Corporation - Newport Beach (United States), <sup>2</sup>Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), <sup>3</sup>Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach (United States), <sup>4</sup>UCI Center for Clinical Research - Irvine (United States), <sup>5</sup>UCI School of Medicine - Irvine (United States)
-  **LP89** **Neurogenesis Hypothesis with a case study- Phase 2A Clinical Trials Results of NA-831 for the treatment of Alzheimer's disease**  
 Markku Kurkinen<sup>1</sup>, Lloyd Tran<sup>1</sup>  
<sup>1</sup>Biomed Industries, Inc. - San Jose (United States)
-  **LP89A** **Cognitive Composite Outcome Measures for Clinical Trials: Can You Have Too Much of a Good Thing?**  
 Xinran Wang<sup>1</sup>, Diane Jacobs<sup>1</sup>, David Salmon<sup>1</sup>, Howard Feldman<sup>1</sup>, Sarah Banks<sup>1</sup>, Steven Edland<sup>1</sup>  
<sup>1</sup>University of California San Diego - La Jolla (United States)
-  **LP89B** **The home-based tDCS in MCI and AD comorbid with depression: behavioral and electrophysiological effects**  
Do Hoon Kim<sup>1</sup>, Yoo Sun Moon<sup>1</sup>  
<sup>1</sup>Chuncheon Sacred Heart Hospital - Seoul (Korea, Republic of)

### THEME: Cognitive assessment and clinical trials

- P141** SKT Short Cognitive Performance Test for the detection of early cognitive decline – data from international validation studies  
Mark Stemmler<sup>1</sup>  
<sup>1</sup>University Of Erlangen-Nuremberg - Erlangen (Germany)
- P142** ImPACT Cognitive Assessment: What are we measuring  
James Gyurke<sup>1</sup>, Phail Schatz<sup>2</sup>  
<sup>1</sup>Riverside Insights - Lutz (United States), <sup>2</sup>Saint Joseph's University - Philadelphia (United States)
- P143** Validation of an objective, speech-based object content score for measuring disease progression in AD  
Jessica Robin<sup>1</sup>, Mengdan Xu<sup>2</sup>, Michael Detke<sup>3</sup>, William Simpson<sup>2</sup>  
<sup>1</sup>Winterlight Labs - Vancouver (Canada), <sup>2</sup>Winterlight Labs - Toronto (Canada), <sup>3</sup>Detke Biopharma Consulting - Indianapolis (United States)
- P144** Relationship between telomere shortening and early subjective depressive symptoms and cognitive complaints in older adults  
Seong-Ho Koh<sup>1</sup>, Myung-Hoon Han<sup>1</sup>, Eun-Hye Lee<sup>1</sup>, Hyun-Hee Park<sup>1</sup>, Seong Hye Choi<sup>2</sup>  
<sup>1</sup>Hanyang University - Seoul (Korea, Republic of), <sup>2</sup>Inha University - Incheon (Korea, Republic of)
- P145** Accuracy of automated scoring of word recall assessments  
Rachel Kindellan<sup>1</sup>, Celia Fidalgo<sup>1</sup>, William Simpson<sup>1</sup>, Jessica Robin<sup>1</sup>  
<sup>1</sup>Winterlight Labs - Toronto (Canada)
- P146** Association of long-term exposure to ambient air pollution with cognitive decline and Alzheimer's disease-related amyloidosis  
Ya-Hui Ma<sup>1</sup>, Lan Tan<sup>2</sup>, Jin-Tai Yu<sup>3</sup>  
<sup>1</sup>Qingdao Municipal Hospital, College Of Clinical Medicine, Qingdao University - Qingdao (China) - Qingdao (China), <sup>2</sup>Qingdao Municipal Hospital, College Of Clinical Medicine, Qingdao University - Qingdao (China), <sup>3</sup>Department Of Neurology And Institute Of Neurology, Huashan Hospital, State Key Laboratory Of Medical Neurobiology And Moe Frontiers Center For Brain Science, Shanghai Medical College, Fudan University - Shanghai (China)
- P147** Pre-Screening Prodromal AD Trial Populations over the Telephone Using a Speech Biomarker for Cognition — Preliminary Results from AUTONOMY Phase 2 AD Trial Recruitment  
Stephen Ruhmel<sup>1</sup>, Johannes Tröger<sup>2</sup>, Nicklas Linz<sup>2</sup>, Janna Herrmann<sup>2</sup>, Mary Quiceno<sup>1</sup>, Kai Langel<sup>1</sup>  
<sup>1</sup>The Janssen Pharmaceutical Companies Of Johnson & Johnson (United States), <sup>2</sup>Ki:elements - Saarbrücken (Germany)
- P148** The difference in trajectories according to early amyloid accumulation in normal cognitive elderly  
Young Ju Kim<sup>1</sup>, Min Young Chun<sup>1</sup>, Hyemin Jang<sup>1</sup>, Hee Jin Kim<sup>1</sup>, Jeong-Yeon Seo<sup>1</sup>, Sang Won Seo<sup>1</sup>  
<sup>1</sup>Samsung Medical Center - Seoul (Korea, Republic of)
- P149** Rater Error Pattern on the CDR Outcome Assessment in Alzheimer's Disease Clinical Trials  
Jordan Barbone<sup>1</sup>, Erin Barney<sup>1</sup>, Jason Cromer<sup>1</sup>, Robyn Leventhal<sup>1</sup>, Lisle Kingery<sup>1</sup>, Svenja Wacker<sup>1</sup>  
<sup>1</sup>Cogstate - New Haven (United States)
- P150** Preliminary psychometric and clinical validation of information processing speed in early Alzheimer's Disease using a smartphone-based remote assessment  
Arnaud M. Wolfer<sup>1</sup>, Irma T. Kurniawan<sup>1</sup>, Kirsten I. Taylor<sup>1</sup>, Florian Lipsmeier<sup>1</sup>, Thanneer M. Perumal<sup>1</sup>  
<sup>1</sup>Roche Pharma Research And Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 - Basel (Switzerland)
- P151** Rater Error Pattern on the MMSE and ADAS-Cog Outcome Assessments in Alzheimer's Disease Clinical Trials  
Svenja Wacker<sup>1</sup>, Jordan Barbone<sup>1</sup>, Erin Barney<sup>1</sup>, Jason Cromer<sup>1</sup>, Lisle Kingery<sup>1</sup>, Robyn Leventhal<sup>1</sup>  
<sup>1</sup>Cogstate - New Haven (United States)
- P152** Preliminary psychometric and clinical validation of executive function in early Alzheimer's diseases using a smartphone-based assessment  
Irma T. Kurniawan<sup>1</sup>, Arnaud M. Wolfer<sup>1</sup>, Christopher Chatham<sup>1</sup>, Eduardo Aponte<sup>1</sup>, Stefan Holiga<sup>1</sup>, Thanneer M. Perumal<sup>1</sup>, Kirsten I. Taylor<sup>1</sup>  
<sup>1</sup>Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124 - Basel (Switzerland)
- P153** Preliminary psychometric and clinical validation of visuospatial working memory deficits in early Alzheimer's Disease measured with a smartphone based digital assessment  
Eduardo A. Aponte<sup>1</sup>, Kirsten I. Taylor<sup>1</sup>, Arnaud M. Wolfer<sup>1</sup>, Christopher Chatham<sup>1</sup>, Thanneer M. Perumal<sup>1</sup>  
<sup>1</sup>Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124 - Basel (Switzerland)
- P154** The Phase 2 LUMINARY Trial Assessing SAGE-718 in Patients with Mild Cognitive Impairment or Mild Dementia due to Alzheimer's Disease  
Aaron Koenig<sup>1</sup>, Shishuka Malhotra<sup>2</sup>, Jeffrey Wald<sup>1</sup>, Jennifer Petrillo<sup>1</sup>, Katrina Paumier<sup>1</sup>, Jason Johannesen<sup>1</sup>, Sigui Li<sup>1</sup>, Michael Quirk<sup>1</sup>, Emily Freitag<sup>1</sup>, James Doherty<sup>1</sup>  
<sup>1</sup>Sage Therapeutics, Inc. - Cambridge, Massachusetts (United States), <sup>2</sup>Neuro-Behavioral Clinical Research, Inc. - North Canton, Ohio (United States)

# POSTER PRESENTATIONS

Friday, December 2<sup>nd</sup> from 8 a.m to 5 p.m

Poster presentations presented onsite in San Francisco are indicated with this icon: 

-  P155 **Longitudinal Evolution of Financial Capacity and Cerebral Tau and Amyloid Burden in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Dementia**  
Kayden Mimmack<sup>1</sup>, Emily Sprague<sup>2,3</sup>, Rebecca Amariglio<sup>1,2,3</sup>, Patrizia Vannini<sup>1,2,3</sup>, Gad Marshall<sup>1,2,3</sup>  
<sup>1</sup>Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States), <sup>2</sup>Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), <sup>3</sup>Center for Alzheimer Research and Treatment - Boston (United States)
-  P156 **Potential Influence of Cognitive Heterogeneity in a Clinical Trial for Mild-to-Moderate Probable Alzheimer's Dementia**  
Diane Jacobs<sup>1</sup>, Yuqi Qiu<sup>2</sup>, David Salmon<sup>1</sup>, Karen Messer<sup>1</sup>, Lia Donahue<sup>3</sup>, Steven Kaplita<sup>3</sup>, Irfan Qureshi<sup>3</sup>, Howard Feldman<sup>1</sup>  
<sup>1</sup>University of California San Diego - La Jolla (United States), <sup>2</sup>School of Statistics, East China Normal University - Shanghai (China), <sup>3</sup>Biohaven Pharmaceuticals, Inc - New Haven (United States)
-  P157 **Impact of Different Rates of Disease Progression in Individuals with Amyloid Positive Alzheimer's Disease - Findings from the Alzheimer's Disease Neuroimaging Initiative**  
Julie M Chandler<sup>1</sup>, Mihaela Georgieva<sup>2</sup>, Urvi Desai<sup>2</sup>, Noam Kirson<sup>2</sup>, Wenyu Ye<sup>1</sup>, Andres Gomez-Lievano<sup>2</sup>, Annalise Hilts<sup>3</sup>, Dody Eid<sup>2</sup>, Angela Zhao<sup>2</sup>, Traci Schilling<sup>1</sup>  
<sup>1</sup>Eli Lilly and Company - Indianapolis (United States), <sup>2</sup>Analysis Group - Boston (United States), <sup>3</sup>Groupe d'Analyse - Montréal (Canada)
- P158 **Causal in silico patient models can inform Alzheimer's disease patient identification and endpoint selection for early-stage clinical trials**  
So-Youn Shin<sup>1</sup>, Shokeen Deepanshi<sup>1</sup>, Apoorva Bharthur<sup>1</sup>, Todd Oakland<sup>1</sup>, Jeanne Latourelle<sup>1</sup>  
<sup>1</sup>GNS Healthcare - Somerville, Ma (United States)
-  P159 **Clinical predictors for conversion to Alzheimer's dementia in patients with mild cognitive impairment using Amyloid PET imaging : Interim results**  
Kyung Won Park<sup>1</sup>, Seon-Jeong Kim<sup>1</sup>, Do-Young Kang<sup>2</sup>, Young-Jin Jeong<sup>2</sup>  
<sup>1</sup>Department of Neurology, Dong-A University College of Medicine - Busan (Korea, Republic of), <sup>2</sup>Department of Nuclear Medicine, Dong-A University College of Medicine - Busan (Korea, Republic of)
-  P160 **Clinical Trajectory of Preclinical AD Over 36 Months in the CHARIOT Study**  
Gerald Novak<sup>1</sup>, Susan Baker<sup>1</sup>, Keith Karcher<sup>1</sup>, David Henley<sup>1,2</sup>, Chi Udeh-Momoh<sup>3</sup>, Oliver Robinson<sup>4</sup>, Geraint Price<sup>3</sup>, Tam Watermeyer<sup>5</sup>, Craig Ritchie<sup>5</sup>, Lefkos Middleton<sup>3,4</sup>  
<sup>1</sup>Janssen R&D - Titusville, Nj (United States), <sup>2</sup>Indiana University School of Medicine - Indianapolis, In (United States), <sup>3</sup>Imperial College Healthcare NHS Trust - London (United Kingdom), <sup>4</sup>AGE Research, School of Public Health, Imperial College of London - London (United Kingdom), <sup>5</sup>Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, University of Edinburgh - Edinburgh (United Kingdom)
-  P161 **Impact of Different Rates of Disease Progression in Individuals with Amyloid Positive Alzheimer's Disease - Findings from the National Alzheimer's Coordinating Center**  
Julie M Chandler<sup>1</sup>, Mihaela Georgieva<sup>2</sup>, Urvi Desai<sup>2</sup>, Noam Kirson<sup>2</sup>, Wenyu Ye<sup>1</sup>, Angela Zhao<sup>2</sup>, Dody Eid<sup>2</sup>, Andres Gomez-Lievano<sup>2</sup>, Annalise Hilts<sup>3</sup>, Traci Schilling<sup>1</sup>  
<sup>1</sup>Eli Lilly and Company - Indianapolis (United States), <sup>2</sup>Analysis Group - Boston (United States), <sup>3</sup>Groupe d'Analyse - Montréal (Canada)
-  P162 **Rescreening on RBANS delayed memory index? Forget about it!**  
Marwan N Sabbagh<sup>1</sup>, Wojciech Michalak<sup>2</sup>, Charlotte Thim Hansen<sup>2</sup>, Lars Lau Raket<sup>2</sup>, Christian Ahmad Wichmann<sup>2</sup>, Alice Clark<sup>2</sup>  
<sup>1</sup>Barrow Neurological Institute - Phoenix, Arizona (United States), <sup>2</sup>Novo Nordisk A/S - Søborg (Denmark)
- P163 **Predictors of memory impairment in mild cognitive impairment with low Mini-Mental State Examination recall scores**  
Seon Young Ryu<sup>1</sup>, Sang Bong Lee<sup>1</sup>, Taek Jun Lee<sup>1</sup>, Yu Jin Jung<sup>1</sup>  
<sup>1</sup>The Catholic University of Korea, Daejeon St. Mary's Hospital - Daejeon (Korea, Republic of)
-  P164 **Increased numbers of modifiable dementia risk factors amplify adverse effects on cognition across the adult lifespan**  
Annalise Laplume<sup>1</sup>, Larissa Mcketton<sup>1</sup>, Brian Levine<sup>1,2,3</sup>, Angela Troyer<sup>4,5</sup>, Nicole Anderson<sup>1,2,6</sup>  
<sup>1</sup>Rotman Research Institute, Baycrest Health Sciences - Toronto (Canada), <sup>2</sup>Department of Psychology, University of Toronto - Toronto (Canada), <sup>3</sup>Department of Medicine (Neurology), University of Toronto - Toronto (Canada), <sup>4</sup>Department Of Psychology, University Of Toronto - Toronto (Canada), <sup>5</sup>Neuropsychology and Cognitive Health Program, Baycrest Health Sciences - Toronto (Canada), <sup>6</sup>Department of Psychiatry, University of Toronto - Toronto (Canada)
-  P165 **Feasibility, Reliability, and Validity of Remote Smartphone Data Collection in Frontotemporal Dementia using the ALLFTD Mobile App**  
Adam Staffaroni<sup>1</sup>, Jack Taylor<sup>1</sup>, Annie Clark<sup>1</sup>, Hilary Heuer<sup>1</sup>, Amy Wise<sup>1</sup>, Masood Manoochehri<sup>2</sup>, Leah Forsberg<sup>3</sup>, Carly Mester<sup>3</sup>, Meghana Rao<sup>3</sup>, Danielle Brushaber<sup>3</sup>, Julio Rojas<sup>1</sup>, Joel Kramer<sup>1</sup>, Bradley Boeve<sup>3</sup>, Howard Rosen<sup>1</sup>, Adam Boxer<sup>1</sup>  
<sup>1</sup>UCSF - San Francisco (United States), <sup>2</sup>Columbia University - New York (United States), <sup>3</sup>Mayo Clinic - Rochester (United States)
-  P166 **Calculating Generalized Recall Probability Using Digital Cognitive Biomarkers Derived from Wordlist Memory Test Assessment**  
Junko Hara<sup>1,2</sup>, Jason Bock<sup>1,3</sup>, Kaavya Shah<sup>4</sup>, Dennis Fortier<sup>1</sup>, Michael Lee<sup>3</sup>  
<sup>1</sup>Embic Corporation - Newport Beach (United States), <sup>2</sup>Pickup Family Neuroscience Institute and Hoag Center for Research and Education, Hoag Memorial Hospital - Newport Beach (United States), <sup>3</sup>Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), <sup>4</sup>University of California at Berkeley - Berkeley (United States)
-  P167 **Digital Cognitive Biomarkers for the ADAS-Cog Word Recall Test: Accuracy and Validity of Classifying Cognitive Impairment**  
Jason Bock<sup>1,2</sup>, Junko Hara<sup>1,3</sup>, Dennis Fortier<sup>1</sup>, Tushar Mangrola<sup>1</sup>, William Shankle<sup>1,2,3</sup>, Michael Lee<sup>2</sup>  
<sup>1</sup>Embic Corporation - Newport Beach (United States), <sup>2</sup>Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), <sup>3</sup>Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach (United States)

- P168** **A novel 2-minute high-frequency assessment of episodic memory, shows diurnality, time varying patterns in fatigue and mood which become more tightly coupled with age**  
Alexander Anwyl-Irvine<sup>1</sup>, Alexander Kaula<sup>1</sup>, Nick Taptiklis<sup>1</sup>, Cashdollar Nathan<sup>1</sup>, Francesca Cormack<sup>1</sup>  
<sup>1</sup>Cambridge Cognition - Cambridge (United Kingdom)
- LP90** **Achieving 98% scoring accuracy in a novel voice-based multi-day learning paradigm**  
Nick Taptiklis<sup>1</sup>, Alex Kaula<sup>1</sup>, Hayley Tseng<sup>1</sup>, Francesca Cormack<sup>1</sup>  
<sup>1</sup>Cambridge Cognition - Cambridge (United Kingdom)
- LP91** **Sex differences in the association between tau PET and cognition in preclinical AD (A4 study)**  
Xin Wang<sup>1</sup>, Erin Sundermann<sup>1</sup>, Sarah Banks<sup>1</sup>  
<sup>1</sup>University of California, San Diego - San Diego (United States)
- LP92** **Stepped-Assessment for Cognitive Screening and Evaluation: MemTrax-CogniFit**  
Curtis Ashford<sup>1</sup>, James Clifford<sup>2</sup>, Michael Bergeron<sup>3</sup>, Jon Andoni<sup>4</sup>, John Ashford<sup>5</sup>, Carlos Rodriguez<sup>6</sup>  
<sup>1</sup>MemTrax, LLC - Redwood City (United States), <sup>2</sup>College of San Mateo - San Mateo (United States), <sup>3</sup>University of Hartford - Hartford (United States), <sup>4</sup>Nebriia University - Madrid (Spain), <sup>5</sup>Stanford - Palo Alto (United States), <sup>6</sup>CogniFit, Inc. - Madrid (Spain)

### THEME: Behavioral disorders and clinical trials

- P169** **A proof-of-concept study to evaluate efficacy of NanoLithium on the progression of Neuropsychiatric symptoms in patients with mild-to-severe Alzheimer's disease**  
Maria Soto<sup>1</sup>, Solene Guilliot<sup>2</sup>, Pierre-Jean Ousset<sup>1</sup>, Davide Angioni<sup>1</sup>, Nathalie Sastre Hengan<sup>1</sup>, Jean-Claude Maurel<sup>2</sup>, Jacques Touchon<sup>3</sup>  
<sup>1</sup>Department Of Geriatrics, Gerontopole, University Hôpital Toulouse, France - Toulouse (France), <sup>2</sup>Medesis Pharma - Baillargues (France), <sup>3</sup>Montpellier School Of Medecine; University Of Montpellier - Montpellier (France)
- P170** **Phase-3 Study of Masupirdine (SUVN-502), a 5-HT6 Receptor Antagonist, For the Potential Treatment of Agitation in Participants with Dementia of Alzheimer's Type**  
Jayarajan Pradeep<sup>1</sup>, Ravula Jyothsna<sup>1</sup>, Jetta Satish<sup>1</sup>, Goyal Vinod Kumar<sup>1</sup>, Benade Vijay<sup>1</sup>, Shinde Anil<sup>1</sup>, Pandey Santosh Kumar<sup>1</sup>, Subramanian Ramkumar<sup>1</sup>, Mohammed Abdul Rasheed<sup>1</sup>, Nirogi Ramakrishna<sup>1</sup>  
<sup>1</sup>Suven Life Sciences Ltd - Hyderabad (India)
- P171** **Safety and Tolerability of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Pooled Results From Three Phase III Trials**  
Daniel Lee<sup>1</sup>, Mary Slomkowski<sup>1</sup>, Nanco Hefting<sup>2</sup>, Dalei Chen<sup>1</sup>, Klaus Larsen<sup>2</sup>, Eva Kohegyi<sup>1</sup>, Mary Hobart<sup>1</sup>, Alpesh Shah<sup>1</sup>, Alvin Estilo<sup>1</sup>, Moeen Panni<sup>1</sup>, Anja Farovik<sup>2</sup>, Maia Miguelez<sup>1</sup>, Pedro Such<sup>2</sup>, George Grossberg<sup>3</sup>  
<sup>1</sup>Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), <sup>2</sup>H. Lundbeck A/S - Valby, Copenhagen (Denmark), <sup>3</sup>Department of Psychiatry and Behavioral Neuroscience at Saint Louis University School of Medicine - St Louis, Missouri (United States)
- LP93** **Effects of Brexpiprazole on Severity of Agitation in Alzheimer's Dementia: An Analysis of Clinical Global Impression data from Two Phase III Fixed-Dose Trials**  
 Daniel Lee<sup>1</sup>, Mary Slomkowski<sup>1</sup>, Nanco Hefting<sup>2</sup>, Dalei Chen<sup>1</sup>, Klaus Larsen<sup>2</sup>, Eva Kohegyi<sup>1</sup>, Mary Hobart<sup>1</sup>, Alpesh Shah<sup>1</sup>, Alvin Estilo<sup>1</sup>, Moeen Panni<sup>1</sup>, Anja Farovik<sup>2</sup>, Maia Miguelez<sup>1</sup>, Pedro Such<sup>2</sup>  
<sup>1</sup>Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), <sup>2</sup>H. Lundbeck A/S - Valby, Copenhagen (Denmark)

### THEME: Health economics and clinical trials

- P172** **Health economic considerations in the development of a preventive Alzheimer's treatment**  
Soeren Matke<sup>1</sup>, Kate Jun<sup>1</sup>, Samantha Chu<sup>2</sup>, Mark Hanson<sup>1</sup>, Eric Reiman<sup>3</sup>, Jeffrey Kordower<sup>4</sup>  
<sup>1</sup>University Of Southern California - Los Angeles (United States), <sup>2</sup>Cornell University - Ithaca (United States), <sup>3</sup>Banner Alzheimer's Institute - Phoenix (United States), <sup>4</sup>Arizona State University - Tempe (United States)
- P173** **Long-Term Care Insurance Service Utilization pattern according to clinical factors of Dementia**  
Jun Hong Lee<sup>1</sup>  
<sup>1</sup>National Health Insurance Service Ilsan Hospital - Goyang-Si (Korea, Republic of)
- P174** **The Impact on R&D Investment of the CMS National Coverage Determination for Amyloid-directed Monoclonal Antibodies in Alzheimer's Disease**  
Duane Schulthess<sup>1</sup>, Harry Bowen<sup>2</sup>  
<sup>1</sup>vital transformation - Wezembeek Oppem (Belgium), <sup>2</sup>Queens University - Charlotte (United States)
- P175** **Bridging clinical trials and health economic models in Alzheimer's disease**  
Linus Jonsson<sup>1</sup>, Ron Handels<sup>2</sup>, Colin Green<sup>1</sup>  
<sup>1</sup>Karolinska Institutet - Stockholm (Sweden), <sup>2</sup>Maastricht University - Maastricht (Netherlands)






-  **LP94** **A more precise diagnosis by means of amyloid-PET contributes to delayed institutionalization, lower mortality and reduced care costs in a tertiary memory clinic setting**  
Wiesje Van Der Flier<sup>1</sup>, Ingrid Van Maurik<sup>1</sup>, Hana Broulikova<sup>1</sup>, Arenda Mank<sup>1</sup>, Els Bakker<sup>1</sup>, Arno De Wilde<sup>2</sup>, Femke Bouwman<sup>1</sup>, Andrew Stephens<sup>3</sup>, Bart Van Berckel<sup>1</sup>, Philip Scheltens<sup>1</sup>  
<sup>1</sup>Amsterdam UMC - Amsterdam (Netherlands), <sup>2</sup>EQT Life Sciences - Amsterdam (Netherlands), <sup>3</sup>Life-MI - Berlin (Netherlands)
-  **LP95** **Economic burden of daily transitions to later stages of AD dementia in the US**  
Moaven Razavi<sup>1</sup>, William Herring<sup>2</sup>, Cai Gillis<sup>3</sup>, Nancy Maserejian<sup>3</sup>, Peter Pemberton-Ross<sup>4</sup>, Mina Nejadi<sup>3</sup>  
<sup>1</sup>Schneider Institutes for Health Policy and Research, Brandeis University - Waltham (United States), <sup>2</sup>RTI Health Solutions - Research Triangle Park (United States), <sup>3</sup>Biogen - Boston (United States), <sup>4</sup>Biogen - Baar (Switzerland)

## THEME: Epidemiology and clinical trials

-  **P176** **Identification of medical conditions as risk factors for mild cognitive impairment – a US claims database study**  
Gang Li<sup>1</sup>, Toschi Nicola<sup>2</sup>, Batrla Richard<sup>3</sup>, Galvin James<sup>4</sup>, Henley David<sup>5</sup>, De Santi Susan<sup>6</sup>, Hampel Harald<sup>6</sup>  
<sup>1</sup>Eisai Inc - Hillsborough (United States), <sup>2</sup>Rome University - Rome (Italy), <sup>3</sup>Eisai Inc - Basel (Switzerland), <sup>4</sup>Miami University - Miami (United States), <sup>5</sup>Janssen - Indianapolis (United States), <sup>6</sup>Eisai Inc - Nutley (United States)
- P177** **Safety of fluorine 18-labeled amyloid tracers: pharmacovigilance validation using a large real-world database**  
Kenichiro Sato<sup>1</sup>, Yoshiki Niimi<sup>2</sup>, Ryoko Ihara<sup>3</sup>, Kazushi Suzuki<sup>4</sup>, Atsushi Iwata<sup>3</sup>, Takeshi Iwatsubo<sup>1</sup>  
<sup>1</sup>University Of Tokyo - Tokyo (Japan), <sup>2</sup>University Of Tokyo Hospital - Tokyo (Japan), <sup>3</sup>Tokyo Metropolitan Geriatric Medical Center Hospital - Tokyo (Japan), <sup>4</sup>National Defense Medical College - Saitama (Japan)
-  **P178** **Diagnosis and clinical trial recruitment of patients with early onset Alzheimer's disease in clinical practice: Single center experience in Japan**  
Masanori Kurihara<sup>1</sup>, Ryoko Ihara<sup>1</sup>, Kenji Ishibashi<sup>2</sup>, Kenji Ishii<sup>2</sup>, Kazutomi Kanemaru<sup>1</sup>, Atsushi Iwata<sup>1</sup>  
<sup>1</sup>Department Of Neurology, Tokyo Metropolitan Geriatric Hospital And Institute Of Gerontology - Tokyo (Japan), <sup>2</sup>Research Team For Neuroimaging, Tokyo Metropolitan Geriatric Hospital And Institute Of Gerontology - Tokyo (Japan)
-  **P179** **Treatment status of Alzheimer's dementia using common data model in South Korea**  
Song Jeong Yun<sup>1</sup>, Jang Jae-Won<sup>1,2</sup>  
<sup>1</sup>Kangwon National University Hospital - Chuncheon (Korea, Republic of), <sup>2</sup>Kangwon National University College of Medicine - Chuncheon (Korea, Republic of)
-  **P180** **Globalization of Alzheimer disease clinical trials: recommendations for trial implementation in low- and middle-income countries**  
Jorge Llibre-Guerra<sup>1</sup>  
<sup>1</sup>Washington University School Of Medicine In St.Louis - St. Louis (United States)
-  **P181** **The Minority Report: An Update on Minority recruitment from a large site in Central Florida**  
Sandra Torres<sup>1</sup>, Sheila Baez-Torres<sup>1</sup>, Stephanie Cassidy<sup>1</sup>, Brandon Lenox<sup>1</sup>, Sean Stanton<sup>1</sup>, Jennifer West<sup>1</sup>  
<sup>1</sup>Orlando, FL (United States)
-  **P182** **Generalizability of cognitive results from clinical trial participants to older adult population: addressing external validity**  
Vahan Aslanyan<sup>1</sup>, Howard N. Hodis<sup>1,2,3</sup>, Jan St. John<sup>1,2</sup>, Naoko Kono<sup>1,2</sup>, Victor Henderson<sup>4</sup>, Wendy J Mack<sup>1</sup>  
<sup>1</sup>Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California - Los Angeles, Ca (United States), <sup>2</sup>Atherosclerosis Research Unit, Keck School of Medicine, University of Southern California - Los Angeles, Ca (United States), <sup>3</sup>Department of Medicine, Keck School of Medicine, University of Southern California - Los Angeles, Ca (United States), <sup>4</sup>Department of Epidemiology and Department of Neurology and Neurological Sciences, School of Medicine, Stanford University - Stanford, Ca (United States)
-  **P183** **Metabolic syndrome, sex, inflammation and cognitive decline: a longitudinal population cohort study**  
Chi-Hun Kim<sup>1</sup>, Tae Hwa Go<sup>2</sup>, Dae Ryong Kang<sup>2</sup>  
<sup>1</sup>Department of Neurology, Hallym University Sacred Heart Hospital - Anyang (Korea, Republic of), <sup>2</sup>Center of Biomedical Data Science, Yonsei University Wonju College of Medicine - Wonju (Korea, Republic of)
-  **P184** **Prevalence Estimations for the Alzheimer's Disease Continuum in the US Health and Retirement Study**  
Amir Abbas Tahami Monfared<sup>1,2</sup>, Quanwu Zhang<sup>1</sup>, Aastha Chandak<sup>3</sup>, Artak Khachatryan<sup>4</sup>, Laura De Benedetti<sup>5</sup>, Noemi Hummel<sup>6</sup>  
<sup>1</sup>Eisai Inc - Nutley (United States), <sup>2</sup>Biostatistics and Occupational Health, McGill University - Montreal (Canada), <sup>3</sup>Certara Inc. - New York (United States), <sup>4</sup>Certara Ltd. - Sheffield (United Kingdom), <sup>5</sup>Certara Canada Corporation - Montreal (United States), <sup>6</sup>Certara GmbH - L rrach (Germany)
- P185** **Association between A/T/N profiles and mortality in patients with cognitive disorders**  
M lina R gy<sup>1,2</sup>, Aline Dugravot<sup>1</sup>, Bernard Hanseeuw<sup>3</sup>, Julien Dumurgier<sup>1</sup>  
<sup>1</sup>CRESS U1153 Epidemiology of Ageing and neurodegenerative diseases (Inserm) - Paris (France), <sup>2</sup>Brain Ageing Lab (Catholic University of Louvain - Brussels (Belgium), <sup>3</sup>Brain Aging Lab (St-Luc Hospital) - Bruxelles (Belgium)
-  **P186** **Ultra high risk and high predictability of Alzheimer's disease onset in people with Down syndrome: implications for clinical trials**  
Juan Fortea<sup>1,2,3</sup>, Alberto Lleo<sup>1,2</sup>, Alexandre Bejanin<sup>1,2</sup>, Maria Florencia Iulita<sup>1,2</sup>  
<sup>1</sup>Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau), Neurology Department, Hospital de la Santa Creu i Sant Pau - Barcelona (Spain), <sup>2</sup>Centro de Investigaci n Biom dica en Red en Enfermedades Neurodegenerativas (CIBERNED) - Madrid (Spain), <sup>3</sup>Barcelona Down Medical Center, Fundaci  Catalana S ndrome de Down - Barcelona (Spain)

-  **LP96** **Asymptomatic extracranial carotid atherosclerosis and its association with incident Alzheimer's dementia**  
 Francesca Vitali <sup>1</sup>, Ikeoluwapo Bolakale-Rufai <sup>1</sup>, Gregory Branigan <sup>1</sup>, Juan Arias <sup>1</sup>, Eric Reinman <sup>1</sup>, Roberta Brinton <sup>1</sup>, Craig Weinkauff <sup>1</sup>  
<sup>1</sup>University of Arizona - Tucson (United States)

### THEME: Animal Models and clinical trials

-  **P187** **The Probucol in Alzheimer's trial: a double-blind RCT investigating cognitive outcomes, cerebral amyloid and brain morphometry based on positive proof-of-concept preclinical findings**  
John Mamo <sup>1</sup>, Roger Clarnette <sup>2</sup>, Virginie Lam <sup>1</sup>, Michael Bynevelt <sup>3</sup>, Gerald Watts <sup>4</sup>, Carolyn Orr <sup>4</sup>, Poh Loh <sup>4</sup>, Christopher Reid <sup>1</sup>, Satvinder Dhaliwal <sup>1</sup>, Suzanne Robinson <sup>1</sup>, Ryusuke Takechi <sup>1</sup>, Robert Adam <sup>5</sup>, Mauro Vaccarezza <sup>1</sup>  
<sup>1</sup>Curtin University - Perth (Australia), <sup>2</sup>Australian Alzheimer's Research Foundation - Perth (Australia), <sup>3</sup>Sir Charles Gardiner Hospital - Perth (Australia), <sup>4</sup>University of Western Australia - Perth (Australia), <sup>5</sup>University of Queensland - Perth (Australia)
-  **P188** **A novel small molecule inhibitor reduces toxic amyloid oligomers to rescue disease in AD mice**  
Vidhu Mathur <sup>1</sup>, Kevin Burk <sup>1</sup>, Xikun Liu <sup>2</sup>, Sagar Gaikwad <sup>3</sup>, Rakez Kaye <sup>3</sup>, Michael T Bowers <sup>2</sup>, Katie Planey <sup>1</sup>, Ambuj Singh <sup>4</sup>  
<sup>1</sup>Acelot Inc. - Santa Barbara (United States), <sup>2</sup>Department of Chemistry and Biochemistry, University of California - Lubbock (United States), <sup>3</sup>Departments of Neurology & Neuroscience & Cell Biology & Anatomy, University of Texas Medical Branch - Galveston (United States), <sup>4</sup>Acelot Inc - Santa Barbara (United States)
-  **P189** **T-type calcium channel modulator AD101 improves cognitive function in animal models of memory and learning impairment and provides a rationale for the potential clinical use of AD101 in the symptomatic treatment of Alzheimer's disease**  
Jan Burmeister <sup>1</sup>, Serge Gauthier <sup>2</sup>, Sharon Rogers <sup>1</sup>  
<sup>1</sup>Amyriad Pharma, Inc. - Los Angeles (United States), <sup>2</sup>McGill University - Montréal (Canada)
-  **P190** **Effects of T-type calcium channel modulator AD101 on the accumulation of Beta Amyloid, Tau and polyubiquitinated proteins in animal models of Alzheimer's Disease**  
Jan Burmeister <sup>1</sup>, Serge Gauthier <sup>2</sup>, Sharon Rogers <sup>1</sup>  
<sup>1</sup>Amyriad Pharma, Inc. - Los Angeles (United States), <sup>2</sup>McGill University - Montréal (Canada)
-  **LP97** **Modulation of peripheral monocytes by a proteasome-based adjuvant (Protollin) for the treatment of Alzheimer's disease**  
Panayota Kolypetri <sup>1</sup>, Lei Liu <sup>1</sup>, Estefania Solana <sup>1</sup>, Christian Gauthier <sup>1</sup>, Tarun Singhal <sup>1</sup>, Seth Gale <sup>1</sup>, Tanuja Chitnis <sup>1</sup>, Dennis Selkoe <sup>1</sup>, Howard Weiner <sup>1</sup>  
<sup>1</sup>BWH - Boston (United States)
-  **LP98** **An efficacious therapy for Alzheimer Disease already exists, and it is commercially exploitable**  
Diego Dolcetta <sup>1</sup>, Stefano Giovagnoli <sup>2</sup>, Dominici Roberto <sup>3</sup>  
<sup>1</sup>Istituto di Neuroscienze di Rosà - Vicenza (Italy), <sup>2</sup>Department of Pharmaceutical Sciences, University of Perugia, Italy - Perugia (Italy), <sup>3</sup>Dep of Biochemistry, Desio Hospital - Brianza (Italy)

### THEME: Proof of Concept/Translational research for Alzheimer Drug Development interventions

-  **P191** **A combination of PET tracers serves as a potential trial biomarker for equilibrative nucleoside transporter 1 (ENT1) inhibition treatment of Alzheimer's disease**  
Ching-Pang Chang <sup>1,2</sup>, Ching-Wen Wu <sup>1,2</sup>, Chien-Yu Lin <sup>1,2</sup>, Kuo-Chen Wu <sup>1,3</sup>, Hsin-Hsien Yeh <sup>4</sup>, Chun-Yi Wu <sup>5</sup>, Chi-Chang Weng <sup>6</sup>, Ling-Wei Hsin <sup>3</sup>, Chun-Jung Lin <sup>3</sup>, Yijuang Chern <sup>1,2</sup>  
<sup>1</sup>Biomedical Translation Research Center, Academia Sinica - Taipei (Taiwan, Republic of China), <sup>2</sup>Institute of Biomedical Sciences, Academia Sinica - Taipei (Taiwan, Republic of China), <sup>3</sup>School of Pharmacy, National Taiwan University - Taipei (Taiwan, Republic of China), <sup>4</sup>Brain research center, National Yang Ming Chiao Tung University - Taipei (Taiwan, Republic of China), <sup>5</sup>Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University - Taipei (Taiwan, Republic of China), <sup>6</sup>Department of Medical Imaging and Radiological Sciences, Chang Gung University - Taoyuan (Taiwan, Republic of China)
-  **P192** **XanaMIA Phase 1b trial with Xanamem® achieves primary endpoints: results and strategic update**  
Michael Woodward <sup>1</sup>, Paul Rolan <sup>2</sup>, Miriam Roesner <sup>2</sup>, Jack Taylor <sup>2</sup>, Tamara Miller <sup>2</sup>, Paul Maruff <sup>3</sup>  
<sup>1</sup>Aged Care Research And Memory Clinic, Austin Health - Melbourne (Australia), <sup>2</sup>Actinogen Medical - Sydney (Australia), <sup>3</sup>Cogstate Ltd - Melbourne (Australia)
-  **P193** **Leveraging untapped national synergies to accelerate representation of Hispanic/Latinos in clinical trials on dementia: the progress of the new Consorcio between the National Association of Hispanic Nurses and the Alzheimer's Association**  
Elena Portacolone <sup>1</sup>, Adriana Perez <sup>2</sup>, Carl V. Hill <sup>3</sup>, Julio C. Rojas <sup>1</sup>  
<sup>1</sup>University California San Francisco - San Francisco (United States), <sup>2</sup>Penn University - Philadelphia (United States), <sup>3</sup>Alzheimer's Association - Chicago (United States)
-  **P194** **Chronic constant light disrupted Circadian Rhythm and induced Alzheimer's Disease-Like Pathology in Rodent and treatment by Fluoxetine**  
 Ashish Sharma <sup>1</sup>, Mohammad Ashu <sup>2</sup>, Adesh K Saini <sup>3</sup>, Rohit Goyal <sup>2</sup>  
<sup>1</sup>Washington University - Missouri (United States), <sup>2</sup>Shoolini University - Solan (India), <sup>3</sup>Mm University - Ambala (India)

# POSTER PRESENTATIONS

Friday, December 2<sup>nd</sup> from 8 a.m to 5 p.m

Poster presentations presented onsite in San Francisco are indicated with this icon: 

-  **P195** **Astrocytic Regulatory mechanism on PM2.5-induced neuronal cell death and neuroinflammation**  
Seol-Heui Han<sup>1</sup>, Ryeong-Eun Kim<sup>2</sup>, Kyoung Ja Kwon<sup>2,3</sup>  
<sup>1</sup>Department Of Neurology, Konkuk Hospital Medical Center, 120-1 Neungdong-Ro, Gwangjin-Gu - Seoul (Korea, Republic of), <sup>2</sup>Department Of Neuroscience, School Of Medicine, Konkuk University - Seoul (Korea, Republic of), <sup>3</sup>Department of Neurology, Konkuk Hospital Medical center, 120-1 Neungdong-ro, Gwangjin-Gu - Seoul (Korea, Republic of)
- P196** **Impact of Semaglutide in Amyloid Positivity (ISAP): Protocol for a Randomised Double-Blind Placebo-Controlled Trial in Amyloid Positive Individuals**  
Ivan Koychev<sup>1</sup>, Amanda Adler<sup>1</sup>, Paul Edison<sup>2</sup>, Brian Tom<sup>3</sup>, Joanne Milton<sup>1</sup>, Joe Butchart<sup>4</sup>, Adam Hampshire<sup>2</sup>, Charles Marshall<sup>5</sup>, Elizabeth Coulthard<sup>6</sup>, Henrik Zetterberg<sup>7</sup>, Francesca Cormack<sup>8</sup>, Catherine Mummery<sup>9</sup>, Rury Holman<sup>1</sup>  
<sup>1</sup>University of Oxford - Oxford (United Kingdom), <sup>2</sup>Imperial College London - London (United Kingdom), <sup>3</sup>University of Cambridge - Cambridge (United Kingdom), <sup>4</sup>Royal Devon University Healthcare NHS Foundation Trust - Exeter (United Kingdom), <sup>5</sup>Queen Mary University of London - London (United Kingdom), <sup>6</sup>University of Bristol - Bristol (United Kingdom), <sup>7</sup>University of Gothenburg - Gothenburg (United Kingdom), <sup>8</sup>Cambridge Cognition - Cambridge (United Kingdom), <sup>9</sup>University College London - London (United Kingdom)
-  **P197** **The novel FKBP51-Hsp90 interaction inhibitor attenuates high-fat-induced cognitive impairment**  
Bengt Winblad<sup>1</sup>, Lisha Wang<sup>1</sup>, Jakub Wojcieszak<sup>1</sup>, Rajnish Kumar<sup>1</sup>, Pavel Pavlov<sup>1</sup>  
<sup>1</sup>Karolinska Institutet - Stockholm (Sweden)
-  **P198** **Intracellular A $\beta$  accumulation in hippocampal neurons leads to endosomal/lysosomal leakage**  
Sophia Schedin Weiss<sup>1</sup>, Yang Gao<sup>1</sup>, Lars Tjernberg<sup>1</sup>  
<sup>1</sup>Karolinska Institutet - Solna (Sweden)
- P199** **ALZ-201, a monoclonal antibody therapy for specific neutralisation of toxic amyloid- $\beta$  in Alzheimer's disease**  
Anders Sandberg<sup>1</sup>  
<sup>1</sup>Alzinova AB - Gothenburg (Sweden)
-  **P200** **Reducing toxic amyloid- $\beta$  oligomers in AD through precise targeting of the molecular mechanisms of oligomer formation with small molecule inhibitors**  
Johnny Habchi<sup>1</sup>, Kerry Jenkins<sup>1</sup>, Samata Pandey<sup>1</sup>, Roxine Staats<sup>1</sup>, Sunehera Sarwat<sup>1</sup>, Benedetta Mannini<sup>1</sup>, Xiaoting Yang<sup>1</sup>, Luke Rajah<sup>1</sup>, Samuel Cohen<sup>1</sup>, Suzanne Brewerton<sup>1</sup>, Alleyn Plowright<sup>1</sup>  
<sup>1</sup>Wren Therapeutics Limited - Cambridge (United Kingdom)
-  **P201** **The bromodomain and extraterminal domain protein inhibitor apabetalone inhibits the neurotoxic kynurenine pathway in monocytes and brain endothelial cells**  
Sylvia Wasiak<sup>1</sup>, Li Fu<sup>1</sup>, Stephanie Stotz<sup>1</sup>, Dean Gilham<sup>1</sup>, Laura Tsujikawa<sup>1</sup>, Chris Sarsons<sup>1</sup>, Jeffrey Kroon<sup>2</sup>, Erik Stroes<sup>2</sup>, Norman Wong<sup>1</sup>, Michael Sweeney<sup>3</sup>, Jan Johansson<sup>3</sup>, Ewelina Kulikowski<sup>1</sup>  
<sup>1</sup>Resverlogix - Calgary (Canada), <sup>2</sup>University of Amsterdam - Amsterdam (Netherlands), <sup>3</sup>Resverlogix - San Francisco (United States)
-  **P202** **A novel therapeutic approach to treat Alzheimer's disease: The brain-specific signal peptide peptidase-like 2b (SPPL2b)**  
Simomne Tambaro<sup>1</sup>, Riccardo Maccioni<sup>2</sup>, Caterina Trivisan<sup>3</sup>, Stefania Zerial<sup>3</sup>, Annika Wagener<sup>4</sup>, Yuniesky Andrade-Talavera<sup>1</sup>, Federico Picciau<sup>2</sup>, Caterina Grassi<sup>5</sup>, Gefei Chen<sup>6</sup>, André Fisahn<sup>1</sup>, Bernd Schröder<sup>7</sup>, Per Nilsson<sup>1</sup>  
<sup>1</sup>Department of Neurobiology, Care Sciences and Society (NVS) Division of Neurogeriatrics, Karolinska Institutet - Solna (Sweden), <sup>2</sup>Department of Biomedical Sciences, Neuroscience and Clinical Pharmacology, University of Cagliari - Cagliari (Italy), <sup>3</sup>Department of life science, University of Trieste - Trieste (Italy), <sup>4</sup>Interdisciplinary center for Neuroscience, Heidelberg University - Heidelberg (Germany), <sup>5</sup>Department of Pharmacy and Biotechnology, University of Bologna - Bologna (Italy), <sup>6</sup>Department of Biosciences and Nutrition, Karolinska Institutet - Huddinge (Sweden), <sup>7</sup>Institute of Physiological Chemistry, Technische Universität Dresden - Dresden (Germany)
-  **P203** **Increased CSF-decorin predicts brain pathological changes driven by Alzheimer's A $\beta$  amyloidosis**  
Richeng Jiang<sup>1</sup>, Una Smalovic<sup>1</sup>, Hazal Haytural<sup>1</sup>, Betty Tijms<sup>2</sup>, Hao Li<sup>1</sup>, Ganna Shevchenko<sup>3</sup>, Johan Gobom<sup>4</sup>, Sofie Nyström<sup>5</sup>, Per Hammarström<sup>5</sup>, Stina Syvänen<sup>3</sup>, Henrik Zetterberg<sup>4</sup>, Bengt Winblad<sup>1</sup>, Jonas Bergquist<sup>3</sup>, Pieter Jelle Visser<sup>2</sup>, Per Nilsson<sup>1</sup>  
<sup>1</sup>Karolinska Institutet - Stockholm (Sweden), <sup>2</sup>Amsterdam UMC - Amsterdam (Netherlands), <sup>3</sup>Uppsala University - Uppsala (Sweden), <sup>4</sup>Sahlgrenska Academy at the University of Gothenburg - Gothenburg (Sweden), <sup>5</sup>Linköping University - Linköping (Sweden)
-  **P204** **Antibodies generated against an A $\beta$ -derived oligomer: Efforts toward a novel Alzheimer's disease immunotherapy**  
Chelsea Marie Parrocha<sup>1</sup>, Adam Kreutzer<sup>2</sup>, Jesse Pascual<sup>3</sup>, Cherie Stringer<sup>3</sup>, Jennifer Nguyen<sup>1</sup>, Ashley Ith<sup>1</sup>, Elizabeth Head<sup>3</sup>, James Nowick<sup>2,1</sup>  
<sup>1</sup>Department of Pharmaceutical Sciences, University of California Irvine - Irvine (United States), <sup>2</sup>Department of Chemistry, University of California Irvine - Irvine (United States), <sup>3</sup>Department of Pathology and Laboratory Medicine, University of California Irvine - Irvine (United States)

# POSTER PRESENTATIONS

Friday, December 2<sup>nd</sup> from 8 a.m to 5 p.m

-  **LP99** **Reduction of plasma p-Tau181 from a Phase1a Randomized Trial of NNI-362 in a healthy aged population consistent with amelioration of tau hyperphosphorylation in human differentiated neuron cultures**  
Raymond Turner<sup>1</sup>, Michelle Mielke<sup>2</sup>, Judith Kelleher-Andersson<sup>3</sup>  
<sup>1</sup>Georgetown Univ. - Washington, Dc (United States), <sup>2</sup>Mayo Clinic - Rochester, Mn (United States), <sup>3</sup>Neuronascent, Inc. - Clarksville, Md (United States)
-  **LP100** **Inhibition of equilibrative nucleoside transporter 1 (ENT1) inhibitor as a novel therapeutic treatment to rescue Alzheimer's disease pathology and cognitive impairment**  
Ching-Wen Wu<sup>1,2</sup>, Ching-Pang Chang<sup>1,2</sup>, Chien-Yu Lin<sup>1,2</sup>, Kuo-Chen Wu<sup>2,3</sup>, Hsin-Hsien Yeh<sup>4</sup>, Chun-Jung Lin<sup>2,3</sup>, Yijuang Chern<sup>1,5</sup>  
<sup>1</sup>Institute of Biomedical Sciences, Academia Sinica - Taipei (Taiwan, Republic of China), <sup>2</sup>Biomedical Translation Research Center, Academia Sinica - Taipei (Taiwan, Republic of China), <sup>3</sup>School of Pharmacy, National Taiwan University - Taipei (Taiwan, Republic of China), <sup>4</sup>Brain research center, National Yang Ming Chiao Tung University - Taipei (Taiwan, Republic of China), <sup>5</sup>Biomedical Translation Research Center - Taipei (Taiwan, Republic of China)
-  **LP101** **Characterizing the molecular determinants of the Lecanemab paratope binding site by combining in silico prediction and in vitro Fab analysis on AD brain extracts**  
Jean-Pierre Bellier<sup>1</sup>, Lei Liu<sup>1</sup>, Dennis J Selkoe<sup>1</sup>  
<sup>1</sup>Brigham and Women's - Boston (United States)
-  **LP102** **Effects of the p38 $\alpha$  kinase inhibitor neflamapimod on the basal forebrain, assessed by structural MRI, in Alzheimer's disease (AD)**  
John Alam<sup>1</sup>, Chen-Pei Lin<sup>2</sup>, Samantha Noteboom<sup>2</sup>, Niels Prins<sup>3</sup>, Frederik Barkhof<sup>4</sup>, Laura Jonkman<sup>2</sup>, Menno Schoonheim<sup>2</sup>  
<sup>1</sup>EIP Pharma - Boston (United States), <sup>2</sup>Amsterdam UMC, Location VUmc, Vrije Universiteit Amsterdam, Department of Anatomy and Neurosciences, Amsterdam Neuroscience - Amsterdam (Netherlands), <sup>3</sup>Brain Research Center - Amsterdam (Netherlands), <sup>4</sup>Amsterdam UMC, Location VUmc, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience - Amsterdam (Netherlands)
-  **LP103** **Connectivity-based amyloid-tau interaction model: stages, stratification, and prediction of clinical benefit**  
Wha Jin Lee<sup>1</sup>, Jesse Brown<sup>2</sup>, Hye Ryun Kim<sup>3</sup>, Renaud La Joie<sup>2</sup>, Hanna Cho<sup>4</sup>, Chul Hyoung Lyoo<sup>4</sup>, Gil Rabinovici<sup>2</sup>, William Seeley<sup>2</sup>, Joon-Kyung Seong<sup>1,3</sup>  
<sup>1</sup>Neuroxt, Inc. - Seoul (Korea, Republic of), <sup>2</sup>University of California, San Francisco - San Francisco (United States), <sup>3</sup>Seoul Women's University - Seoul (Korea, Republic of), <sup>4</sup>Gangnam Severance Hospital - Seoul (Korea, Republic of), <sup>5</sup>Korea University - Seoul (Korea, Republic of)
-  **LP104** **MRI-based real-world implementation for predicting regional tau pathology and its application to amyloid-lowering treatment indication**  
Wha Jin Lee<sup>1</sup>, Hanna Cho<sup>2</sup>, Chul Hyoung Lyoo<sup>2</sup>, Joon-Kyung Seong<sup>1,3</sup>  
<sup>1</sup>Neuroxt, Inc. - Seoul (Korea, Republic of), <sup>2</sup>Gangnam Severance Hospital - Seoul (Korea, Republic of), <sup>3</sup>Korea University - Seoul (Korea, Republic of)
-  **LP105** **Hydroxylated docosahexaenoic acid as an alternative therapeutic approach for Alzheimer disease in terms of efficacy and safety**  
Victoria Llado<sup>1,2</sup>, Sebastià Parets<sup>3,2</sup>, Joan Cabot<sup>3,2</sup>, Marc Miralles<sup>3,2</sup>, Maria Antònia Fiol-Deroque<sup>2</sup>, Laura Trujillo-Estrada<sup>4</sup>, Paula Fernández-García<sup>3,5</sup>, Xavier Busquets<sup>2</sup>, Antonia Gutiérrez<sup>4</sup>, Pablo Vicente Escribá<sup>6,3</sup>, Manuel Torres<sup>6</sup>  
<sup>1</sup>Laminar Pharma Inc - Acton, Ma (United States), <sup>2</sup>Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands - Palma (Spain), <sup>3</sup>R&D Department, Laminar Pharmaceuticals - Palma (Spain), <sup>4</sup>Department of Cell Biology, University of Malaga, CIBERNED, IBIMA - Málaga (Spain), <sup>5</sup>Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands - Palma (Spain) - Palma (Spain) - Palma (Spain), <sup>6</sup>Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands - Palma (Spain)
-  **LP105A** **Rigor and Replication in Alzheimer's Therapeutic Development: A Case Study**  
Adrian Heilbut<sup>1</sup>, Jesse Brodtkin<sup>2</sup>, Patrick Markey<sup>3</sup>, Enea Milioris<sup>4</sup>  
<sup>1</sup>Logphase Research - New York (United States), <sup>2</sup>Behavioral Instruments - New Jersey (United States), <sup>3</sup>Berlin (Germany), <sup>4</sup>London (United Kingdom)

## THEME: Digital Health/E-Trials

- P205** **Assessment of deep learning algorithm of diagnosing Alzheimer's disease with Korean elderly**  
Jong Bin Bae<sup>1</sup>, Ji Won Han<sup>1</sup>, Ki Woong Kim<sup>1,2,3,4</sup>, Jun Sung Kim<sup>2,5</sup>  
<sup>1</sup>Department Of Neuropsychiatry, Seoul National University Bundang Hospital, Gyeonggido, Korea - Seongnam (Korea, Republic of), <sup>2</sup>Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Korea - Seoul (Korea, Republic of), <sup>3</sup>Department of Psychiatry, Seoul National University, College of Medicine, Seoul, South Korea - Seoul (Korea, Republic of), <sup>4</sup>Department of Brain and Cognitive Science, Seoul National University College of Natural Sciences, Seoul, South Korea - Seoul (Korea, Republic of), <sup>5</sup>Department of Neuropsychiatry, Seoul National University Bundang Hospital, Gyeonggido, Korea - Seongnam (Korea, Republic of)
- P206** **A case-control clinical trial on the diagnostic performance for Alzheimer's Disease of a deep learning-based classification system using brain magnetic resonance imaging of Korean elderly**  
Jun Sung Kim<sup>1,2</sup>, Jong Bin Bae<sup>1</sup>, Subin Lee<sup>3</sup>, Ji Won Han<sup>4</sup>, Ki Woong Kim<sup>4,5,2</sup>  
<sup>1</sup>Department Of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Korea - Seongnam (Korea, Republic of), <sup>2</sup>Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Korea - Seoul (Korea, Republic of), <sup>3</sup>Department Of Electrical And Computer Engineering, Seoul National University, Seoul, Korea - Seoul (Korea, Republic of), <sup>4</sup>Department Of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Korea - Seoul (Korea, Republic of), <sup>5</sup>Department of Psychiatry, Seoul National University, College of Medicine, Seoul, South Korea - Seoul (Korea, Republic of)
-  **P207** **The Effect of Home-based Cognitive Training Using Workbook and Tablet PC in Presenile Dementia Patients**  
Jay Kwon<sup>1</sup>, Kyeongsoo Lee<sup>2</sup>, Tae-You Kim<sup>3</sup>, Tae-Kyeong Eom<sup>1</sup>  
<sup>1</sup>Department Of Neurology, Changwon Fatima Hospital - Changwon (Korea, Republic of), <sup>2</sup>Department Of Neurology, Samsung Medical Center - Changwon (Korea, Republic of), <sup>3</sup>Department Of Neurology, Busan Wilis Hospital - Busan (Korea, Republic of)

# POSTER PRESENTATIONS

Friday, December 2<sup>nd</sup> from 8 a.m to 5 p.m

Poster presentations presented onsite in San Francisco are indicated with this icon: 

- P208** Efficacy of the 'Finger-to-brain' game on cognitive function of older adults with mild cognitive impairment: a randomized controlled crossover trial  
Ji Won Han<sup>1,2</sup>, Dong Gyu Moon<sup>1</sup>, Jung Uk Shin<sup>1</sup>, Yeseung Park<sup>3</sup>, Min Jeong Kwon<sup>3</sup>, Hae In Kim<sup>3</sup>, Woori Moon<sup>1</sup>, Dae Jong Oh<sup>4,2</sup>, Jong Bin Bae<sup>1,2</sup>, Ki Woong Kim<sup>5,2,3</sup>  
<sup>1</sup>Department Of Neuropsychiatry, Seoul National University Bundang Hospital - Seongnam-Si (Korea, Republic of), <sup>2</sup>Department of Psychiatry, Seoul National University College of Medicine - Seoul (Korea, Republic of), <sup>3</sup>Department Of Brain And Cognitive Science, Seoul National University College Of Natural Sciences - Seoul (Korea, Republic of), <sup>4</sup>Department Of Psychiatry, Smg-Snu Boramae Medical Center - Seoul (Korea, Republic of), <sup>5</sup>Department Of Neuropsychiatry, Seoul National University Bundang Hospital - Seongnam-si (Korea, Republic of)
-  **P209** Feasibility, acceptability, and adherence of a remote smartphone-based self-assessment of cognition, function, and behavior in early Alzheimer's disease  
Thanneer Malai Perumal<sup>1</sup>, Arnaud Wolfer<sup>1</sup>, Miguel Veloso<sup>2</sup>, Irma T. Kurniawan<sup>1</sup>, Gollou Keita<sup>3</sup>, Niels Hagenbuch<sup>4</sup>, Beijue Shi<sup>5</sup>, Foteini Orfanidou<sup>6</sup>, David Watson<sup>7</sup>, Mercè Boada Rovira<sup>8</sup>, Kirsten I. Taylor<sup>2</sup>  
<sup>1</sup>Roche Pharma Research And Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd - Basel (Switzerland), <sup>2</sup>Roche Pharma Research And Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., - Basel (Switzerland), <sup>3</sup>Cytel Inc., - Geneve (Switzerland), <sup>4</sup>Global Product Development Data And Statistical Sciences, F. Hoffmann-La Roche Ltd. - Basel (Switzerland), <sup>5</sup>Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., - Basel (Switzerland), <sup>6</sup>Global Product Development, Personalized Healthcare, Digital Health, F. Hoffmann-La Roche Ltd., - Basel (Switzerland), <sup>7</sup>Alzheimer's Research And Treatment Center - Wellington (United States), <sup>8</sup>Networking Research Center On Neurodegenerative Diseases (ciberned), Instituto De Salud Carlos Iii - Madrid (Spain)
- P210** Effect of internet-based mindfulness training on cognitive and psychological well-being and EEG brain activity in the elderly: preliminary results  
Samantha Galluzzi<sup>1</sup>, Mariangela Lanfredi<sup>1</sup>, Alberto Chiesa<sup>2</sup>, Cristina Festari<sup>1</sup>, Serena Meloni<sup>1</sup>, Roberta Rossi<sup>1</sup>, Evita Tomasoni<sup>1</sup>, Davide Moretti<sup>1</sup>, Michela Pievani<sup>1</sup>  
<sup>1</sup>IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli - Brescia (Italy), <sup>2</sup>Istituto Mente e Corpo and Associazione di Psicologia Cognitiva - Scuola di Psicoterapia Cognitiva - Bologna, Rome (Italy)
-  **P211** Increasing Study Power via Frequent Speech-Based Assessments of Cognition  
Gabriela Stegmann<sup>1</sup>, Shira Hahn<sup>1</sup>, Julie Liss<sup>1</sup>, Visar Berisha<sup>1</sup>, Kimberly Mueller<sup>2</sup>  
<sup>1</sup>Arizona State University and Aural Analytics - Scottsdale, Az (United States), <sup>2</sup>University of Wisconsin - Madison - Madison, Wi (United States)
-  **P212** A Multimodal Deep Learning Approach to Prediction of Cognitive Decline and its Potential Application in Clinical Trials for Alzheimer's Disease  
Caihua Wang<sup>1</sup>, Yuanzhong Li<sup>1</sup>, Hiroyuki Yamaguchi<sup>2</sup>, Hisateru Tachimori<sup>3</sup>, Atsushi Sekiguchi<sup>4</sup>, Yuichi Yamashita<sup>2</sup>  
<sup>1</sup>Imaging Technology Center, FUJIFILM Corporation - Kanagawa (Japan), <sup>2</sup>Department of Information Medicine, National Institute of Neuroscience, National Center of Neurology and Psychiatry - Tokyo (Japan), <sup>3</sup>Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry - Tokyo (Japan), <sup>4</sup>Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry - Tokyo (Japan)
-  **P213** Preliminary Results of a Digital Pilot to Improve AD Trial Retention by Managing Caregiver Stress  
Rosemary Laird<sup>1,2</sup>, Jessica Branning<sup>1</sup>  
<sup>1</sup>ClinCloud Clinical Trials - Viera (United States), <sup>2</sup>Navigating Aging Needs LLC - Orlando (United States)
- P214** Brain Network Difference between Mild Cognitive Impairment and Alzheimer's Disease Dementia Using EEG  
Hong Yuseong<sup>1</sup>, Baik Kyoungwon<sup>2</sup>, Park Ukeob<sup>1</sup>, Ye Byoung Seok<sup>2</sup>, Kang Seung Wan<sup>1</sup>  
<sup>1</sup>iMediSync Inc. - Seoul (Korea, Republic of), <sup>2</sup>Yonsei University College of Medicine - Seoul (Korea, Republic of)
-  **P215** Using Ecological Momentary Assessment to Measure Real-World Effects of a Combined Computerized Cognitive and Functional Skills training Program in Mild Cognitive Impairment  
Philip Harvey<sup>1</sup>, Peter Kallestrup<sup>2</sup>, Sara Czaja<sup>3</sup>  
<sup>1</sup>University of Miami Miller School of Medicine - Miami (United States), <sup>2</sup>i-Function - Miami (United States), <sup>3</sup>Weill Cornell Medical Center - New York (United States)
-  **P216** The effects of home-based cognitive intervention with chat-bot on brain function in patients with amnesic mild cognitive impairment  
Geon Ha Kim<sup>1</sup>, Bori Kim<sup>1</sup>, Jee Hyang Jeong<sup>1</sup>  
<sup>1</sup>EwhaW.University - Seoul (Korea, Republic of)
- P217** Remote computer-based cognitive training: short- and long-term benefits on cognition and daily living in patients with Alzheimer's disease  
Samar Dimachki<sup>1</sup>, Franck Tarpin-Bernard<sup>2</sup>, Stéphanie De Chalvron<sup>2</sup>, Bernard Croisile<sup>3</sup>, Hanna Chainay<sup>1</sup>  
<sup>1</sup>Laboratoire d'Étude des Mécanismes Cognitifs, Université Lyon 2 - Lyon (France), <sup>2</sup>Scientific Brain Training SA - Lyon (France), <sup>3</sup>Service de Neuropsychologie, Centre Mémoire de Ressource et de Recherche de Lyon, Hôpital Neurologique - Lyon (France)
-  **P218** Taking care of family dementia caregivers: A qualitative examination of patient perspectives and perceived health outcomes after receiving usual care and after a digitally supported care management program  
Olga Klein<sup>1</sup>, Antonia Karras<sup>2</sup>, Wolfgang Hoffmann<sup>3,4</sup>, Stefan Teipel<sup>1,2</sup>, Ingo Kilimann<sup>1,2</sup>  
<sup>1</sup>Deutsches Zentrum fuer Neurodegenerative Erkrankungen - Rostock (Germany) - Rostock (Germany), <sup>2</sup>Clinic for Psychosomatics and Psychotherapy, University Medical Center Rostock - Rostock (Germany), <sup>3</sup>Deutsches Zentrum fuer Neurodegenerative Erkrankungen - Greifswald (Germany), <sup>4</sup>Institute for Community Medicine, Section Epidemiology and Community Health, University Medicine Greifswald - Greifswald (Germany)
-  **P219** Intuition: a brain health study using multimodal digital biomarkers to decipher cognitive profiles of individuals at-risk for Alzheimer's and related dementias  
Monroe Butler<sup>1</sup>, Anton Porsteinsson<sup>2</sup>, Sean Kenny<sup>1</sup>, Hansen Lenyoun<sup>3</sup>, Matt Hobbs<sup>1</sup>, Roland Brown<sup>1</sup>, Matt Bianchi<sup>3</sup>, James Williams<sup>1</sup>, Audrey Gabelle<sup>1</sup>, Shibeshih Belachew<sup>1</sup>, Intuition Study Scientific Committee Intuition Study Scientific Committee<sup>1</sup>  
<sup>1</sup>Biogen - Cambridge (United States), <sup>2</sup>University of Rochester Medical Center - Rochester (United States), <sup>3</sup>Apple - Cupertino (United States)

# POSTER PRESENTATIONS

Friday, December 2<sup>nd</sup> from 8 a.m to 5 p.m

-  **P220** **Cognitive health in underrepresented populations: early learnings from the Intuition brain health study**  
Rhoda Au<sup>1</sup>, Monroe Butler<sup>2</sup>, Hanson Lenyoung<sup>3</sup>, Sean Kenny<sup>2</sup>, Roland Brown<sup>2</sup>, Paramita Saha-Chaudhuri<sup>2</sup>, Matt Bianchi<sup>3</sup>, James Williams<sup>2</sup>, Audrey Gabelle<sup>2</sup>, Shibeshih Belachew<sup>2</sup>, Intuition Study Scientific Committee Intuition Study Scientific Committee<sup>2</sup>  
<sup>1</sup>Boston University School of Medicine - Boston (United States), <sup>2</sup>Biogen - Cambridge (United States), <sup>3</sup>Apple - Cupertino (United States)
-  **P221** **Analyzing Facial Expressions and Poses Captured During Video Chats for Early Identification of MCI - Proof of Concept Study: I-CONNECT Project**  
Muath Alsuhaibani<sup>1</sup>, Ali Pourramezan Fard<sup>1</sup>, Hiroko Dodge<sup>2,3</sup>, Mohammad Mahoor<sup>1</sup>  
<sup>1</sup>School of Electrical and Computer Engineering, University of Denver - Denver (United States), <sup>2</sup>Layton Aging and Alzheimer's Disease Center, Oregon Health & Science University - Portland (United States), <sup>3</sup>Oregon Center for Aging and Technology (ORCATECH), Oregon Health & Science University - Portland (United States)
- P222** **Using AI and Natural Language Processing Algorithms to Screen Older Adults with Mild Cognitive or Early Alzheimer's Disease**  
Stephanie Melgar-Donis<sup>1,2</sup>, Jarid Siewierski<sup>3</sup>, Rohola Zandie<sup>1,3</sup>, Daniel Pittman<sup>1</sup>, Lombe Chileshe<sup>1</sup>, Hojjat Abdollahi<sup>3</sup>, Maryam Habibi<sup>3</sup>, Brock Soicher<sup>3</sup>, Eshrat Emamian<sup>3</sup>, Mohammad Mahoor<sup>3,4</sup>  
<sup>1</sup>University of Denver - Denver (United States), <sup>2</sup>DreamFace Technologies, LLC, <sup>3</sup>DreamFace Technologies, LLC - Centennial, Co (United States), <sup>4</sup>University of Denver - Denver (United States)
-  **LP106** **Development of a machine learning model to diagnose dementia using questionnaires assessing subjective memory complaints and depressive symptoms**  
Myeongju Kim<sup>1</sup>, Jieun Hong<sup>1</sup>, Jinbyeong Park<sup>1</sup>, Jiwon Han<sup>1</sup>, Ki Woong Kim<sup>1</sup>  
<sup>1</sup>Seoul National University Bundang Hospital - Seongnam-Si (Korea, Republic of)
-  **LP107** **The Community Engaged Digital Alzheimer's Research (CEDAR) Study: Digital Engagement Strategies to Increase ADRD Research Participation of Black Americans**  
Anna Aaronson<sup>1,2,3</sup>, Miriam Ashford<sup>1,2,3</sup>, Danqi Zhu<sup>4</sup>, Heining Cham<sup>4</sup>, Catherine Conti<sup>1,2,3</sup>, Xinyue Deng<sup>4</sup>, Roxanne Alaniz<sup>5</sup>, R. Scott Mackin<sup>2,3</sup>, Michael Weiner<sup>1,2,3</sup>, Desiree Byrd<sup>6</sup>, Robert W Turner<sup>7</sup>, Carl Hill<sup>8</sup>, Rachel Nosheny<sup>2,3</sup>, Monica Rivera Mindt<sup>4,9</sup>  
<sup>1</sup>Northern California Institute for Research and Education (NCIRE), Department of Veterans Affairs Medical Center - San Francisco (United States), <sup>2</sup>Veterans Affairs Advanced Research Center - San Francisco (United States), <sup>3</sup>University of California, San Francisco - San Francisco (United States), <sup>4</sup>Department of Psychology, Latin American Latino Studies, African and African American Studies, Fordham University - New York (United States), <sup>5</sup>Alaniz Marketing - Novato (United States), <sup>6</sup>CUNY, Queens College - Queens (United States), <sup>7</sup>George Washington University - Washington (United States), <sup>8</sup>Alzheimer's Association - Chicago (United States), <sup>9</sup>Department of Neurology, Icahn School of Medicine at Mount Sinai - New York (United States)
-  **LP108** **Questionnaire-based Computer Assisted Diagnosis (CADx) is useful for identifying Alzheimer's Disease**  
Timothy Daly<sup>1</sup>, David Weisman<sup>2</sup>  
<sup>1</sup>Sorbonne Université - Paris (France), <sup>2</sup>Abington Neurological Associates - Abington (United States)
-  **LP109** **Advancing Measurement in Alzheimer's Disease and Related Disorders Through Digitizing Assessment of Meaningful Aspects of Health**  
Pip Griffiths<sup>1</sup>, Chao-Yi Wu<sup>2</sup>, Danielle Stefko<sup>3</sup>, Lucy Cesnakova<sup>4</sup>, Jennifer Goldsack<sup>5</sup>  
<sup>1</sup>The Digital Medicine Society - Saumur (France), <sup>2</sup>The Digital Medicine Society - Portland (United States), <sup>3</sup>The Digital Medicine Society - Nashville (United States), <sup>4</sup>The Digital Medicine Society - Prague (Czech Republic), <sup>5</sup>The Digital Medicine Society - Sarasota (United States)

## THEME: AD Clinical trials and COVID-19

-  **LP110** **Sustained accelerated cognitive decline in older adults as a result of the Covid-19 pandemic: Analysis of the PROTECT UK study data**  
Anne Corbett<sup>1</sup>, Clive Ballard<sup>1</sup>, Byron Creese<sup>1</sup>, Adam Hampshire<sup>2</sup>, Dag Aarsland<sup>3</sup>, Helen Brooker<sup>1</sup>  
<sup>1</sup>University of Exeter - Exeter (United Kingdom), <sup>2</sup>Imperial College London - London (United Kingdom), <sup>3</sup>King's College London - London (United Kingdom)

It is reminded that the papers presented during the Congress, whatever their form (oral, written or poster) are placed under the sole responsibility of their authors and co-authors. In no case, the positions, research, results presented during the CTAD Congress & published in the JPAD are likely to engage the responsibility of the Congress.

CTAD would like to thank its 2022 privileged partners  
for their continued support.

## Platinum Sponsor



Alzheimer's  
**Drug Discovery**  
Foundation

## Gold Sponsors





Clinical Trials on Alzheimer's Disease

Graphic Design: Melanie Vaisselle - @Tiemey

# Follow us on social media!



[@CTADConference](https://twitter.com/CTADConference)  
[#CTAD22](https://twitter.com/CTADConference)



[CTAD Conference](https://www.facebook.com/CTADConference)



[CTAD Alzheimer](https://www.linkedin.com/company/CTADAlzheimer)

Email: [ctad@ant-congres.com](mailto:ctad@ant-congres.com)  
[www.ctad-alzheimer.com](http://www.ctad-alzheimer.com)





# CTAD Alzheimer 2023

Clinical Trials on Alzheimer's Disease



©Mircea Costina

**October 24-27, 2023**  
**Boston, MA - USA**

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11  
Monte Carlo '12 / San Diego '13 / Philadelphia '14 / Barcelona '15 / San Diego '16  
Boston '17 / Barcelona '18 / San Diego '19 / Virtual '20 / Boston '21 / San Francisco '22

[www.ctad-alzheimer.com](http://www.ctad-alzheimer.com)

Email: [ctad@ant-congres.com](mailto:ctad@ant-congres.com)

